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CHAPTER I 
 
THE ROLE OF HEMOZOIN IN THE PATHOGENESIS OF MALARIA 
 
Introduction 
Malaria is one of the oldest diseases known to mankind; yet, it remains one of the 
most significant concerns to humanity today, threatening nearly 40% of the world’s 
population.1 Malaria was first documented centuries ago by Medieval Italians who 
correlated periodic fevers with exposure to bad marsh air (i.e., mala “bad” and aria “air”) 
that comes to Rome every summer. However, it was not until the late 1800’s that the 
disease was attributed to parasites carried by mosquitoes that often sequester near 
stagnant water during the summer months. 
Malaria is a disease primarily of the tropics, but can also be found in various 
regions of the Middle East and Asia (Figure 1). Each year between 300 and 500 million 
people become infected, resulting in over 1 million deaths annually.1 Although eradicated 
from most of the world by the mid 1960’s, malaria’s resurgence in the past decade poses 
significant social, economical, and health risks on a global scale. This is especially true 
for third world countries, where poverty assumes both cause and effect roles for disease 
transmission. Furthermore, malaria infections are becoming progressively more 
challenging due to parasitic resistance to common antimalarial drugs and vector 
resistance to insecticides.2   
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Figure 1. Geographic distribution of malaria.3   
 
Lifecycle of Plasmodium falciparum 
The first major advancement in deciphering the origin of infection was made by 
Charles Lavaran in 1880 when he observed parasites within erythrocytes collected from 
malaria victims. Nearly twenty years later, Carlos Finlay and Sir Ronald Ross 
independently suggested and demonstrated that malaria was transmitted between humans 
via infected mosquitoes.4, 5  
Since that time, much has been uncovered related to malaria pathogenesis.  
Infection is caused by one of four species of Plasmodium that target humans: falciparum, 
vivax, ovale, and malariae. The most serious, and often fatal, form of malaria is caused by 
P. falciparum, which is responsible for nearly 80% of malaria cases. Regardless of 
species, Plasmodium parasites have a complex lifecycle with several stages in both the 
mosquito vector and human host (Figure 2).6 Transmission occurs when an infected 
female Anopheles mosquito takes a blood-meal and sporozoites, the infective parasite 
form present in salivary ducts of the mosquito, enter the host’s body. Sporozoites quickly 
(~1 h) target the liver where they reside for 5-15 days while undergoing asexual fission, 
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resulting in the generation of thousands of merozoites. Hepatic cells eventually rupture 
and release the merozoites into circulation initiating the intraerythrocytic phase. Within 
erythrocytes, merozoites mature to a feeding form (i.e., trophozoite) which catabolizes 
host hemoglobin (Hb) as a source of nutrition essential for development and maturation, 
ultimately producing another passage of merozoites. After a 48 or 72 h period, RBCs 
rupture in a synchronized burst and release debris and parasites into circulation. 
Merozoites complete the asexual phase by differentiating into gametocytes and returning 
to the mosquito during a subsequent blood meal, or repeat the intraerythrocytic cycle by 
invading new RBCs. Notably, many clinical manifestations of malaria, including periodic 
fever, chills, headache, nausea, muscle spasms, and anemia, coincide with this 
intraerythrocytic phase and synchronized burst.  
RBC 
cycle
Sexual Mosquito 
Phase
Asexual Human 
Phase
immune response  
Figure 2. Lifecycle of the malaria parasite. (Top) The sexual cycle produces sporozoites 
within the body of the mosquito. (Bottom) During a blood-feed, sporozoites are 
transmitted from the salivary glands of an infected mosquito to a human host. Parasites 
undergo two asexual reproductions, first within hepatocytes and then within erythrocytes. 
Hemozoin is formed during the intraerythrocytic cycle. 
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Hemoglobin Catabolism and Hemozoin Formation 
During the intraerythrocytic phase, host Hb is catabolized through a series of 
enzymatic processes as summarized in Figure 3.  By virtue of the indispensable need for 
nutrition, this process continues repeatedly during infection. Briefly, parasites ingest 
nearly 80% of host Hb through pinocytosis via cytostomes.7 Within the digestive vacuole, 
Hb is initially digested into a mixture of peptides by aspartic acid- (i.e., plasmepsins), 
cysteine- (i.e., falcipains), and metallo- (falcilysin) proteinases. These peptides are then 
digested to individual amino acids by exopeptidases within the cytosol of the parasite 
where they are used for growth and maturation. Given that Hb is degraded to its simplest 
form, monomeric heme (Fe(II) protoporphyrin IX, Fe(II)-PPIX) is also released into the 
digestive food vacuole of the parasite.8, 9  
Although heme is a vital cofactor for a diverse set of proteins involved in 
respiration, oxygen transport, and drug detoxification, the accumulation of free heme has 
toxic effects. Heme is capable of binding lipid bilayers, thus inhibiting protease activity 
and catalyzing lipid peroxidation resulting in cell lysis.10, 11 Mammalian cells metabolize 
heme via heme oxygenease (HO-1); however, Plasmodium parasites (and several other 
blood-feeding organisms, including the blood fluke Schistosoma mansoni and the kissing 
bug Rhodnius prolixus) lack this enzyme. Detoxification of heme released during 
hemoglobin catabolism is essential for parasite survival. Consequently, a mechanism has 
evolved whereby >95% of the free heme is sequestered into the insoluble aggregate 
hemozoin (Hz) or malaria pigment (Figure 4).12 As most of the heme is occluded within 
the crystal, the parasite protected. Several antimalarials (e.g., quinolines) act during the 
degradation of hemoglobin and subsequent production of Hz and are thought to complex 
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with the heme, thereby inhibiting the growth of the biomineral and exposing parasites to 
a toxic environment.13 
 
food vacuole
RBC
Hb
Plasmepsins
Falcilysin
Amino Acids
heme
hemozoin
parasite
Falcipains
 
Figure 3. Process of hemoglobin degradation and heme detoxification by 
intraerythrocytic malaria parasites. Hemoglobin is degraded within the digestive food 
vacuole of the parasite by a group of aspartic acid proteinases (plasmepsins PfPM1, 
PfPM2, PfPM4, and PfHAP), cysteine proteinases (falcipains PfFP2, PfFP2′, and PfFP3), 
and the metalloproteinase falcilysin. As a result of the liberated toxic heme, hemozoin is 
formed. Adapted from reference 14. 
 
Hemozoin Formation 
Slater et al. demonstrated that Hz contains bonds between the Fe (III) 
center of one heme unit and a propionate side chain of another.16 This result 
suggested that Hz was a polymer comprised of [Fe(III)-PPIX]n chains. The 
eventual acquisition of a resolved crystal structure by Pagola et al., however, led 
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Figure 4. Electron micrograph of a parasitized erythrocyte. Hemozoin is formed within 
the acidic digestive food vacuole of the parasite.15 
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Figure 5. Molecular representation of a growing hemozoin crystal. Structurally, the 
biomineral is an aggregate of hydrogen bonded five-coordinate Fe (III)-PPIX dimers, 
joined by reciprocating monodentate carboxylate linkages between the central iron of one 
monomer and a propionic acid side chain of a second monomer. Adapted from reference 
17. 
Digestive Vacuole 
Red Blood Cell 
Hemozoin 
Parasite 
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to the determination that the fundamental bonds comprising the Hz dimer (Figure 5) are 
reciprocal head-to-tail Fe(III)- carboxylate coordinate bonds between the central iron of 
one heme monomer and the propionic carboxylate side chain of a second heme 
monomer.17 Dimeric units are held together by hydrogen bonds, leading to chain 
extension and crystal growth. 
The mechanism of Hz formation in vivo is a subject of much debate and, 
consequently, a topic of active research. Three mechanisms have been proposed thus far: 
enzymatic activity mediated by a heme polymerase, nucleation by a template protein, and 
promotion via a lipid-mediated process. Among the first to explore Hz formation, Slater 
and Cerami reported that P. falciparum trophozoite extracts incubated with hematin 
(Fe(III)-PPIX-OH) under physiological conditions led to Hz formation.18 The authors 
proposed that formation was catalyzed by an unknown heat- and sodium dodecyl sulfate 
(SDS) sensitive-heme polymerase that was present in the extract. Studies performed by 
Chou and Fitch using Plasmodium berghei (murine malaria) extracts supported this 
theory.19 However, attempts at identifying and purifying this putative polymerase were 
unsuccessful. Dorn et al. later challenged the presence of a putative heme polymerase by 
demonstrating that Hz formation occurred spontaneously in the presence of heat-
inactivated native Hz and synthetic Hz.20 The results of these studies suggested that Hz 
formation was autocatalytic, but were unable to provide a basis for the nucleation of the 
initial Hz crystal.  
The second potential mechanism of Hz formation mentioned above was based on 
the ability of a protein, specifically histidine-rich proteins II and III (HRP-II and III), to 
act as a nucleation site for crystal growth.21 HRPs comprise a family of proteins that 
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manifest a tandem tripeptide (Ala-His-His) repeat motif that represents a hypothetical 
biomineralization template. Sullivan and coworkers showed that HRPII was indeed able 
to promote Hz formation.21 Furthermore, Ziegler et al. utilized a dendrimer to present the 
tripeptide unit and similarly demonstrated Hz formation.22 These results indicate that this 
recurring domain may provide a scaffold which promotes heme nucleation and growth, 
resulting in Hz formation.  Although HRPs mediate Hz formation in vitro, their 
authenticity in vivo has been contested, as studies have shown HRPs localize outside of 
the digestive food vacuole, and thus away from the site of Hz formation. Furthermore, Hz 
formation in P. falciparum clones lacking HRP-II and -III genes was normal.23 Together, 
these results suggest that Hz formation proceeds by another mechanism in vivo. 
The final proposed mechanism of Hz formation was first addressed by Bendrat et 
al., who suggested that lipids are responsible for inducing and mediating biomineral 
nucleation.24 The authors specified that the seemingly autocatalytic formation previously 
observed by synthetic hemozoin was merely a result of contaminating phospholipids 
from commercial heme preparations (which are prepared by extraction from intact 
erythrocytes). Several groups have demonstrated the ability of polar membrane lipids24 
and neutral lipid bodies25-29 to nucleate Hz formation in vitro; and recently, neutral lipid 
nanospheres enveloping hemozoin crystals within P. falciparum digestive vacuoles were 
identified.26 These observations are intriguing as lipid droplets provide an optimal site for 
concentrating lipophilic heme from an aqueous environment, furthering the suggestion 
that lipid promotion appears plays a significant role in Hz formation in vivo.  
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Synthetic Hemozoin 
Current malaria research employs the use of two chemically and structurally 
identical crystal forms of the malaria pigment.  The first is native Hz, the biosynthetic 
material isolated from parasitized erythrocytes, and the second is synthetic Hz, herein 
referred to as β-hematin (BH).30 The fundamental difference between the two forms is the 
array of host- and parasite-derived lipids, proteins, and nucleic acids that are adsorbed 
onto the surface of native Hz.31, 32 Given the vast number of pigment preparations that 
can be derived from these basic forms, the state of the material must be well-defined in 
order to interpret experimental results. Crude Hz is pigment that is isolated from 
parasitized erythrocytes and gently washed to remove cellular debris but left with a lipid 
coat adsorbed onto the hydrophobic porphyrin plane.33  Purified Hz refers to crude Hz 
whose lipid coat has been removed by detergent34 or organic solvent extraction.35  BH, on 
the other hand, has been prepared and purified from hemin and is consequently devoid of 
all biologically-derived components.36-39  Several groups have reported conflicting results 
concerning the effects of Hz and BH in both in vitro and in vivo systems, including pro-
inflammatory,40 anti-inflammatory,36 and oxidative stress responses . These differences 
are likely attributable to the purity of the preparation, the amount of biomineral used, and 
the method of immune cell activation (e.g., lipopolysaccharide (LPS), interferon-γ (IFN-
γ), LPS+IFN-γ, or phorbol myristate acetate (PMA)).  
BH can be synthesized several ways. Bohle and coworkers reported a 
dehydrohalogenation reaction that occurs under anhydrous conditions in an inert 
atmosphere at room temperature over the course of three months.37 An alternate 
preparation by Slater et al., referred to as the aqueous acid-catalyzed method, proceeds at 
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a high temperature (70 ºC) over several hours.30 Characterization of the products from 
both synthetic routes demonstrates material that is chemically, spectroscopically, and 
crystallographically identical to HZ. 39, 41, 42 Morphologically, however, the Bohle method 
produces BH most similar to hemozoin isolated from P. falciparum (Figure 6).43 
 
 
Figure 6. Native hemozoin isolated from the parasite P. falciparum (top), BH synthesized 
from a dehydrohalogenation reaction (middle), and BH synthesized from a rapid aqueous 
acid-catalyzed reaction (bottom).43, 44 
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Immune Response to Malaria 
 The host immune response to malarial infection is multifactorial, including 
complex innate and adaptive responses to the parasites, composite native Hz, Hz-derived 
lipid peroxidation products, and other cellular debris. Not unexpectedly, countless 
interactions between an array of malaria toxins and host cells result in adverse biological 
effects (e.g., periodic fever, chills, headache, nausea, muscle spasms, and anemia). 
Although an early immune response is essential for protective immunity, an over-
stimulated response likely contributes to malaria pathogenesis: the destruction of 
parasites from the body results in considerable tissue damage, and the secretion of soluble 
factors causes adverse systemic effects.45, 46 Consequently, the outcome of malarial 
infection relies upon a delicate balance between under- and over-activation of immune 
responses. 
The release of foreign debris from ruptured RBCs provides a stimulus for innate 
immune activation and subsequent release of soluble factors including pro-inflammatory 
cytokines and chemokines. These molecules are responsible for varying levels of disease 
susceptibility, including cerebral malaria and anemia, and ultimately, disease progression, 
morbidity, and mortality. TNFα was the first cytokine characterized to play a role during 
malaria.47, 48  It has since been demonstrated that TNFα secretion can be induced by 
macrophages and T cells in response to parasitized RBCs, Hz, and glycolipids (e.g., the 
glycosylphosphatidylinositol (GPI) moiety).49 TNFα regulates the production of 
chemokines and cytokines such as interleukin 1 (IL-1), which is the predominant 
cytokine responsible for the fever.50 Notably, anti-TNF therapy reduced the fevers of 
children infected with P. falciparum,51, 52 demonstrating the synergism that exists during 
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the inflammatory response. Although other pro-inflammatory molecules, including IL-12, 
IL-18, and interferon γ (IFNγ),53-55 are also present in high levels, the production of 
immune cell effectors is dynamic over the course of infection. The production of several 
anti-inflammatory cytokines, including IL-4, IL-10, and transforming growth factor 
(TGF) β is apparent in later stages, indicating an effort to maintain inflammatory 
balance.56 However, patients still exhibit inflammation after the clearance of parasites 
from circulation, demonstrating long-term immune dysregulation.57 
 
Biological Activity of Hemozoin 
Accumulating evidence suggests that many of the clinical symptoms associated 
with malaria are not caused directly by the parasite, but by endogenous species generated 
during interactions with parasite-derived species such as Hz.53, 58  Each time the 
intraerythrocytic cycle is completed, parasitized RBCs rupture and release debris, 
including approximately 200 μmol Hz, into the vasculature.59 An innate immune 
response is triggered and phagocytic cells (i.e., monocytes, neutrophils, and 
macrophages) become activated. Notably, Hz-laden cells, which accumulate in the 
spleen, liver, and brain, exhibit dysfunctional antigen processing and macrophage 
functions; Hz-laden macrophages are unable to induce MHC class II molecules, repeat 
phagocytosis, or generate a microbicidal burst (i.e. reactive oxygen and nitrogen species) 
upon stimulation. 60  
In light of these factors, the interplay between Hz and the host immune system is 
of extreme interest. Confocal microscopy studies demonstrate that hemozoin 
phagocytosed by monocytes is localized within the phagolysosome but remains 
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undegraded for up to 72 h (Figure 7). From these observations, it was suggested that the 
persistence of Hz may be either an intrinsic property of the biomineral or 
immunomodulation mediated by composite Hz. During a typical innate response, foreign 
material within a phagocytic cell is primarily degraded by the production of microbicidal 
 
 
Figure 7. Hz stability. Utilizing the native fluorescence of the heme moiety, confocal 
microscopy was used to monitor the stability of Hz within phagolysosomes as a function 
of time. Images show Hz (A) 1 h and (B) 72 h after phagocytosis by human monocytes.60 
 
 
agents including reactive oxygen species (ROS) and reactive nitrogen species (RNS), 
mediated by NADPH oxidase (NOX) and inducible nitric oxide synthase (iNOS), 
respectively (Figure 8).61 Constitutively expressed NOX catalyzes the reduction of O2 to 
superoxide anion (O2·-) (Figure 9), which can rapidly be converted to the hydroxyl radical 
(HO·), hypochlorous acid (HOCl), and hydrogen peroxide (H2O2).62-64 Inducibly 
expressed iNOS catalyzes the production of nitric oxide (NO)65 (Figure 10) which reacts 
with O2 and forms RNS such as NO2, N2O3, NO2– and NO3–. Cumulatively, ROS and 
RNS degrade foreign material.  
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Figure 8. Representation of the pathways mediating microbicidal burst. Upon 
phagocytosis, foreign material is localized within a phagolysosome. NADPH oxidase and 
inducible nitric oxide synthase (iNOS) synergize to produce reactive oxygen and nitrogen 
species that function to degrade the foreign material. Adapted from reference 61. 
 
 
Given that phagocytosis of Hz markedly decreases production of both ROS and 
RNS in culture,33, 66, 67 evidence initially indicated that Hz was not degraded within 
phagolysosomes because microbicidal burst was impaired. Biochemical studies 
examining the degradation of BH in vitro have since been conducted.68 It is now known 
that BH is degraded by physiologically relevant concentrations of ROS (hydrogen 
peroxide and sodium hypochlorite) and RNS (DeaNo, a nitric oxide releasing agent).68 
Furthermore, macrophage-like cells loaded with opsonized-BH produced normal levels of 
microbicidal agents and degraded the biomineral nearly 80% within 72 h (Figure 11).68 
These markedly disparate results suggest that the immunological activity resulting from 
native Hz is not an intrinsic property of the pigment itself, but of a toxin(s) that is 
presented on its surface.69  
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Figure 9. Schematic illustrating the assembly of NADPH oxidase. Upon stimulation, 
protein kinase C (PKC) phosphorylates the cytosolic phagocyte oxidase complex 
mediating its translocation to the membrane. This results in activation of the NADPH 
oxidase complex which subsequently catalyzes the production of reactive oxygen species. 
 
 
 
Figure 10. Signaling cascades leading to the generation of nitric oxide. LPS and IFN-γ 
activate the NF-κB and JAK/STAT signaling pathways, respectively, to mediate iNOS 
expression and subsequent NO production.   
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Figure 11. BH stability. Utilizing the native fluorescence of the heme moiety, confocal 
microscopy was used to monitor the stability of BH within phagolysosomes as a function 
of time. Images show BH (A) 1.5 h and (B) 72 after phagocytosis by RAW 264.7 
macrophage-like cells.68 
 
 
Lipid Peroxidation Products as Non-Specific Malaria Toxins 
Lipid peroxidation products represent potential non-specific toxins that are 
associated with Hz and introduced into the cell during phagocytosis. Extraction of the 
biological material associate with crude Hz identified an array of host- and parasite-
derived lipids, proteins, and nucleic acids.31 Analysis of the lipid fraction identified 
secondary lipid peroxidation products including 5-, 8-, 9-, 11-, 12-, and 15-
hydroxyeicosatetraenoic acids (HETEs) and 9- and 13- hydroxyoctadecadienoic acids 
(HODEs), derived form arachidonic acid (AA) and linoleic acids (LA), respectively.32 
Furthermore, Schwarzer et al. measured the level of 4-hydroxy-2-nonenal (HNE) in Hz-
laden monocytes70 at the highest intracellular HNE concentration in any biological 
system observed to date.71 The biological activity of many of these lipid peroxidation 
products has been evaluated. For example, 15-HETE mediates several cellular effects 
including in enhanced vascular permeability and edema, increased chemotaxis and 
chemokinesis, and RBC adherence to endothelia (all of which are classic features of 
malarial infection).32  HNE is highly reactive with nucleophilic sites in biomolecules and 
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is capable of forming covalent adducts and crosslinks,72 impairing enzymatic activity,8, 73-
75 and triggering changes in gene expression.76, 77 Given that Hz is clearly involved in the 
pathogenesis of malaria, the activity of these Hz-associated lipid peroxidation encourages 
further investigation of putative roles in the immunomodulation that occurs during 
malarial infection. 
 
Dissertation Aims 
 
The goal of this dissertation is to investigate the role of fatty acid oxidation in the 
disruption of macrophage function. The ability of the biologically naïve synthetic 
analogue of hemozoin, β-hematin (BH), to mediate lipid peroxidation is demonstrated in 
Chapter II. The known biological activity of HNE and 15-HETE suggests possible 
involvement in malaria pathophysiology. Therefore, Chapter III examines the cellular 
responses to individual components of Hz (BH, HNE, and 15-HETE) in the context of 
malaria infection using global microarray technology. The ability of HNE to modulate 
MMP9 regulation and NF-κB signaling was suggested by a number of differentially 
expressed transcripts and correlates with documented malaria pathophysiology. Thus, 
Chapter IV discusses the ability of HNE to disrupt the programmed functions of a 
triggered immune response and examines the specific mechanisms leading to altered 
matrix metalloproteinase 9 (MMP9) and inducible nitric oxide synthase (iNOS) 
expression. 
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CHAPTER II 
 
β-HEMATIN-MEDIATED OXIDATION OF POLYUNSATURATED FATTY ACIDS 
 
Introduction 
While immune activity is essential for protective immunity, a modulated response 
contributes to malaria pathogenesis.53 There is a positive clinical correlation between the 
severity of infection and the presence of Hz in phagocytic cells, which has led to a 
myriad of studies investigating the immunological activity of Hz. The identification of a 
lipid coat adsorbed to Hz prompted several investigations focused on dissecting the 
make-up of the composite material. Schwarzer et al. assessed the isomeric distribution of 
P. falciparum Hz-derived HETEs and identified not only the formation of six structural 
HETE isomers, but also equivalent stereoisomeric ratios of each structural isomer.32 
Additionally S. mansoni Hz-derived HETEs were distributed across all positional and 
racemic isomers, albeit with a higher level of 12(S)- versus 12(R)-HETE, suggesting the 
presence of 12-lipoxygenase activity.78 Together these observations indicate that Hz-
mediated lipid peroxidation is non-enzymatic in nature. It is well-established that heme 
compounds are effective mediators of non-enzymatic lipid oxidation, supporting the 
premise that reactive lipid peroxidation products arise from the oxidation of lipids by Hz. 
Consequently, the studies presented in Chapter II investigate the ability of BH to drive 
the oxidation of arachidonic acid and examine the biological activity of the secondary 
oxidation products.  
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Lipid peroxidation 
The mechanisms associated with lipid peroxidation involve non-enzymatic or 
enzymatic reactions between molecular oxygen and a lipid molecule. The enzymatic 
metabolism of AA, a 20 carbon ω-6 fatty acid containing four double bonds (20:4), 
occurs by three major routes and produces regio- and stereo-specific products: 
lipoxygenase (LOX) enzymes which form HETEs, leukotrienes, and lipoxins; 
cyclooxygenase (COX) enzymes which form prostaglandins, prostacyclins, and 
thromboxanes; and cytochrome P-450 monooxygenase enzymes which form epoxides.79  
Non-enzymatic oxidation of AA, the focus of Chapter II, results in a mixture 
comprised of six hydroperoxide species which differ by the position of the hydroperoxide 
moiety along the carbon backbone: C5, C8, C9, C11, C12, and C15. These primary lipid 
peroxidation products are referred to as N-HPETEs, where N identifies the carbon atom 
modified by the hydroperoxide group. Importantly, these intermediates lead to a diverse 
array of secondary lipid peroxidation species including complex mixtures of regio- and 
strereo-isomers of isoprostanes, HETEs, HNE, and isoketals (IsoK), among other 
products (Figure 12).  
 
Non-enzymatic lipid peroxidation in biological systems 
Free radical-mediated lipid peroxidation proceeds through a mechanism consisting of 
three distinct steps: initiation, propagation, and termination (Figure 13). The initiation 
step begins with the abstraction of a bis-allylic hydrogen atom from a lipid (LH) by an 
initiator (In) to form a pentadienyl resonance stabilized carbon-centered radical (L·). 
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Figure 12. Peroxidation of arachidonic acid. The generation of secondary oxidation 
products, including isoprostanes, HETEs, HNE, and isoketals, arises from a 
peroxyeicosatetraenoic acid intermediate. 
  
 
Mono-allylic and alkyl hydrogens can also be abstracted; however, bis-allylic hydrogens 
have the weakest C–H bond strength (ΔH = 75 kcal/mol relative to 88 and 101 kcal/mol 
for mono-allylic and alkyl C–H bonds, respectively) thereby making this abstraction the 
most favorable.80  In the presence of molecular oxygen an alkyl radical reacts to form a 
peroxyl radical (LOO·). LOO· can propagate hydrogen abstraction from another lipid 
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molecule to form a second L· and a lipid hydroperoxide (LOOH).  LOOH can dissociate 
to form a hydroxyl radical (HO·) and an alkoxyl radical (LO·), the latter of which 
generates an alcohol (LOH) and L· through yet another hydrogen abstraction. Finally, 
termination of this chain reaction occurs when two radical species, produced during 
initiation or propagation, react to form non-radical products. These steps are summarized 
in Figure 14. 
Initiation In· +    LH InH + L·
Propagation L· +     O2 LOO·
LOO· +    LH LOOH + L·
LOOH       LO· + HO·
LO· +    LH    LOH + L·
Termination L· + L· non-radical
L· +   LOO· non-radical
 
Figure 13. Free radical reaction chain involved in the autoxidation of lipids. 
 
LH
initiator
O2
L ·
LOO ·
LOOH
LH
 
Figure 14. Non-enzymatic lipid peroxidation scheme. The circle represents the 
propagation cycle.   
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Iron-mediated lipid peroxidation 
Given that iron is essential for both growth and survival, it can be considered the 
most important metal found in the body. However, it is also well established that iron is 
intimately associated with lipid peroxidation.81 Iron and free heme (released during 
hemoglobin catabolism) mediate the generation of several redox active species including 
peroxide and both superoxide and hydroxyl radicals. In the presence of iron, lipid 
peroxides decompose to radicals by a Fenton-type (iron-catalyzed Haber–Weiss) reaction 
(Figure 15): LOOH reacts with Fe2+ to generate LO·. Fe3+ has also been shown to 
generate LOO· which can subsequently react with lipids to propagate additional radical 
reactions. 
 
Fe2+ + LOOH Fe3+ + LO· + HO-
Fe3+ + LOOH Fe2+ + LOO· + H+
LOO· + LH L· + LOOH 
 
Figure 15. Iron-mediated lipid peroxidation. 
 
It is also recognized that redox cycling of heme iron contributes to lipid 
peroxidation.82 Heme iron can cycle through multiple oxidation states (Figure 16) 
including the reactive ferryl (Heme–FeIV═0) and perferryl (Heme–FeV═0 or ·Heme–
FeIV═0) complexes ultimately generating lipid radicals and propagating the reactions 
shown in Figure 15.   
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Figure 16. Proposed Hz-mediated lipid peroxidation pathways associated with redox 
cycling of heme-iron. Adapted from reference 82. 
 
Summary 
Lipid peroxidation products are non-specific Hz toxins that are introduced into 
cells during phagocytosis. Heme compounds are effective mediators of non-enzymatic 
lipid oxidation, supporting the premise that these products arise from the oxidation of 
lipids by Hz. Herein, the ability of BH to mediate the peroxidation of arachidonic acid is 
demonstrated. Additionally, the immunomodulatory activity of native Hz is modeled 
using constitutive components in a cell culture system. Results indicate that lipid 
peroxidation products generated during reactions between BH and ghost membranes are 
biologically active and responsible for impaired PMA-activated NADPH oxidase and 
LPS-stimulated inducible nitric oxide synthase (iNOS) activities. Furthermore, the results 
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suggest that Hz-mediated lipid peroxidation products are the underlying basis of Hz 
immunomodulation.  
 
Experimental 
 
Materials 
Sodium bicarbonate, monobasic sodium phosphate, dibasic sodium phosphate, o-
phosphoric acid 85%, dimethyl sulfoxide (DMSO), hexane, 2-propanol, acetic acid, and 
Hepes were obtained from Fisher. N-(1-naphthyl)ethylenediamine (NED), sulfanilimide, 
hemin chloride (bovine), Pipes, Sepharose 2B, 3,3’,5,5’-tetramethylbenzidine liquid 
substrate (TMB), and lipopolysaccharide (LPS) were obtained from Sigma. Anhydrous 
methyl alcohol, and 2,6-lutidine were obtained from Acros. Arachidonic acid was 
obtained from Nu-Chek Prep, Inc. Dulbecco’s phosphate buffered saline (PBS) and 
RPMI 1640 media with 2 g/L sodium bicarbonate were obtained from Gibco. RPMI was 
supplemented with 10% fetal bovine serum (FBS) (Atlanta Biologicals) and 100 μg/mL 
penicillin-streptomycin (P/S) (Invitrogen) before use. 4-hydroxy-2-nonenal (HNE) was 
purchased from Calbiochem. Packed RBC were a donation from the VUMC Blood Bank. 
All chemicals were used as received unless otherwise noted. 
 
β-hematin synthesis and characterization 
β-hematin (BH) was synthesized via a dehydrohalogenation reaction as previously 
described37, 68 using purified hemin chloride (Fluka). Briefly, in an inert atmosphere 0.3 g 
of hemin chloride was dissolved in 5 mL of 2,6-lutidine with stirring. Forty mL of 1:1 
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DMSO/anhydrous MeOH was added to the flask which was then sealed, covered in foil, 
and left undisturbed. After 90 days, crude BH was collected via vacuum filtration (0.45 
µm filter) and exhaustively washed in MeOH, DMSO, 0.1 M NaHCO3 (pH 9.0), and 
deionized water. UV-visible spectroscopy was used to monitor BH purity, as determined 
by baseline absorption of the Soret band for heme in the supernatant of the washes. BH 
was dried at 150 ºC for 48 h and formation was confirmed by powder X-ray diffraction 
(XRD), Fourier Transform Infrared (FT-IR) Spectroscopy, and scanning electron 
microscopy (SEM): XRD studies (0.02 step size, 25s preset time, scan range 4 to 35 º2θ) 
were performed with a Scintag X1 h/h automated powder diffractometer with a copper 
target, a Peltier-cooled solid-state detector and a zero-background silica (510) sample 
support. KBr pellets for IR studies were prepared from dried BH samples and spectra 
were acquired using an ATI Mattson Genesis Series FT-IR spectrophotometer. For SEM 
analyses, BH was suspended in ethanol, sonicated, applied to a polished aluminum 
specimen mount, and dried at 25 ºC overnight. The sample was sputter-coated with gold 
for 20 s and imaged using a Hitachi S4200 scanning electron microscope at 1.0 kV 
accelerating voltage. Particles were determined to have an average length of 0.9 ± 0.3 
µm. 
 
 
Cell culture 
 Murine macrophage-like RAW 264.7 cells (American Type Culture Collection 
TIB-71, Manassas, VA) were cultured under standard incubation conditions (37 ºC, 5% 
CO2) and grown in complete culture media (RPMI supplemented with 5% FBS (Atlanta 
Biologicals, Atlanta, GA) and 1 μg/mL P/S (Cellgro MediaTech, Herndon, VA)). Cells 
 26
were plated at a density of 5 × 105 cells/well in 24 well plates or 4 × 106 cells/well in 6 
well plates and incubated for 24 h prior to treatment. 
 
Erythrocyte ghost preparation 
 Ghosts were prepared according the procedure by Derham et al. with minor 
modifications.83 Packed red blood cells (RBCs, 3.0 mL) were suspended in 12.0 mL of 
phosphate buffered saline (PBS, 5 mM NaH2PO4 supplemented with 150 mM NaCl, pH 
8.0) and centrifuged at 1000 × g for 10 min. The supernatant was discarded and the pellet 
was resuspended in PBS. After four washes, the pellet was resuspended in phosphate 
buffer (5 mM NaH2PO4, pH 8.0) at a 10% hematocrit. The sample was rigorously shaken 
and placed on ice for 15 min prior to loading 15.0 mL (6% of the bed volume) onto a 
Sepharose 2B column (2.5 cm × 50 cm) equilibrated in 15 mM Pipes buffer with 0.1 mM 
EDTA (pH 6.0) maintained at 4 ºC. Erythrocyte ghosts were eluted with 20 mM Hepes 
buffer supplemented with 146 mM sodium chloride (pH 7.4) at flow rate of 15 mL/h. The 
absorbance of fractions was monitored at 280 nm and fractions containing RBC ghosts 
were pooled and collected by centrifugation (10 700 × g, 15 min, 4 ºC). Ghost 
membranes were disrupted by alternately vortexing with glass beads (2 min) and resting 
on ice (2 min) for a total of five cycles.   
Reactions between RBC ghosts and BH were prepared in test tubes with a total 
volume of 2 mL. RBC ghosts, normalized to 1 mg protein/mL via the BioRad Protein 
Assay, were combined with BH (0.75 mg/mL) in RPMI 1640 complete medium. Samples 
were stirred for 24 h at RT and centrifuged for 15 min at 5500 rpm.  Supernatant was 
collected and immediately used for experiments. 
 27
 
Cell treatment 
 Cells were washed once with Dulbecco’s PBS (DPBS) and untreated or treated in 
triplicate with serum-opsonized BH (0.1 mg/mL), HNE (EMD Biosciences, San Diego, 
CA), 15-S-HETE (Cayman Chemical, Ann Arbor, MI), or BH/ghost membrane reaction 
supernatant. Opsonization was performed as previously described.84 Immediately 
following treatment, LPS was added to all wells at a final concentration of 1 μg/mL.  
 
Generation of lipid peroxides 
Arachidonic acid (10 mM) was oxidized in 2 mL of 100 mM phosphate buffer 
(chelexed, pH 7.4) in the presence of BH (0.48 mM) for 4h at RT. For samples to be 
assayed for isoketal generation, pyridoxamine dihydrochloride (100 µM) was added at t = 
2 h. After extraction of the reaction mixtures with diethyl ether (3 × 2 mL), the organic 
layers were combined and condensed, and the residue was reconstituted in 200 µL of LC 
mobile phase.  
 
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
LC-MS/MS analysis of HETE products was performed using a ThermoFinnigan 
LTQ linear ion trap mass spectrometer equipped with a Waters Acquity UPLC system. 
Products were separated on a Thermo Hypersil GOLD C18 column (2.1 × 150 mm, 1.9 
μm). Solvent A (10 mM ammonium carbonate in acetonitrile/water (10:90)) and solvent 
B (10 mM ammonium carbonate in acetonitrile/water (90:10)) were used with a flow rate 
of 600 μL/min at the following gradient: 0–0.25 min 30% B isocratic phase; 0.25–9 min, 
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linear gradient from 30–45% B; 9–10 min isocratic phase at 45% B; 10–10.5 min, linear 
gradient from 45–30% B; 10.5–17 min isocratic phase at 30% B. The sample injection 
volume was 10 μL. The mass-spectrometer was operated in negative ion mode and tuned 
as follows: spray voltage of 3.8 kV, a capillary temperature of 300 ºC, capillary voltage 
of 50 V, and tube lens offset 103.3 V. Product scan spectra of HETE isomers ([M-H+] 
m/z 319) were acquired from 85 m/z to 350 m/z. Individual HETE isomer standards were 
used to establish fragmentation patterns, and unique m/z were chosen to extract ion 
profiles for each isomer. 
LC-MS/MS analysis of isoketal products was performed using a ThermoFinnigan 
TSQ Quantum triple quadrupole equipped with a ThermoFinnigan Surveyor LC. 
Products were separated on a Magic Bullet C18AQ micro column (3 µm, 100 Å, 
Michrom BioResources, Auburn, CA) with the gradient programmed from 100% solvent 
A (5 mM ammonium acetate with 0.1% acetic acid) to 100% solvent B 
(acetonitrile/methanol 95:5) from 0.5 min to 3 min and then continuing at 100% B for an 
additional 1.5 min. The column was then equilibrated to 100% A for 2.5 min. The flow 
rate was set to 190 µL/min and the injection volume was 5 µL. The mass spectrometer 
was operated in positive ion mode with the following parameters: spray voltage of 3.7 
kV, a capillary temperature of 210 ºC, capillary voltage of 35 V, tube lens offset 90 V, 
source CID of 5 V, and collisional energy of 30 eV. Product scan spectra of the Isok-PM-
lactam adduct ([M+H+] m/z 501) were acquired from 50 m/z to 520 m/z. Selected 
reaction monitoring was used to confirm m/z 501→ m/z 152 and m/z 501→ m/z 332 
transitions, calculated as -17 Da (deamidation by fragmentation of the β-amine) from the 
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parent Isok-PM-lactam mass. With both instruments, data was acquired and analyzed 
using Thermo-Finnigan Xcaliber software. 
 
Measurement of reactive oxygen and nitrogen species 
Measurement of reactive oxygen species (ROS) was accomplished using luminol-
dependent luminescence. Three hours after treatment, cells were washed with PBS and 
NADPH oxidase was activated by the addition of 1000 mL of 100 nM PMA in PBS. 
After 4 min, 950 mL of this supernatant was collected into a luminescence tube followed 
by the addition of 50 mL of 1 mM luminol in PBS. Luminescence was immediately 
measured using a Monolight 3010 luminometer for 10 s. NO levels were indirectly 
assessed by measurement of nitrite via the Griess assay. Twenty-four hours after 
treatment, supernatant (100 μL) was collected and combined with 100 μL Griess reagent 
(1:1, 1% sulfanilimide in 5% phosphoric acid/0.1% N-(1-naphthyl)ethylenediamine). 
After five minutes, the absorbance of the azo complex was measured at 540 nm using a 
Bio-Tek Synergy HT Multidetection Microplate Reader. Nitrite levels were determined 
by comparison with a standard curve. 
 
Results and Discussion 
 
Native Hz is an immunomodulatory material.33, 49, 60, 66, 85 Accumulating evidence 
suggests that the basis of the modulatory activity is not a result of the intrinsic biomineral 
structure, but of the biomineral’s reactivity with endogenous lipids.32, 68, 86 Consequently, 
the ability of BH to mediate lipid peroxidation was investigated. 
 30
 
β-hematin (BH) synthesis and characterization 
BH was prepared using a modification of the Bohle dehydrohalogenation 
method.37 Relying on the differential solubilities of hemin chloride and BH,87 monomeric 
heme and small heme aggregates were removed by exhaustive washings in MeOH, 
DMSO, 0.1 M NaHCO3 (pH 9.0), and deionized water.  Purification was assessed by 
monitoring the absorbance of the Soret band of heme in the washes. As shown in Figure 
17, initial MeOH washes (washes 1-3) removed residual hemin chloride, and NaHCO3 
(washes 3-5) and DMSO (washes 5-9) solubilized monomeric heme and aggregates.88  
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Figure 17. β-hematin purification. Absorbance of the Soret band of heme was measured 
in MeOH (washes 1-3), NaHCO3 (washes 3-5), DMSO (washes 5-9), and NaHCO3 
(washes 10-12) supernatants to monitor the purity of BH. Inset shows detail at low 
absorbance values.88 
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To ensure that purified BH is spectroscopically and crystallographically identical 
to Hz, the synthetic material was characterized by FT-IR spectroscopy, SEM, and XRD 
(Figures 18 and 19).9, 28, 41 KBr pellets of BH were analyzed by FT-IR, and distinctive 
bands were observed at 1210 and 1662 cm-1, corresponding to C-O and C=O vibrational 
stretching of the Fe-carboxylate linkage, respectively. XRD spectra demonstrated the 
appropriate line pattern distinguished by a peak at 7 º2θ that is nearly double the signals 
at 22 and 24 º2θ. Finally, SEM micrographs showed needle-like crystals with well-
defined facets. BH characterized as described was deemed pure and used for the studies 
presented herein. 
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Figure 18. BH characterization. (A) FT-IR spectroscopic analysis and (B) XRD line 
pattern of the synthetic material. 68 
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Figure 19. BH crystals. (A) Scanning electron micrograph of synthetic hemozoin 
crystallites shows needles with well-defined facets. (B)Histogram of BH particle size 
distribution.44  
 
 
BH-mediated 4-hydroxynonenal (HNE) formation 
Transition metals mediate the non-enzymatic decomposition of both arachidonic 
acid and linoleic acid-derived lipid hydroperoxides.81, 89-91 Given that this intermediate 
has been identified as a precursor of HNE, the ability of BH to mediate HNE formation 
was assessed.88 BH was incubated with arachidonic acid under either aerobic or 
anaerobic conditions, and lipid peroxidation products were extracted and analyzed by 
LC-MS. BH-mediated HNE formation was confirmed by comparison of LC retention 
time and MS (M+H+ [m/z 157] and M+H+-H2O [m/z 139]) (Figure 20) with a HNE 
standard. Quantitation was performed by UV analysis of normal phase liquid 
chromatograms compared with a standard curve, and relative to autoxidation, BH 
mediated the generation of HNE in a dose-, time-, and oxygen-dependent manner (Figure 
21).88  
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Figure 20. MS analysis of HNE produced from BH-mediated peroxidation of arachidonic 
acid. (A) Chromatogram showing the elution profile of HNE. (B) The mass spectrum 
acquired for the peak eluting at 10.9 min demonstrates a singly charged HNE [M+H]+ 
species at m/z 157.88 
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Figure 21. BH-mediated HNE formation. (A) HNE forms as a function of BH 
concentration. (B) HNE forms as a function of time under aerobic conditions (blue line). 
Anaerobic conditions (red line) inhibit HNE formation.88 
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BH-mediated hydroxyeicosatetraenoic acid (HETE) formation 
The ability of BH to mediate the generation of HNE confirmed the putative 
reactivity of the dimeric iron core. This result prompted investigation of BH’s ability to 
mediate the formation of HETEs, which are associated with Hz in a native state. During a 
non-enzymatic reaction, the reduction of a peroxyl radical generates racemic mixtures of 
hydroxylated fatty acids. Therefore, the distribution of HETE isomers was of interest. 
Hydrophobic interactions suggest that lipid peroxidation products generated by BH 
would be preferentially adsorbed to the surface of the biomineral. To confirm this 
interaction, reactions were centrifuged to pellet BH, supernatant was removed, and BH 
was washed three times with phosphate buffer prior to extraction. As shown in Figure 22, 
LC-MS/MS analysis revealed that a series of compounds with m/z 319 Da (M-H+) 
(indicative of the isobaric carboxylate anion of HETE) were associated with the BH 
pellet. Given that collision-induced disassociation (CID) of positional isomers will yield 
isomer-specific patterns, all m/z 319 species were fragmented, and the products scans 
were collected. As an example, Figure 23 shows the tandem mass spectrum extracted 
from the peak at 3.25 min; this peak was determined to be 15-HETE based on the 
fragmentation pattern, particularly the strong m/z 319Æ219 transition. Specific detection 
of all six positional HETE isomers (5-, 8-, 9-, 11-, 12-, and 15-HETE) was achieved 
through MS/MS by monitoring unique m/z 319ÆX transitions, where X represents 
isomer-specific fragmentation. All isomers were validated by comparison of 
fragmentation patterns and retention times with standards. The distribution of isomers 
indicates the preferential formation of 15-HETE relative to all others 
(15>>11≈5≈12>8>9). Notably, 15- and 5-HETE have been reported to as the 
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predominant isomers of both iron-catalyzed and Hz-mediated arachidonic acid 
peroxidation.86, 92, 93  
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Figure 22. Reverse phase LC-MS/MS analysis of HETEs produced from BH-mediated 
peroxidation of arachidonic acid. Chromatograms showing (A) total ion current (TIC) of 
m/z 319 and (B-G) MS/MS extracted ion profiles for m/z unique to each isomer.  
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Figure 23. 15-HETE mass spectrum. The M-H+ isobaric ion was subjected to collision 
induced disassociation, and product ions were scanned from m/z 85 to m/z 350. The 
fragmentation pattern of the peak (m/z 319) eluting at 3.25 min identifies 15-HETE. 
 
 
BH-mediated isoketal (IsoK) formation 
The non-enzymatic generation of HNE and HETEs mediated by BH mirrors the 
lipid peroxidation products associated with Hz. As an independent measure of the ability 
of the dimeric core to generate biologically active species from arachidonic acid, the 
production of isoketals (IsoK) was assessed. IsoK are 1,4-dicarbonyl compounds and, 
consequently, are readily reactive with proteins via lysine residues, forming pyrrole, 
lactam, and hydroxylactam adducts. Pyridoxamine (PM) has proven to be an effective 
scavenger of IsoK94 and, therefore, was added to the reactions to scavenge IsoK as they 
were generated.95 As shown in Figure 24, BH-mediated the formation of IsoK, and 
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scavenging of IsoK by PM was readily achieved. Selected reaction monitoring (SRM) 
confirmed m/z 501Æ152 and 501Æ332 transitions indicative of a PM/IsoK lactam 
adduct. To further characterize the species, the molecular ion was subjected to CID, and 
product ions were scanned from m/z 50 to m/z 520 (Figure 25). The CID spectrum is 
characteristic of an IsoK/PM lactam adduct: deamidation of PM gives rise to m/z 152 
and, when accompanied by a loss of H2O, m/z 332, as well as loss of H2O from the parent 
and product ions (i.e., m/z 314 and 483).  
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Figure 24. Selected Reaction Monitoring of IsoK/PM lactam adduct. The [M+H]+ ion 
(m/z 501) formed by adduction of isoketal to pyridoxamine was subjected to collision 
induced disassociation and m/z 501Æ152 and m/z 501Æ332 transitions were monitored. 
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Figure 25. Mass spectrum of IsoK/PM lactam adduct fragmentation. The [M+H]+ ion 
formed by adduction of Isoketal to pyridoxamine was subjected to collision induced 
disassociation, and product ions were scanned from m/z 50 to m/z 520. 
 
 
 
 
BH-mediated ghost membrane peroxidation 
In order to examine the reactivity of BH in an appropriate model system, the 
ability of the biomineral to mediate peroxidation of lipids derived from erythrocyte 
membranes (i.e., ghost cells) was examined. Ghost cells, obtained by RBC lysis and 
purified by gel filtration chromatography (Figure 26), were incubated with BH. As shown 
in Figure 27, BH mediated the generation of a complex array of products. Comparison of 
the retention times with previous analyses that examined arachidonic acid peroxidation 
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suggested that several products may be positional HETE isomers. Thus, LC-MS was used 
to investigate the non-enzymatic formation of HETEs as previously described. Similar to 
the generation of HETE isomers from arachidonic acid described above, BH-mediated 
the formation of all six HETE isomers from ghost membranes (Figure 28). Based on peak 
area, the distribution of isomers was the same as BH-mediated arachidonic acid oxidation 
(i.e., 15-HETE>>11≈5≈12>8>9). 
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Figure 26. Purification of erythrocyte ghost cells. RBC were lysed and ghost cells were 
purified by gel filtration chromatography. The absorbance of fractions was monitored 
(280 nm) to identify ghost cells. Relevant fractions were pooled, and ghost cells were 
collected by centrifugation.68 
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Figure 27. Normal phase HPLC analysis of red blood cell ghost peroxidation. (A) Elution 
profile of RBC ghost autoxidation. (B) Elution profile of BH-mediated RBC ghost 
peroxidation. Comparison of chromatogram complexity between autoxidation and BH-
mediated oxidation suggests the production of a number of lipid peroxidation species 
mediated by BH prompting further investigation.    
 
 
 BH-mediated ghost membrane peroxidation reactions were examined for IsoK 
formation. However, IsoK were not detected in these studies. It should be noted that the 
prevailing difference between in vitro arachidonic acid- and ghost membrane-
peroxidation mediated by BH is the presence of protein in ghost membrane samples. It is 
likely that IsoK were indeed formed but were unable to be detected due to their proclivity 
to adduct lysine residues of protein. In fact, phospholipid-esterified Isok have been shown 
to adduct lysine residues of protein (presumably membrane) in an in vivo model of 
oxidative stress, and Isok directly covalently modified aminophospholipids in vitro.96, 97 
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Figure 28. Reverse phase LC-MS/MS analysis of HETEs produced from BH-mediated 
peroxidation of ghost membranes. Chromatograms showing (A) total ion current (TIC) of 
m/z 319 and (B-G) MS/MS extracted ion profiles for m/z unique to each isomer.  
 
 
Proposed mechanisms of BH-mediated lipid peroxidation 
Given that Hz is an insoluble particulate material, mechanistic studies are 
intrinsically difficult to perform. Although it has been shown that free heme is not 
liberated from Hz98 or BH99 during reactions that generate lipid peroxides, the specific 
mechanisms mediating lipid peroxidation remain unknown. Accumulating evidence 
suggests that the oxidizing ability of the Hz is dependent upon the presence of 
hydroperoxides. Transition metal-mediated decomposition of lipid hydroperoxides likely 
 42
occurs by a one electron reduction to an alkoxyl radical.81, 89-91 In support of this premise, 
electron paramagnetic resonance (EPR) studies demonstrated the formation of methoxyl 
and tert-butoxyl radical adducts when purified Hz was incubated with tert-
butylhydroperoxide (tert-BuOOH) in the presence of the spin-trap DMPO.98 BH-
mediated HNE formation likely proceeds via a similar pathway. 
From a peroxyeicosatetraenoic acid radical intermediate (Figure 12), three major 
non-enzymatic routes occur. First, the reaction can be quenched and reduced to form 
HETEs; second, the radical can undergo β-fragmentation and Hock cleavage to produce 
short chain aldehydes such as HNE; and finally, the radical can undergo two rounds of 
cyclization with adjacent unconjugated double bonds to form bicycloendoperoxides that 
are reduced to the PGH2 intermediate. Schneider et al. provide evidence that autoxidation 
of both HPODE isomers (9S- and 13S-) forms 4-hydroperoxy-2-nonenal (4-HPNE), the 
precursor of HNE, by distinct pathways depending on the location of the hydroperoxy 
group.93 13(S)-HPODE forms a dihydroperoxide that undergoes Hock cleavage to form 
HPNE. 9(S)-HPODE directly undergoes Hock cleavage which generates an alkenal that 
oxygenates to form HPNE (Figure 29). Analogous mechanisms describing the formation 
of HNE from arachidonic acid are proposed using 11- and 15-HPETE as the precursors of 
4-HPNE.93 Alternatively, the non-enzymatic formation of the PGH2 intermediate leads to 
the formation of several isoprostanes and isoketals. Figure 30 illustrates the mechanism 
proposed by Zagorski and Salomon for the rearrangement of PGH2 to isoketals.100 
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Figure 29. Proposed mechanisms for the formation of HPNE from the non-enzymatic 
oxidation of 13(S)- and 9(S)-HPODE.93 
 
 
 
 
Figure 30. Proposed mechanism for the formation of isoketal from the non-enzymatic 
oxidation of arachidonic acid via the prostaglandin H2 intermediate.93 
 
 
 
Biological activity of lipid peroxidation products 
Not all lipid peroxidation products are biologically active; however, those species 
that are active extend their activity through two major pathways. The first pathway is 
exemplified by HETE isomers which serve as ligands for the constitutively expressed 
PPARγ receptor.101 In monocytes, PPARγ binding triggers signaling involved in 
differentiation and key regulatory functions. The second pathway results from extremely 
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reactive lipid peroxidation species that manifest activity through adduction to cellular 
nucleophiles. HNE is reactive with proteins, forming primarily Michael addition adducts 
with cysteine residues, and to a lesser extent, lysine and histidine residues. Under 
physiological conditions, the concentration of cysteine-derived sulfhydryl anions is 
relatively low, thus establishing the rate limiting step. HNE also forms hemiaminal 
adducts with lysine residues which dehydrate to form imines, although both of these 
reactions are reversible, rendering a majority of HNE in a free form (Figure 31). The 
kinetics of HNE’s reactivity with protein was examined by incubating synthetic HNE 
with a five molar excess of bovine serum albumin (BSA).102 Within 80 minutes, 50% of 
the free HNE was depleted demonstrating the potential for disrupted enzyme activity and 
cellular function. 
 
 
 
Figure 31. Scheme showing the formation of HNE adducts with protein nucleophiles. 
 
 
Compared to HNE, IsoK are extensively more reactive with protein.  Studies 
parallel to the HNE reactivity experiment described above examined IsoK reactivity and 
demonstrated that 50% of free IsoK remained only 20 s after initiating the reaction with 
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BSA.102  This rapid decline can be explained by essentially irreversible reactions which 
drive the reaction of free isoketals to an adducted form.103 These adducted forms include 
imine (Schiff base), pyrrole, lactam, and hydroxylactam adducts with lysine residues of 
proteins, as shown in Figure 32. 
 
 
Figure 32. Scheme showing the formation of isoketal adducts with lysine residues. 
Adapted from reference 103. 
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Impact of lipid peroxidation products on microbicidal burst 
Given the markedly different fates of BH and Hz within phagocytic cells, 
presumably due to lipid peroxidation products impairing ROS and RNS production,60, 68 
the effects of several constitutive components of Hz (i.e., BH, HNE, and 15-HETE) on 
microbicidal burst were examined.68 As illustrated in Figure 33, BH has no inhibitory 
activity toward the generation of ROS or RNS. These observations are consistent with 
studies involving cultured B10R, BV2 and N11 microglial cell lines and peritoneal 
macrophage cells which demonstrated that neither BH nor purified Hz impairs NOX or 
iNOS activities.104-106  
 
A                                                                  B 
        
Figure 33. Effect of BH on the production of microbicidal agents.68 Cells were treated 
and assayed as described in the experimental procedures. (A) ROS production was 
measured using the DCF-DA assay. (B) RNS was assessed using the Griess assay. 
Abbreviations: C, unstimulated cells; PMA, phorbol-12-myristate-13-acetate; BH, β-
hematin; LPS, lipopolysaccharide.  
 
 
In contrast to BH, both HNE and 15-HETE had a significant effect on 
microbicidal burst. As shown in Figure 34, PMA-stimulated RAW 264.7 cells treated 
with HNE demonstrated a concentration-dependent inhibition of NOX activity with an 
EC50 value of 45.9 μM; LPS-activated iNOS activity was even more sensitive to HNE 
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treatment with an EC50 value of 9.2 μM. 68 HNE has been shown to alter the activity of 
protein kinase C, a key signaling protein required for NOX activation in monocyte-
derived macrophages107 and likely explains decreased levels of O2·- in human neutrophils 
treated with HNE (EC50 27 μM).108 Notably, HNE was shown to form covalent adducts to 
PKC in RAW 264.7 culture (assessed by western blot) and with recombinant PKC βII 
protein in vitro (assessed by proteomic adduct mapping analysis), supporting a role for 
HNE in the inhibition of NOX activity through PKC inactivation.109 There is also 
precedence of HNE impairing iNOS activity in RAW 264.7 cells: serum-withdrawal, 
which activates cells via NFκB resulting in the production of NO, is unable to mediate 
NO production when cell are cultured in the presence of HNE.110  HNE has been shown 
to covalently adduct to IKK, inhibiting kinase activity74 which explains decreased levels 
of NO as a result of impaired NFκB signaling. 
 
A                                                                  B 
 
 
Figure 34. Effect of HNE on the production of microbicidal agents.68 Cells were treated 
and assayed as described in the experimental procedures. (A) ROS production was 
measured using the DCF-DA assay. (B) RNS was assessed using the Griess assay.  
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Human monocytes treated with 15-HETE exhibit markedly reduced levels of 
ROS, which approach basal levels by 15 μM.111 Consistent with this report, 15-HETE 
significantly impaired PMA-stimulated NOX activity in RAW 264.7 macrophage cells 
(EC50 8.0 μM) (Figure 35).68 Although iNOS activity was also affected by 15-HETE, 
inhibition was less substantial than it was with NOX. While 15-HETE clearly alters ROS 
and RNS production, albeit to vastly different levels, the specific mechanisms leading to 
inhibition remain unknown. PPARγ agonists have been shown to antagonize the activity 
of transcription factors NF-κB and AP-1, thereby inhibiting the expression of iNOS in 
murine macrophages.112 iNOS expression was also shown to be abrogated through a 
PPARγ-independent NF-κB inhibitory mechanism by 15-deoxy-prostaglandin J2, a 
PPARγ ligand. 113  Therefore, it is likely that 15-HETE exerts its activity by similar 
PPARγ-dependent and -independent inhibitory mechanisms. 
 
A                                                                  B 
 
Figure 35. Effect of 15-HETE on the production of microbicidal agents.68 Cells were 
treated and assayed as described in the experimental procedures. (A) ROS production 
was measured using the DCF-DA assay. (B) RNS was assessed using the Griess assay.  
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Given that both HNE and 15-HETE demonstrated the ability to modulate 
microbicidal burst, the effects of BH-mediated ghost membrane peroxidation on 
macrophage response were explored: BH was incubated with ghost cell membranes and 
activated cells were treated with various amounts of the reaction supernatant. NOX 
activity in PMA-stimulated RAW cells was inhibited in a concentration-dependent 
manner, as was the activation of iNOS in LPS-stimulated cells (Figure 36). Importantly, 
there was no detectable inhibition of ROS or RNS production upon treatment with BH or 
ghost supernatants alone. These results demonstrate that the inhibitory NOX and iNOS 
activities within RAW 264.7 cells are due to the products from the reaction between BH 
and ghosts, not the biomineral itself.  
 
A                                                                             B 
                
Figure 36.  Inhibitory effect of the products generated from the interaction of BH with 
ghost cells.68 Cells were treated and assayed as described in the experimental procedures. 
(A) Inhibition of ROS production was measured using luminol-enhanced 
chemiluminescence. (B) Inhibition of RNS was assessed using the Griess assay.  
 
 
 
 
 
 
 50
 Conclusions  
In light of the results discussed and the data presented thus far, the following 
sequence of events is proposed: First, synchronized erythrocyte rupture releases Hz into 
an environment filled with cellular debris. This setting provides substrate for non-
enzymatic Hz-catalyzed peroxidation which results in a gradient of primary and 
secondary lipid peroxidation products.32, 70, 78, 86 Next, particulate Hz (laden with 
biologically active lipid species) triggers a phagocytic response and serves as a vehicle to 
deliver toxic species into immune cells.61 Finally, immune cells are rendered functionally 
impaired, yet viable, resulting in propagation of the infection and immune response.60, 68, 
84, 107, 114  
In order to clarify the basis of Hz-mediated immunomodulation, it is necessary to 
understand the ways in which cellular functions are perturbed by individual components 
of Hz. Although an ineffective microbicidal burst illustrates that downstream signaling 
events can be modulated indirectly by the Hz moiety, the specific mechanisms and 
cellular targets responsible for the modulation remain unknown. Furthermore, the altered 
cellular responses represent but two of numerous possible modulations, prompting further 
exploration of global cellular changes in response to Hz and its components. 
Consequently, Chapter III focuses on the global impact of individual Hz components. 
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CHAPTER III 
 
ANALYSIS OF GENE EXPRESSION CHANGES MEDIATED BY INDIVIDUAL 
CONSTITUENTS OF HEMOZOIN 
 
 
Introduction 
It has been suggested that the immunological activity of hemozoin (Hz) does not 
stem from the heme moiety itself, but from toxins such as lipid peroxidation products 
present on the biomineral’s surface and introduced into the cell during phagocytosis. In 
Chapter II, the immunomodulatory response to native Hz was recapitulated using 
constitutive components of Hz in a model system.68 Macrophage-like cells treated with 
the reaction supernatant resulted in a dose-dependent impairment of PMA-activated NOX 
and LPS-stimulated iNOS activities. Neither BH- nor ghost-supernatant alone altered 
NOX or iNOS activity, indicating that lipid peroxidation products generated during 
reactions between BH and ghost membranes are responsible for the inhibitory effects. 
Furthermore, biologically relevant levels of the individual lipid peroxidation products 
HNE and 15-HETE mimicked the dysfunctional response to hemozoin phagocytosis, 
suggesting the basis of Hz activity.68, 114, 115  
Hz toxicity in monocytes is associated with high levels of HNE and 15-HETE.32, 
70 HNE is highly reactive with nucleophilic sites in biomolecules and is capable of 
forming covalent adducts and crosslinks, impairing enzymatic activity, and triggering 
changes in gene expression.8, 72-77 15-HETE mediates its biological activity upon binding 
the nuclear PPARγ receptor and has been reported to augment RBC adherence to 
endothelia, enhance vascular permeability and edema, and increase chemotaxis and 
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chemokinesis, three hallmarks of malarial infection. 32, 61, 101, 116, 117 In light of these 
findings, the responses of innate immune cells to specific and nonspecific malaria toxins 
were of particular interest.  
Global effects of the individual components of Hz remain largely unexplored in 
the context of malaria; therefore, microarray technology was used to explore gene 
expression changes in activated RAW 264.7 macrophage-like cells exposed to constituent 
components of native Hz. Chapter III is divided into two parts: expression changes 
mediated by HNE and BH are presented in Part I, and expression changes mediated by 
15-HETE are presented in Part II.  Gene expression patterns were analyzed in the context 
of biological processes and networks to examine the downstream effects of both specific 
and non-specific damage, and comparisons were made with cellular alterations that are 
observed during malarial infection. 
 
Experimental 
 
Cell culture 
Murine macrophage-like RAW 264.7 cells (American Type Culture Collection 
TIB-71, Manassas, VA) were cultured under standard incubation conditions (37 ºC, 5% 
CO2) and grown in RPMI supplemented with 5% FBS (Atlanta Biologicals, Atlanta, GA) 
and 1 μg/mL P/S (Cellgro MediaTech, Herndon, VA). Cells were plated at a density of 4 
× 106 cells/well in 6 well plates and incubated for 24 h prior to treatment.  
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Cell treatment 
Cells were washed once with Dulbecco’s PBS (DPBS) and treated with 35 μM 
HNE (EMD Biosciences, San Diego, CA), 0.1 mg/mL serum-opsonized BH, 10 μL of 
0.05% serum-opsonized latex bead (0.1μm), or 40 μM 15(S)-HETE (Cayman Chemicals) 
per 1 × 106 cells. Opsonization was performed as previously described.84 Immediately 
following treatment, LPS was added to all wells at a final concentration of 1 μg/mL. 
After either 6 or 24 h incubation, cells were washed three times with DPBS and either 
scraped from wells for RNA extraction or incubated for 15 minutes at 37 ºC in 
CellStripper non-enzymatic cell dissociation buffer (Cellgro MediaTech) for flow 
cytometric analysis. 
 
Flow cytometry 
Adherent cells (4 × 106/well) were dissociated by a 5-15 minute incubation at 37 
ºC with 500 μL CellStripper; cell suspensions were pipetted up and down to release the 
remaining loosely adhered cells and transferred to round bottom flow cytometry tubes 
(Falcon). Complete culture media (1000 mL) was added to the suspensions to quench the 
dissociation buffer. Samples were centrifuged at 1500 RPM for 5 min, media was 
removed, and cells were washed with PBS. Assays were performed on a BD LSRII Flow 
Cytometer. Cell death was determined by the Vybrant Apoptosis Assay Kit II 
(Invitrogen) according to the manufacturer’s instructions. Briefly, cells were harvested, 
resuspended in assay buffer, and stained with Alexa Fluor 488 conjugated Annexin V and 
propidium iodide (PI). An apoptosis positive control was prepared by treating cells with 
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10 μM camptothecin (Sigma) for 4 h prior to staining. Single color stains were used as 
compensation controls, and at least 10 000 events per sample were collected for the 
determination of cell populations using FACSDiva v6.1-1 software. Sample analysis was 
performed using FloJo v8.8.2 software (Treestar). 
 
RNA isolation and microarray analysis 
Three biological replicates (composed of six pooled wells) per sample were 
treated as described above. Total RNA was isolated using the Versagene RNA 
purification and DNase treatment kits, following manufacturer’s recommendations. 
Microarray analysis was performed by the Vanderbilt Microarray Shared Resource. 
Three biological replicates of each treatment were analyzed for quality (Agilent 2100 
Bioanalyzer, Agilent Technologies, Palo Alto, CA). One (1) μg of Total RNA (30ng 
mRNA) was used to generate First Strand cDNA using the NanoAmp RT-IVT labeling 
kit according to manufacturer’s protocol. Following first strand synthesis,second strand 
synthesis was completed.  The resulting cDNA was then purified using an ABI kit 
provided column and the entire reaction was used in an IVT reaction to generate cRNA 
or DIG labeled cRNA.  The cRNA was then purified using a kit provided column, 
assessed for quality on an Agilent Bioanalyzer, and reverse transcribed to make ss cDNA. 
Samples prepared from 6 h incubations were fragmented, labeled with terminal deoxy 
transferase with biotin, hybridized to an Affymetrix mouse gene 1.0ST arrays per 
manufacturer’s protocol, and detected with Streptavidin-Phycoerythrin. Samples obtained 
from 24 h incubations were fragmented, hybridized to an ABI mouse genome survey 
microarray per manufacturer’s protocol, and detected with the addition of the 
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chemiluminescence reaction substrate. Expression values were quantile normalized and 
filtered (S/N >3 and flag value <5000, ABI arrays). Partek 6.4 and GeneSpring GX 7.3.1 
software were used to determine statistically significant differentially expressed genes 
from probes altered by ≤ or ≥ 1.8-fold (0.01 p-value cutoff, Benjamini-Hochberg multiple 
testing correction) in treated stimulated cells (experimental) relative to stimulated cells 
(control). Genes were classified according to genes ontology (GO) terms using the web-
based tool, FatiGO v2.0 (http://www.babelomics.org).118 In accordance with MIAME 
procedure, microarray data have been submitted to the NCBI Gene Expression Omnibus 
and can be found under series GSE13281 and GSE15070.  
 
Pathway and network analysis 
Ingenuity Pathways Analysis (IPA) was used for gene expression analysis 
(Ingenuity Systems®, www.ingenuity.com). A dataset containing gene identifiers and 
expression values was uploaded into the application.  Each identifier was mapped to its 
corresponding gene object in the Ingenuity knowledge base (IKB).  These focus genes 
were overlaid onto a global molecular network developed from information contained in 
the IKB, and networks were algorithmically generated based on their connectivity. The 
Functional Analysis of each network identified the biological functions that were most 
significant to the genes in the network and Canonical Pathway Analysis identified the 
pathways from the IPA library of canonical pathways that were most significant to the 
dataset.  Fischer’s exact test was used to calculate a p-value determining the probability 
that that each biological function assigned to a network or the association between the 
genes in the dataset and the canonical pathway are explained by chance alone. 
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Real-time reverse transcription polymerase chain reaction  
Quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) 
was used to validate the expression levels of several genes identified as differentially 
expressed by microarray analysis. Quadruplicate measurements for n = 3 biological 
replicates per sample were performed. cDNA was reverse-transcribed from 0.5 μg of total 
RNA using random hexamer primers and Superscript II Reverse Transcriptase 
(Invitrogen). Reactions were purified using Qiagen’s PCR Purification Kit following the 
manufacturer’s protocol. Following RT, all assays were performed with Applied 
Biosystems TaqMan FAM labeled 20× probes. Ywhaz was chosen as the endogenous 
control based on results obtained from an Applied Biosystems mouse endogenous control 
array. cDNA amplification was performed using  TaqMan 2× Universal PCR Master Mix 
(Applied Biosystems) according to the manufacturer’s directions.  Standard Taqman 
cycling conditions were used as specified by the manufacturer.  Cycling and data 
collection were performed using the Applied Biosystems 7900 HT instrument and 
analysis performed using the manufacturer’s SDS software package to calculate Ct values 
for each detector. Ct values were processed based on the comparative Ct method, where 
the relative transcript level of each target gene was calculated according to the equation 
2–ΔCt, where ΔCt is defined as Cttarget gene – CtYwhaz. 
 
Enzyme-linked immunosorbant assays  
Enzyme-linked immunosorbant assays (ELISAs) were used to measure the levels 
of soluble proteins secreted into culture medium. RAW 264.7 cells (4 × 106 cells/well in 
6 well plates) were plated and incubated for 24 h. The cells were washed once with 
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DPBS and treated in triplicate with LPS (1 μg/mL) or HNE (35 μM) + LPS (1 μg/mL 
final). Cell culture medium was collected and analyzed using commercial ELISA 
reagents (R&D Systems) according to protocol using 96-well Immulon 2HB plates 
(Thermo Electron Corp.). Briefly, capture antibody was added to wells and incubated at 
25 ºC overnight. Three washes (300 μL each) were performed after this and all 
subsequent steps using phosphate buffered saline (PBS) supplemented with 0.05% 
Tween-20. Wells were blocked with 300 μL of 5% Fraction V bovine serum albumin 
(Fisher Scientific) in PBS for 1 h at 37 ºC. Three-fold serial dilutions of collected culture 
medium (1:1–1:2187) in complete medium and two-fold dilutions of recombinant protein 
in complete medium were added to wells and incubated for 1 h at 37 ºC. Wells were 
incubated with the appropriate biotinylated detection antibody for 1 h at 37 ºC and 
subsequently incubated with streptavidin-HRP for 10 min at 37 ºC. After addition of 
3,3',5,5',-tetramethylbenzidine liquid substrate (100 μL, Sigma Aldrich), the enzymatic 
reaction was quenched with 50 μL of 2M H2SO4. The absorbance of samples was then 
measured spectrophotometrically at 450 nm. Culture medium and recombinant protein 
were used as negative and positive controls, respectively. 
 
Nomenclature 
Nomenclature for genes and proteins is as described by the Mouse Genome 
Informatics (MGI) database guidelines: both murine and human protein names are 
capitalized (MMP9), murine genes are italicized with the first letter capitalized (e.g., 
Mmp9), and human genes are italicized and capitalized (e.g., MMP9). 
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Results and Discussion 
 
Part I: Comparative Analysis of the Gene Expression Response to HNE, BH, and 
Latex Beads  
 
The immunomodulation observed during Plasmodium blood stage infection is 
believed to be a result of the host response to parasite products. Although genome-wide 
expression analyses has been examined in the blood of human victims,119, 120 malaria 
positive tissue,121 and murine122-124 and monkey125 malaria models, the specific 
components responsible for altered expression have not been identified. Given the 
relationship between high levels of Hz, severity of infection, and disruption of 
macrophage function, the present study used microarray technology to profile expression 
changes mediated by Hz-derived components in a model macrophage-like cell line 
(RAW 264.7 cells). Given the unquestionable reactivity of HNE and ability of the heme 
moiety to mediate lipid peroxidation, HNE and BH were targeted as the native Hz 
components 
 
 
Analysis of gene expression changes in BH- or HNE-treated, LPS-stimulated RAW 
264.7 cells 
 
LPS stimulated macrophage-like RAW 264.7 cells were exposed to 0.1 mg/mL 
BH or 35 μM HNE for 6 or 24 h. The concentrations of BH and HNE were chosen based 
on reported estimates of Hz (100 μM) in brain capillaries of malaria victims 126 and HNE 
(40 μM) levels in Hz-fed monocytes.70 Phagocytosis of opsonized-latex beads and -BH 
was examined by flow cytometry. Latex bead fluorescence (Figure 37) was detected in 
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86% and 99% of the gated parent population at 6 and 24 h, respectively, demonstrating 
the level of phagocytosis.  
A B
 
 
Figure 37. Latex bead phagocytosis. LPS (0.1 μg/mL) stimulated RAW 264.7 cells were 
treated with serum-opsonized fluorescent red latex beads for (A) 6 h or (B) 24 h and 
analyzed by flow cytometry. Untreated control cell populations (blue tinted) were 
overlaid with the latex bead treated cell population (orange tinted) to demonstrate the 
increase in fluorescence upon phagocytosis.44 
 
 
 Accumulation of Hz within monocytes has been shown to considerably increase 
both depolarized and conventional side scatter.127 In BH treated cells, phagocytosis of the 
total population was indicated by a marked increase in conventional side scatter mean 
fluorescence versus control cells (Figure 38). It was previously shown by confocal 
microscopy that opsonized BH was ingested by RAW 264.7 cells and localized within the 
phagolysosome.68  
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Figure 38. BH phagocytosis. LPS (0.1 μg/mL) stimulated RAW 264.7 cells were (A) 
untreated or treated with 0.1 mg/mL serum-opsonized BH for (B) 6 h or (C) 24 h and 
analyzed by flow cytometry. Consistent with phagocytosis of the biomineral, density 
plots demonstrate that BH treatment markedly increased the side scatter of the total 
population at both timepoints.44 
 
 
HNE induces cytotoxic and mutagenic effects in several cell types, albeit at 
differing concentrations.71 It has been established that the concentration of exogenous 
HNE necessary to elicit a cellular response can be orders of magnitude higher than an 
endogenous steady state level.128 Therefore, the cytotoxicity profiles of HNE in RAW 
264.7 cells were evaluated by flow cytometry. LPS-stimulated cells were treated with 
varying concentrations of HNE for 24 h and changes in viable, apoptotic, and dead cell 
populations were measured. Figure 39 (A and B) illustrates the analysis of stimulated 
cells treated 35 μM HNE.  The percent of viable cells at increasing concentrations of 
HNE (0-35 μM) for 24 h was calculated and is shown in Figure 39 (C). Results 
demonstrate that concentrations of HNE up to 35 μM are well tolerated by RAW 264.7 
cells.  
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Statistically significant (p ≤ 0.01) gene expression changes (fold change ≥1.8 relative to 
control), where expression is considered a measurement of the RNA abundance at the 
time of isolation, were identified by microarray analysis. Within each treatment category, 
 
Figure 39. Viability of HNE-treated cells. LPS (0.1 μg/mL) stimulated RAW 264.7 cells 
were (A) untreated or (B) treated with 35 μM HNE for 24 h and stained with apoptosis 
and necrosis-specific stains. Three populations were observed by flow cytometric 
analysis: viable cells, apoptotic cells, and necrotic cells. Viable cells are negative for both 
Alexa Fluor 488 conjugated annexin V and PI, apoptotic cells are positive for Alexa 
Fluor 488 conjugated annexin V, and necrotic cells are positive for PI. (C) Viable cells 
within total cell populations treated with HNE (0-35 μM) for 24 h were determined.   
 
 
 62
differentially expressed genes were sorted into lists based on the direction of regulation 
and compared to identify common changes relative to untreated stimulated cells (Figure 
40, A-D). In order to identify expression changes dependent on interactions of BH rather 
than those due to phagocytosis, differentially expressed genes were controlled by a  
 
Figure 40. Overlapping genes with significant differential expression mediated by BH 
and HNE. Venn diagrams show the intersection of genes that were altered by 0.1 mg/mL 
BH with those altered by either latex bead or 35 μM HNE treatment. Numbers represent 
statistically significant (p ≤ 0.01) genes up- or down-regulated ≥1.8-fold relative to LPS 
stimulated cells at 24 h. (A) down-regulated genes identified at 6 h, (B) up-regulated 
genes identified at 6 h, (C) down-regulated genes identified at 24 h, (D) up-regulated 
genes identified at 24 h.44 
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corresponding particulate latex bead challenge. Six hours post-challenge, there were no 
significant gene expression changes mediated by latex bead phagocytosis, and only a 
small group (i.e., 39 genes) altered by BH phagocytosis. Steady-state mRNA levels (24 
h) demonstrate that nearly 70% of the genes differentially expressed by BH are in 
common with the ‘inert’ latex bead control, indicating that the response to BH is 
predominantly phagocytic. 
Consequently, phagocytosis-related genes were identified and disregarded for 
remaining analyses. The number of genes differentially expressed by HNE or BH 
treatment indicates the degree of perturbation by each of the native Hz-associated 
components. HNE treatment altered a significantly larger group of genes than BH 
treatment, suggesting a more serious impact on cellular function. 
Ingenuity Pathway Analysis (IPA) was used to perform a functional analysis of 
each dataset. IPA functional analysis ranks molecular and cellular functions according to 
Fischer’s Exact Test p-value. Those categories exhibiting p < 0.001 are shown in Table 1 
for both BH and HNE treatment datasets at 6 and 24 h timepoints. The magnitude of 
response to either BH or HNE treatment is evident from the number of significantly 
affected biological processes identified by IPA. At 6 h, both BH and HNE affect a 
diverse group of functions including ‘Cell Signaling’, ‘Cellular Development’, 
‘Molecular Transport’, and ‘Small Molecule Biochemistry’ among others. By 24 h, the 
cellular response to BH is minimal. Given that BH does not impair microbicidal 
functions, is sensitive to microbicidal agents, and is degraded upon phagocytosis in RAW 
264.7 cells,68 it was not surprising to find that the steady-state response to BH was 
modest. The degree of perturbation by HNE at 24 h complements literature observations 
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regarding its extensive reactivity with cellular nucleophiles.8, 72-77 Expression changes 
mediated by BH and HNE indicate differential cellular responses to both treatments as a 
function of time. There is, however, some overlap in the early and late response to HNE, 
primarily associated with ‘Stress Response’, ‘Cell Cycle’, ‘Immune Response’, 
‘Metabolic Process’, and ‘Gene Expression’ (listed within Table 2).   
 
Functional analysis of interaction networks 
Biological interaction networks were generated by mapping differentially 
expressed genes unique to HNE and BH treatment to the molecules in the Ingenuity 
knowledge database (IKB) based on known interactions in the canonical literature. Each 
network is associated with a numerical value, a ‘score’, to indicate the likelihood that the 
focus genes occur in the network by random chance. Networks scoring 10 or higher 
(score is defined as –log (p-value)) are considered significant.  
Among the 39 genes modulated by BH phagocytosis at 6 h, 27 were eligible for 
analysis based on IPA criteria, mapping to 2 relevant interaction networks. The most 
significant network (Figure 41 A) has a score of 25 and associates 11 focus genes 
involved predominantly with ‘Carbohydrate Metabolism’ (p = 3.76 × 10-3), ‘Gene 
Expression’ (p = 5.93 × 10-3), and ‘Small Molecule Biochemistry’ (p = 5.98 × 10-3). 
Interestingly, the network predicted interactions with several transcriptional regulators 
(Hnf4a, Jdp2, Jun, Mafk, Fos, and Elk3). Gene expression alterations of 113 IPA network 
eligible genes were mediated by BH treatment at 24 h, mapping to eight significant  
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Table 1. Functional analysis of BH and HNE datasetsa 
p-valuea Biological Function BH HNE 
 6 h 24 h 6 h 24 h 
Amino Acid Metabolism   < 10-4 2.03 × 10-4 
Carbohydrate Metabolism 5.54 × 10-4    
Cell Cycle 5.54 × 10-4 7.24 ×10-4 < 10-4 < 10-4 
Cell Death 2.41 × 10-4  < 10-4 < 10-4 
Cell Morphology  7.10 × 10-4 < 10-4 < 10-4 
Cell Signaling 5.61 × 10-4  < 10-4  
Cell-To-Cell Signaling and 
Interaction < 10
-4  < 10-4 < 10-4 
Cellular Assembly and 
Organization  1.61 × 10
-4 < 10-4 < 10-4 
Cellular Compromise   < 10-4  
Cellular Development 5.54 × 10-4  < 10-4 < 10-4 
Cellular Function and 
Maintenance 2.84 × 10
-4  < 10-4 < 10-4 
Cellular Growth and 
Proliferation   < 10
-4 < 10-4 
Cellular Movement   < 10-4 < 10-4 
DNA Replication, 
Recombination, and Repair   < 10
-4 < 10-4 
Free Radical Scavenging 5.54 × 10-4    
Gene Expression   < 10-4 < 10-4 
Lipid Metabolism 5.54 × 10-4    
Molecular Transport 5.54 × 10-4  < 10-4  
Post-Translational 
Modification  6.25 × 10
-4 < 10-4 < 10-4 
Small Molecule 
Biochemistry 5.54 × 10
-4  < 10-4 2.03 × 10-4 
Vitamin and Mineral 
Metabolism   < 10
-4  
a Ingenuity Pathway Analysis uses a right-tailed Fisher Exact Test to calculate p-values. 
Significance values for each dataset indicate the probability that the association between 
the genes and the given molecular and cellular functions are due to random chance.  
 
functional interaction networks. The network shown in Figure 41 B linked 13 focus genes 
with 22 additional molecules with a significance score of 21. Of the products encoded by 
these genes, 17 are localized in the nucleus and 9 are transcriptional regulators. This 
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particular network associates several genes that are involved in ‘Cell Cycle’ (p = 1.87 × 
10-4). Consistent with this function, the network predicted interactions with several cell 
division genes (Bhlbh2, Hdac2, Gas1 and Cdk4).  
HNE mediated 591 network eligible expression changes at 6 h which mapped to 
31 significant networks. The most significant interaction network (Figure 41 C) 
incorporates 31 focus genes with a score of 45, and is indicative of ‘Immunological 
Disease’ (p = 5.74 × 10-3). This network is enriched with focus genes encoding receptor 
molecules such as Cxcr4, Ccr1, Il4r, Il13ra1, and Fcgr1a (CD64), and cytokines Ccl4, 
Il1rn, Ccl7, and Il10. Analysis of the genes differentially expressed by HNE treatment at 
24 h resulted in 492 network eligible focus genes mapping to 28 significant networks. 
The interaction network shown in Figure 41 D incorporated 26 focus genes with 9 
additional genes by direct interactions with a score of 36, and is primarily related to  
‘Inflammatory Disease’ (p = 1.67 × 10-14), ‘Tissue Development’ (p = 1.36 × 10-13), and 
‘Cellular Growth and Proliferation’ (p = 3.40 × 10-12). The network contains 11 genes 
encoding products that are secreted into the extracellular space including cytokines 
(Cxcl3, Il6, and Tnf), growth factors (Igf1, Pdgfb, Tgfb1, and Vegfa), and peptidases (F10 
and Mmp9) among other molecules (Dcn and Timp1).    
 
HNE-mediated gene expression response 
Previously, gene expression changes in human ARPE-1976 and RKO human 
colorectal carcinoma cells77 dosed with HNE have been examined by microarray 
analysis. Albeit under different conditions than the current study (e.g., cell line, 
concentration of HNE, and presence of stimulant), several commonalities are apparent. 
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Figure 41. Ingenuity network analysis. Genes altered ≥1.8-fold (p ≤ 0.01) in either BH- or 
HNE-treated RAW 264.7 cells (i.e., focus genes) were overlaid onto a global molecular 
network developed from information contained in the Ingenuity knowledge base (IKB).  
Networks of these focus genes were then algorithmically generated based on their 
connectivity. Network showing direct interactions between focus genes altered by (A) 
BH treatment at 6 h, (B) BH treatment at 24 h, (C) HNE treatment at 6 h, and (D) HNE 
treatment at 24 h. Genes or gene products are represented as nodes, and the biological 
relationship between two nodes is represented as an edge (line).  The intensity of the node 
color indicates the degree of up- (red) or down- (green) regulation. 
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For example, exposure to 4 μM HNE for 4 h repressed the expression of genes whose 
products are involved in signal transduction, transcriptional regulation/DNA binding, 
xenobiotic metabolism/stress response, and cell cycle regulation.76 Comparison with the 
early response to HNE in the current study demonstrates consistent regulation of a group 
of identical genes including Ccna2, Cdc25a, Ccr1, Il18, Bcl2l1, Ier3, Id1, Top2a, Zfp36, 
and Lyn (Table 2). 
     Gene expression responses of RKO human colorectal carcinoma cells to either 
subcytotoxic (5 or 20 μM) or cytotoxic (60 μM) concentrations of HNE has also been 
examined.77 At 20 μM HNE, 6 h post-treatment, the primary observation was an 
antioxidant response. The present study mirrors several of the expression changes at 6 h, 
including stress response genes (Gclm, Hmox1, Dnajb4, Txnrd1) among others (Riok3, 
Hbp1, Zbtb20, Rit1, Arrdc3, Gabarapl1,Ccna2, Ccnf, Ccnb1, Cenpa, Fbxo5, Mki67, 
Plk1, Ier3, and Top2a) (Table 2).   
 
Validation of microarray results 
qRT-PCR was used to confirm several genes susceptible to differential regulation 
by HNE and BH at 6 h and 24 h (Table 3). Analysis was focused on selected genes 
implicated in the host response to malaria. The results shown in Figure 42 are expressed 
as fold change relative to untreated stimulated cells (control). At 6 h, RT-PCR confirmed 
that HNE repressed the expression of chemokine (C-C motif) ligand 2 (Ccl2), colony 
stimulating factor 3 (granulocyte) (Csf3), tissue inhibitor of metalloproteinase 1 (Timp1), 
matrix metalloproteinase 9 (Mmp9), Csf2, interleukin (Il) 1 alpha (Il1a) and 1 beta (Il1b), 
and BH down-regulated colony stimulating factor 2 (granulocyte-macrophage) (Csf2) 
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relative to untreated stimulated cells. At 24 h, HNE enhanced expression of Mmp9, 
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, epsilon 
(Nfkbie), inhibitor of kappaB kinase epsilon (Ikbke), tumor necrosis factor (Tnf), and 
Csf3. Concurrently, Timp1 and chemokine (C-C motif) ligand 5 (Ccl5) genes were 
repressed. RT-PCR analyses of BH-treated cells at 24 h confirmed Il1a stimulation and 
FBJ osteosarcoma oncogene (Fos) suppression. These results are consistent with the 
microarray data. ELISA studies showed that HNE treatment induced MMP9 and CSF3 
translation and release relative to stimulated, untreated cells (Figure 43). 
 
Table 2. Select Gene Expression Changes Mediated by HNEa 
Fold Change Gene 
Symbol 
Description 
6 h 24 h 
MGI 
Gene ID 
Cell Cycle 
Atm ataxia telangiectasia mutated homolog (human)  1.9 107202 
Atr Ataxia telangiectasia and rad3 related  3.8 108028 
Bub1 budding uninhibited by benzimidazoles 1 homolog (S. cerevisiae) -2.7  1100510 
Bub1b budding uninhibited by benzimidazoles 1 homolog, beta (S. cerevisiae) -2.8  1333889 
Ccna2 cyclin A2 -5.1  108069 
Ccnb1 cyclin B1 -5.2  88302 
Ccnd1 cyclin D1  1.9 88313 
Ccnf cyclin F  -4.1  102551 
Ccng2 cyclin G2 -2.9  1095734 
Ccr1 chemokine (C-C motif) receptor 1 -3.1  104618 
Cdc20 cell division cycle 20 homolog (S. cerevisiae) -2.3  1859866 
Cdc25a cell division cycle 25 homolog A (S. pombe) -1.9  103198 
Cdc25c cell division cycle 25 homolog C (S. pombe) -3.5  88350 
Cdk6 cyclin-dependent kinase 6  1.9 1277162 
Chek1 checkpoint kinase 1 homolog (S. pombe) -2.3  1202065 
Dbf4 DBF4 homolog (S. cerevisiae) -2.0  1351328 
E2f2 E2F transcription factor 2  2.0 1096341 
Fen1 flap structure specific endonuclease 1  2.5 102779 
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Table 2, continued. 
 
Gadd45a growth arrest and DNA-damage-inducible 45 
l h
 2.5 107799 
Mki67 antigen identified by monoclonal antibody Ki -4.0  106035 
Msh5 mutS homolog 5 (E. coli)  6.2 1329021 
Mutyh mutY homolog (E. coli)  3.1 1917853 
Mxd1 MAX dimerization protein 1 -4.7  96908 
Ndc80 NDC80 homolog, kinetochore complex component (S. cerevisia) -2.4  1914302 
Pa2g4 proliferation-associated 2G4  2.3 894684 
Pcna proliferating cell nuclear antigen  2.3 97503 
Plk1 polo-like kinase 1 (Drosophila) -8.6  97621 
Rad23a RAD23a homolog (S. cerevisiae)  2.2 105126 
Rad51 RAD51 homolog (S. cerevisiae)  16.3 97890 
Rbl1 retinoblastoma-like 1 (p107)  2.7 103300 
Riok3 RIO kinase 3 1.9  1914128 
Sass6 spindle assembly 6 homolog (C. elegans) -2.4 -4.6 1920026 
Suv39h1 suppressor of variegation 3-9 homolog 1 (Drosophila)  2.4 1099440 
Tgfb transforming growth factor, beta 1  2.0 98725 
Xaf1 XIAP associated factor 1 -2.1 -87.4 3772572 
Zwilch Zwilch, kinetochore associated, homolog (Drosophila) -2.3  1915264 
Cell Signaling 
Fcgr1a Fc fragment of IgG, high affinity Ia, receptor (CD64) -4.4 -13.6 95498 
Fcgr2b Fc fragment of IgG, low affinity IIb, receptor (CD32) -7.7 -2.9 95499 
Cellular Development 
Cd83 CD83 molecule -2.4 -2.4 1328316 
Ifi16 interferon, gamma-inducible protein 16 -4.1 -11.6 96429 
Irf7 interferon regulatory factor 7 -3.4 -51.3 1859212 
Mafb v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (avian) -4.4 -2.2 104555 
Dyserythropoiesis 
Ccl5 chemokine (C-C motif) ligand 5  -22.5 98262 
Traf3 Tnf receptor-associated factor 3  -2.3 108041 
Tsc22d3 TSC22 domain family, member 3  -3.6 1196284 
ECM degradation 
Mmp9 Matrix metalloproteinase 9 -4.0 5.3 97011 
Timp1 Tissue inhibitor of metalloproteinase 1 -8.5 -1748.4 98752 
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Table 2, continued. 
 
Gene Expression 
Axud1 AXIN1 up-regulated 1 -3.0 -1.8 2387989 
Batf2 basic leucine zipper transcription factor, ATF-
like 2
-1.8 -3.1 1921731 
Ddx58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 -2.4 -14.2 2442858 
Mx1 myxovirus (influenza virus) resistance 1, 
interferon-inducible protein p78 (mouse)
-7.9 -43.4 97243 
Pcgf5 polycomb group ring finger 5 -1.8 -2.1 1923505 
Phf11 PHD finger protein 11 -2.9 -13.7 1918441 
Sp100 SP100 nuclear antigen -2.8 -4.4 109561 
Glutathione Metabolism 
G6pd2 glucose-6-phosphate dehydrogenase 2 1.8 2.0 105977 
G6pdx glucose-6-phosphate dehydrogenase X-linked 2.1  105979 
Gclc glutamate-cysteine ligase, catalytic subunit 8.6  104990 
Gclm glutamate-cysteine ligase , modifier subunit 7.6  104995 
Gss glutathione synthetase 2.4  95852 
Gsta1 glutathione S-transferase, alpha 1 (Ya) 7.2 30.7 1095417 
Gstp1 glutathione S-transferase, pi 1 1.8  95865 
Idh1 isocitrate dehydrogenase 1 (NADP+), soluble 3.3  96413 
Pgd phosphogluconate dehydrogenase 2.4  97553 
Immune Response 
Adrb2 adrenergic, beta-2-, receptor, surface 4.1 2.2 87938 
C5r1 complement component 5, receptor 1  3.5 88232 
Casp4 caspase 4, apoptosis-related cysteine peptidase -2.2 -2.4 107700 
Ccl17 chemokine (C-C motif) ligand 17  3.1 1329039 
Ccl2 chemokine (C-C motif) ligand 2 -44.8  98259 
Ccl22 chemokine (C-C motif) ligand 22 -12.3  1306779 
Ccl4 chemokine (C-C motif) ligand 4 -2.1  98261 
Ccl6 chemokine (C-C motif) ligand 6 -3.1  98263 
Ccl7 chemokine (C-C motif) ligand 7 -22.6 -2.3 99512 
Ccr1 chemokine (C-C motif) receptor 1 -3.1  104618 
Cd14 CD14 antigen 2.2 88318
Cd300lf CD300 antigen like family member F -3.9  2442359 
Cd40 CD40 antigen -4.3  88336 
Cd44 CD44 antigen -2.6  88338 
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Table 2, continued. 
 
Cd86 CD86 antigen -1.8  101773 
Cenpa centromere protein A -2.3  88375 
Cfb complement factor B -7.4  105975 
Clec12a C-type lectin domain family 12, member a -1.9  3040968 
Clec2d C-type lectin domain family 2, member d -4.1  2135589 
Clec4n C-type lectin domain family 4, member n -2.4  1861231 
Clec5a C-type lectin domain family 5, member a -1.8  1345151 
Csf2 colony stimulating factor 2 (granulocyte-macrophage) -12.1  1339752 
Csf3 colony stimulating factor 3 (granulocyte) -18.2 18.0 1339751 
Cxcl1 chemokine (C-X-C motif) ligand 1  2.7 108068 
Cxcl14 chemokine (C-X-C motif) ligand 14 -2.7  1888514 
Cxcr4 chemokine (C-X-C motif) receptor 4 2.5  109563 
Dcn Decorin  -4.0 94872 
Ercc1 excision repair cross-complementing rodent repair deficient -1.8  95412 
F10 coagulation factor X  4.1 103107 
Fbxo5  F-box protein 5  -4.0  1914391 
Gbp1 Guanylate binding protein 1 -3.1 -16.8 95666 
Gbp3 guanylate nucleotide binding protein 3 -3.7  1926263 
Gbp5 guanylate nucleotide binding protein 5 -5.9  2429943 
H28 histocompatibility 28 -6.3  95975 
Hdc histidine decarboxylase -8.8 -3.1 96062 
Icam1 intercellular adhesion molecule 1 1.8 7.5 96392 
Igf1 insulin-like growth factor 1  2.1 96432 
Il10 Interleukin 10 -4.7  96537 
Il10ra Interleukin 10 receptor, alpha  3.7 96538 
Il13ra1 Interleukin 13 receptor, alpha 1 -3.4  105052 
Il18 Interleukin 18 -2.0  107936 
Il18rap interleukin 18 receptor accessory protein -2.8  1338888 
Il1a Interleukin 1 alpha -66.6  96542 
Il1b Interleukin 1 beta -32.7  96543 
Il1f6 Interleukin 1 family, member 6 -12.6  1859324 
Il1rl1 Interleukin 1 receptor-like 1 -3.6  98427 
Il1rn Interleukin 1 receptor antagonist -6.8  96547 
Il27 Interleukin 27 -6.4  2384409 
Il4ra Interleukin 4 receptor, alpha -2.9  105367 
Il6 Interleukin 6 -43.3 -11.2 96559 
Isg20 interferon stimulated exonuclease gene 20kDa -3.1 -7.6 1928895 
Ltb lymphotoxin B -1.9  104796 
Nlrc4 NLR family, CARD domain containing 4 2.3 2.7 3036243 
Oasl2 2'-5' oligoadenylate synthetase-like 2 -5.1  1344390 
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Table 2, continued. 
 
Pgdfb platelet derived growth factor, B polypeptide  3.2 97528 
Pla2g7 phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma) 3.1 10.7 1351327 
Pou2f2 POU domain, class 2, transcription factor 2 -1.9  101897 
Rsad2 radical S-adenosyl methionine domain containing 2 -4.4  1929628 
Tnf tumor necrosis factor  8.7 104798 
Traf3ip2 Traf3 interacting protein 2 -1.8  2143599 
Ube2L6 ubiquitin-conjugating enzyme E2L 6 -1.8 -2.3 1914500 
Vegfa vascular endothelial growth factor A  -2.4 103178 
Interferon-associated Signaling or Regulation 
H2-Bf histocompatibility 2, complement component factor B  -51.0 105975 
H2-DMb2 histocompatibility 2, class II, locus Mb2  -5.1 95923 
H2-Q1 histocompatibility 2, Q region locus 1  -3.2 95928 
H2-Q5 histocompatibility 2, Q region locus 5  -2.1 95934 
H2-T23 histocompatibility 2, T region locus 23  -9.4 95957 
H2-T9/H2-
T22 
histocompatibility 2, T region locus 
9;histocompatibility 2, T region locus 22  -5.2 95965 
Ifi202b interferon activated gene 202B -3.8  1347083 
Ifi203 interferon activated gene 203 -3.7  96428 
Ifi204 interferon activated gene 204 -3.7  96429 
Ifi205 interferon activated gene 205 -4.3  101847 
Ifi47 interferon gamma inducible protein 47 -3.0  99448 
Ifih1 interferon induced with helicase C domain 1 -2.0  1918836 
Ifit1 interferon-induced protein with tetratricopeptide repeats 1 -3.6  99450 
Ifit2 interferon-induced protein with tetratricopeptide repeats 2 -6.3  99449 
Ifit3 interferon-induced protein with tetratricopeptide repeats 3 -3.3  1101055 
Irf8 interferon regulatory factor 8 -2.6  96395 
Jak2 Janus kinase 2 -1.7  96629 
Mx2 myxovirus (influenza virus) resistance 2 -7.3  97244 
Oas1a 2'-5' oligoadenylate synthetase 1A -2.0  2180860 
Ptges prostaglandin E synthase  4.7 1927593 
Stat1 signal transducer and activator of transcription 1 -2.2 -10.8 103063 
Stat3 signal transducer and activator of transcription 3 -2.1  103038 
Stat5a signal transducer and activator of transcription 5A -2.1  103036 
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Table 2, continued. 
 
Metabolic Process 
Adh7 alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide 8.0 2.3 87926 
Hbp1 high mobility group box transcription factor 1 2.9  894659 
Mov10 Mov10, Moloney leukemia virus 10, homolog (mouse) -2.2 -2.5 97054 
Oas3 2'-5'-oligoadenylate synthetase 3, 100kDa -2.4 -8.3 2180850 
Parp12 poly (ADP-ribose) polymerase family, member 12 -2.1 -4.9 2143990 
Serpinb1b serine (or cysteine) peptidase inhibitor, clade B, member 1b 2.8 4.3 2445361 
Tiparp TCDD-inducible poly(ADP-ribose) polymerase -1.8 -2.9 2159210 
NF-kB signaling 
Ikbke inhibitor of kappaB kinase epsilon  3.2 1929612 
Nfkbia nuclear factor of kappa light chain gene enhancer in B-cells inhibitor, alpha  1.8 104741 
Nfkbie nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, epsilon  3.6 1194908 
Oxidative Stress Response 
Abcc1 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 2.1  102676 
Akr1a4 aldo-keto reductase family 1, member A4 (aldehyde reductase) 1.8  1929955 
Aox1 aldehyde oxidase 1 2.2  88035 
Cat Catalase 3.1  88271 
Dnajb4 DnaJ (Hsp40) homolog, subfamily B, member 4 5.3  1914285 
Ephx1 epoxide hydrolase 1, microsomal 2.0 3.2 95405 
Hmox1 heme oxygenase (decycling) 1 6.0  96163 
Mapk14 mitogen-activated protein kinase 14 2.0  1346865 
Pik3cb phosphatidylinositol 3-kinase, catalytic, beta polypeptide 2.3  1922019 
Prdx1 peroxiredoxin 1 2.9 3.1 99523 
Raf1 v-raf-leukemia viral oncogene 1 2.2  97847 
Sod2 superoxide dismutase 2, mitochondrial  1.7 98352 
Sqstm1 sequestosome 1 3.1  107931 
Txnrd1 thioredoxin reductase 1 2.1  1354175 
Xdh xanthine dehydrogenase 2.0  98973 
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Table 2, continued. 
 
Signal Transduction 
Fcrl1 Fc receptor-like 1 3.5 3.9 2442862 
Lyn Yamaguchi sarcoma viral (v-yes-1) oncogene 
homolog
-1.9  96892 
Rasgrp3 RAS guanyl releasing protein 3 (calcium and 
DAG-regulated)
3.9 4.4 3028579 
Rit1 Ras-like without CAAX 1 2.1  108053 
Small Molecule Biochemistry 
Cp ceruloplasmin (ferroxidase) -7.7 -6.0 88476 
Slc7A2 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 -5.2 -5.2 99828 
Cell Structure 
Gsn Gelsolin  2.5 95851 
Stmn1 stathmin 1  10.8 96739 
Tuba4 tubulin, alpha 4  2.5 1095410 
Ubiquitin-Proteasome Pathway 
Fbxl17 F-box and leucine-rich repeat protein 17 1.8  1354704 
Fbxl20 F-box and leucine-rich repeat protein 20 2.1  1919444 
Fbxo22 F-box only protein 22  3.0 1926014 
Fbxo30 F-box protein 30 2.0  1919115 
Fbxo31 F-box protein 31 1.8  1354708 
Herc3 hect domain and RLD 3 2.3  1921248 
Map1lc3b microtubule-associated protein 1 light chain 3 beta 2.0  1914693 
Psmc3ip proteasome (prosome, macropain) 26S subunit, ATPase 3, interacting protein  6.4 1098610 
Psmd12 proteasome (prosome, macropain) 26S subunit, non-ATPase, 12  2.0 1914247 
Rnf128 ring finger protein 128 4.2  1914139 
Rnf167 ring finger protein 167 1.9  1917760 
Ube2d3 ubiquitin-conjugating enzyme E2D 3 (UBC4/5 homolog, yeast)  2.4 1913355 
Ube2i ubiquitin-conjugating enzyme E2I  3.0 107365 
Ube2t ubiquitin-conjugating  7.1 1914446 
Ube4b ubiquitination factor E4B, UFD2 homolog (S. cerevisiae) 1.8  1927086 
Uchl1 ubiquitin carboxy-terminal hydrolase L1  4.4 103149 
Usp18 ubiquitin specific protease 18  -224.6 1344364 
Other 
Arrdc3 arrestin domain containing 3 7.0  2145242 
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Table 2, continued. 
 
Bcl2l11 BCL2-like 11 (apoptosis facilitator) 2.0  1197519 
Epsti1 epithelial stromal interaction 1 (breast) -2.1 -10.6 1915168 
Gabarapl1 gamma-aminobutyric acid (GABA(A)) receptor-associated protein-like 1 2.8  1914980 
Id1 inhibitor of DNA binding 1  -2.0  96396 
Ier3 immediate early response 3 -2.0  104814 
Ifi203 interferon activated gene 203 -3.7 -5.2 96428 
Klhl6 Kelch-like 6 (Drosophila) -1.9 -3.8 2686922 
Map1d methionine aminopeptidase 1D 1.8 1.9 1913809 
Ms4A6D membrane-spanning 4-domains, subfamily A, member 6D -2.3 -3.9 1916024 
Top2a topoisomerase (DNA) II alpha 13.2  98790 
Trim30 tripartite motif-containing 30 -7.2 -31.8 98178 
Uvrag UV radiation resistance associated gene -1.9 -1.8 1925860 
Zak sterile alpha motif and leucine zipper containing kinase AZK -1.9 -4.0 2443258 
Zbp1 Z-DNA binding protein 1 -5.7 -69.4 1927449 
Zbtb20 zinc finger and BTB domain containing 20 3.6  1929213 
Zfp36 zinc finger protein 36 -1.9  99180 
a Genes altered ≥1.8-fold (p ≤ 0.01) up or down in LPS stimulated HNE-treated cells 
relative to LPS stimulated cells. Fold changes (FC) represent the average of three 
independent biological experiments. 
 
 
Table 3. Taqman Gene Expression Assays Used for Quantitative Real-Time RT-PCR 
 
Treatment Gene Assay ID Amplicon length 
6 h BH, 6 h HNE Csf2 Mm00438328_m1 71 
6 h HNE Ccl2 Mm00441242_m1 74 
6 h HNE Il1b Mm00434228_m1 90 
6 h HNE, 24 h BH Il1a Mm00439620_m1 68 
6 h, 24 h HNE Mmp9 Mm00442991_m1 76 
6 h, 24 h HNE Timp1 Mm00441818_m1 90 
6 h, 24 h HNE Csf3 Mm00438334_m1 106 
24 h HNE Ccl5 Mm01302428_m1 71 
24 h HNE Tnf Mm00443258_m1 81 
24 h HNE Nfkbie Mm00500796_m1 78 
24 h HNE Ikbke Mm00444862_m1 66 
24 h BH Fos Mm00487425_m1 59 
a Each assay consists of two unlabeled PCR primers and a FAM dye-
labeled TaqMan MGB (minor groove binder) probe. 
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Figure 42. Quantitative real-time RT-PCR validation of microarray results. RAW 264.7 
cells were stimulated with 0.1 μg/mL LPS and untreated or treated with (A) 35 μM HNE 
for 6 h, (B) 0.1 mg/mL BH for 6 h, (C) 35 μM HNE for 24 h, or (D) 0.1 mg/mL BH for 
24 h. White bars represent vsalues determined by microarray experiments for 
comparison. Black bars represent fold-changes assessed by qRT-PCR (treated, stimulated 
cells relative to stimulated controls) ( X  ± 99% confidence interval for quadruplicate 
measurements of n = 3 biological replicates). Abbreviations: chemokine (C-C motif) 
ligand (Ccl); colony stimulating factor (Csf); tissue inhibitor of metalloproteinase 1 
(Timp1); matrix metalloproteinase 9 (Mmp9); interleukin 1 (Il1); tumor necrosis factor 
(Tnf); nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, 
epsilon (Nfkbie); inhibitor of kappaB kinase, epsilon (Ikbke); and FBJ osteosarcoma 
oncogene (Fos).44 
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Figure 43. ELISA validation of microarray results. Equivalent numbers of cells (4 × 
106/well) were stimulated with LPS (1 µg/mL) in the absence or presence of 35 μM HNE 
for 24 h. CSF3 (colony stimulating factor 3 [granulocyte]) and MMP-9 (matrix 
metalloproteinase 9) released into the culture medium were analyzed by ELISA. Fold 
changes (HNE-treated stimulated cells relative to stimulated controls) are shown ( X  ± 
SD for triplicate measurements, representative of three independent experiments).44 
 
 
Differential gene expression in the context of malaria pathogenesis 
Microarray data from this study were compared to two groups of genes. The first 
group consists of specific genes or gene products that are associated with human120, 121 or 
murine122, 124 models of malarial infection, and/or BH or Hz85, 129 exposure. The second 
group includes genes that are classified with specific biological processes that are over-
expressed in a murine P. yoelii model 124 and/or naturally-acquired P. falciparum 
infections119 (e.g., cell-cell signaling, defense response, immune response, inflammatory 
response, and signal transduction, among others). Complete lists of differentially 
expressed genes altered by either HNE or BH treatment that fall within these categories 
are listed in Appendix A.  
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Stress response 
Regulation of antioxidant response element (ARE) gene expression is controlled 
by the transcription factor NRF2, whose activity is suppressed through the formation of a 
complex with its inhibitor Keap1. Disruption of NRF2/Keap1 complex liberates NRF2, 
allowing its nuclear translocation and subsequent transactivation of ARE-dependent gene 
expression. Consistent with previous findings in a variety of cell types,71, 77 a potent 
“oxidative stress response mediated by Nrf2” was observed at both 6 h and 24 h 
following HNE treatment, suggesting an effort to reduce cellular damage (Table 2). 
Expression of genes encoding phase I and II metabolizing enzymes and antioxidant 
response proteins was significantly enhanced by HNE. Activation of a stress response is 
consistent with an increase of Prdx1 in the spleens of P. berghei infected mice122 and 
Sod2 and Hmox1 in both the blood of acute pediatric malaria victims120 and Hz-loaded 
placental tissue.121 A common stress response is heme oxygenase (decycling) 1 (Hmox1) 
induction. In the current study Hmox1 expression is induced by both HNE and BH at 6 h. 
This observation is in agreement with up-regulated Hmox1 expression in mouse 
peritoneal macrophages (PM) treated with BH.105  
 
Cell cycle checkpoint signaling 
The present data indicate a broad ‘DNA replication, Recombination, and Repair’ 
response to HNE at 6 and 24 h. Early expression of several genes associated with 
checkpoint control is repressed. By 24 h, however, a dramatic DNA damage response 
including the induction of a number of genes associated with G1/S cell cycle checkpoint 
regulation was observed (Figure 44 and Table 2). Since HNE can form adducts with 
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deoxyguanosine residues,130 activation of cell cycle checkpoint signaling genes suggests 
an effort to ameliorate DNA injury. The presence of damaged DNA is consistent with 
enhanced expression of excision repair (Fen1, Rad23a, Rad51, and Gadd45a), and 
mismatch repair (Msh5, Pcna, and Mutyh) genes at 24 h. Notably, increased ATM and 
RAD23A expression has also been identified in whole blood of P. falciparum infected 
children.120 
 
 
 
Figure 44. Ingenuity canonical pathway analysis. Differentially expressed genes were 
mapped to the Ingenuity Canonical Pathway library to identify significantly altered 
canonical signaling pathways. ‘IL-10 Signaling’ was influenced by 35 μM HNE at 6 h. 
Genes or gene products are represented as nodes and the intensity of the node color 
indicates the degree of up- (red) or down- (green) regulation.44 
 
Ubiquitin-proteasome pathway 
In addition to its reactivity with DNA, HNE readily modifies proteins through 
adduction to cysteine, histidine, and lysine residues.72 In some cases, these covalent 
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modifications have been shown to impair enzymatic activity.8, 73-75 One route for 
clearance of damaged or misfolded proteins is through the ubiquitin proteasome pathway, 
and proteosomal degradation of HNE-modified ubiquitinated alcohol dehydrogenase has 
been demonstrated.131 In the present study, HNE mediated the induction of several 
ubiquitin- and 26S proteasome-associated genes at 6 h and 24 h (Table 2). Furthermore, 
HNE mediated the repression of a deubiquitinating enzyme, Usp18, which is purported to 
remove ubiquitin adducts from a wide range of substrates. Taken together, these 
alterations indicate activation of the ubiquitin-proteasome pathway, which may represent 
an effort to degrade HNE-modified protein. 
 
Structural genes 
Several cytoskeleton organization and biogenesis genes were susceptible to 
induction by BH and HNE. Analysis of the steady-state expression changes showed that 
BH treatment led to the induction of Tuba4 and Pstpip2 (Table 4), and HNE up-regulated 
Gsn, Tuba4, and Stmn1 expression (Table 2). Although tubulin is up-regulated, stathmin 
has been shown to sequester tubulin and disrupt polymerization.83  Studies have shown 
tubulin-HNE adducts and disrupted microtubule organization in Neuro 2A cells,132 and 
HNE-mediated cytoskeletal alterations in both bovine lung microvascular endothelial133 
and P19 neuroglial cultures.134  In the context of malaria infection, GSN and PSTPIP2 are 
induced in the blood of pediatric malaria victims120 suggesting cellular cytoskeletal 
alterations. 
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Table 4. Select Gene Expression Changes Mediated by BHa 
Fold Change Gene 
Symbol Description 6 h 24 h 
MGI Gene 
ID 
Interferon-associated Signaling or Regulation 
H2-Ab1 histocompatibility 2, class II antigen A, beta 1  -1.8 103070 
H2-Q1 histocompatibility 2, Q region locus 1  -4.8 95928 
Immune Response 
Ccl2 chemokine (C-C motif) ligand 2  2.2 98259 
Ccl6 chemokine (C-C motif) ligand 6  5.4 98263 
Cd2 CD2 antigen  102.4 88320 
Csf2 
colony stimulating factor 2 (granulocyte-
macrophage) -12.1  1339752 
Cxcl2 chemokine (C-X-C motif) ligand 2  1.9 1340094 
Ereg Epiregulin  13.2 107508 
Fos FBJ osteosarcoma oncogene  -3.6 95574 
Il1a interleukin 1 alpha  6.0 96542 
Il20 interleukin 20  2.4 1890473 
Oxidative Stress Response 
Hmox1 heme oxygenase (decycling) 1 6.0  96163
Cell Structure 
Pstpip2 
proline-serine-threonine phosphatase 
interacting protein 2  6.1 1335088 
Tuba4  tubulin, alpha 4  1.9 1095410 
a Genes altered ≥1.8-fold (p ≤ 0.01) up or down in LPS stimulated BH-treated cells 
relative to LPS stimulated cells. Fold changes (FC) represent the average of three 
independent biological experiments. 
 
 
Macrophage activation 
An exacerbated inflammatory response is assumed to play a significant role in 
malaria pathogenesis. In an effort to uncover the basis of the inflammatory activity, Hz 
has been examined as a contributing agent. Previously, in vitro studies have shown that 
Hz phagocytosis reduces IL6 and stimulates TNFα,85 in concord with HNE treatment in 
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the current study. Both purified Hz and synthetic Hz (i.e., BH) led to the induction of 
Ccl3 (Mip1a), Ccl4 (Mip1b), and Tnf in murine macrophages and human peripheral 
mononuclear cells.129 Later work demonstrated that BH induced the expression and 
secretion of chemokines (MIP-1α, MIP-1β, MIP-2 (CXCL2), MCP-1 (CCL2), 
RANTES), chemokine receptors (CCR1, CCR2, CCR5, CXCR2, and CXCR4), cytokines 
(IL-1β and IL-6), and myeloid related proteins (S100A8, S100A9,and S100A8/A9) in 
vivo.40 This microarray analysis demonstrates that BH had a modest effect on the 
induction of immune response genes at 6 h and 24 (Table 4). HNE treatment, however, 
drastically repressed expression of immune/inflammatory response genes (Figure 45) and  
 
 
Figure 45. Ingenuity canonical pathway analysis. Differentially expressed genes were 
mapped to the Ingenuity Canonical Pathway library to identify significantly altered 
canonical signaling pathways. ‘Role of BRCA1 in DNA Damage Response’ was 
influenced by 35 μM HNE at 24 h. Genes or gene products are represented as nodes and 
the intensity of the node color indicates the degree of up- (red) or down- (green) 
regulation.44 
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interferon-signaling and -regulated genes at 6h. By 24 h, the response was reversed and 
the induction of a large group of immune/inflammatory response genes was identified 
(Table 2). Notably, this change in response over time may explain the often contradictory 
interpretation of Hz and immune cell interactions reported in the literature.33, 36, 40, 49, 85, 
135, 136 
A number of specific studies probing the inflammatory response to malaria are 
consistent with the observed HNE-mediated gene expression changes: murine kidneys 
infected with P. berghei parasites display increased expression of TNFα,137 and P. 
falciparum exposed CHO cells exhibit increased levels of TNFα, GCSF (CSF3), and 
TGFβ.138 Several individual expression changes also correspond with responses observed 
in microarray analyses of genuine or experimental malaria. For example, messages for 
LY96, CD14 and C5R1 in whole blood of pediatric victims 120 CD2, C5R1 and IL10RA in 
placental malaria,121  and Cd2 in a P. yoelii infected mice124 are consistent with enhanced 
expression by HNE in the current microarray analysis.  
Although HNE and BH augment the expression of genes involved in mounting an 
immune response, they repress the expression of a number of genes central to a cell’s 
antigen presenting ability (Tables 2 and 4). The present study identified significant (p < 
0.05) steady-state repression of antigen major histocompatibility complex (MHC) class 
II-associated genes in both HNE- and BH-treated cells (H2-Q1/H2-Q2). Likewise, HNE 
decreased expression of H2-T23, Cfb (H2-Bf), H2-DMb2, H2-Q5, and H2-T22/H2-T9, 
while BH down-regulated H2-Ab1 expression. Notably, Hz loading has been implicated 
as a factor contributing to both impaired monocyte MHC class II antigen presentation84 
and defective dendritic cell function.101, 139 The ability of HNE, and to a lesser extent BH, 
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to suppress MHC II expression implies two Hz components involved in the defective 
responses. Furthermore, elevated levels of TGF-β and PGE2 are associated with T-cell 
inhibition.140 HNE enhanced the expression of genes encoding Tgfb and Ptges and may 
contribute to the impaired T-cell activity observed upon Hz phagocytosis.  
 
NF-κB signal transduction 
The LPS mediated pathway to produce nitric oxide (NO) is well characterized and 
entails NF-κB signal transduction. In quiescent cells, NF-κB is sequestered by inhibitory 
proteins (IκB) in the cytoplasm. Upon activation, IκB kinase (IKK) phosphorylates IκB, 
triggering its polyubiquitination and subsequent degradation. Once NF-κB is liberated 
from IκB, NF-κB translocates to the nucleus and regulates gene expression, including 
iNOS.  
It has been shown that serum withdrawal in RAW 264.7 cells results in the 
activation of NF-κB, expression of iNOS, and synthesis of NO. However, serum 
withdrawal-mediated IκB phosphorylation and downstream signaling was abolished in 
HNE treated cells.110 In accord with this data, HNE prevented NO production in LPS-
stimulated RAW 264.7 cells.68 HNE has been shown to covalently adduct to IKK, 
inhibiting kinase activity thus preventing the phosphorylation of IκB.74 As a result, IκB 
degradation and NF-κB translocation are impaired.  
Unlike HNE, there are a wide range of observations regarding the effects of Hz 
and BH on iNOS activity and NO synthesis. For example, both BH and purified Hz do 
not inhibit IFNγ mediated NO in B10R murine macrophage cells.35 Similarly, RAW 
264.7 cells stimulated by LPS and loaded with BH exhibit normal NO levels.68 In 
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contrast, LPS-mediated NO production is reduced in BH treated murine PM.105 
Skorokhod et al. found that levels of NO are not impaired in several murine phagocytic 
cell lines after crude Hz or BH loading, but determined that human monocytes are unable 
to produce NO when stimulated with either LPS or IFNγ.141 Furthermore, native Hz 
decreases NO in LPS or IFNγ stimulated murine PM suggesting that a non-heme moiety 
component is responsible for the dysfunction.67 This varied group of results demonstrates 
the need for careful extrapolation of NO production data based on cell type, stimulatory 
molecule, and the state of the Hz preparation.  
In the present study, HNE, and not BH, had an impact on NF-κB related gene 
expression (Table 2). Early changes in expression indicate repression of the NF-κB 
pathway (down-regulated Cd40, Nfkb1, and Nfkbiz levels) by HNE. However, at 24 h, 
IKK (i.e., Ikbke) and IκB (Nfkbia, Nfkbie) expression is enhanced. Notably, transcript 
abundance does not necessarily correlate with protein level or kinase activity. In accord 
with the HNE studies mentioned above, IKK expression may be increased because the 
available enzyme is inactivated by HNE.  Due to the numerous gene expression 
modulations mediated by HNE, it seems probable that most are a result of downstream 
effects of HNE interactions. The increase of IKK expression, however, may be a direct 
response to dysregulated kinase activity.  
 
Extracellular matrix degradation 
A current hypothesis is that expression changes of ECM genes may have direct 
involvement in malaria pathogenesis, particularly in cases of cerebral malaria (CM). CM 
is a severe complication of P. falciparum infection that is characterized by adherence of 
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parasitized RBC to the cerebral microvasculature. Analysis of the brain vessels from CM 
mouse models reveals Hz accumulation not only within parasites, but also free and within 
phagocytic cells.142  Furthermore, examination of the cortex of post-mortem CM victims 
shows inflammation, swelling, and a slate-gray discoloration, commonly attributed to Hz 
deposition.143 Compelling evidence indicates that both systemic and local cytokine 
release contribute to the disease pathophysiology, particularly in the brain of CM victims. 
Blood brain barrier (BBB) destruction is a major factor associated with CM.144 Matrix 
metalloproteinases (MMPs), secreted enzymes involved in ECM remodeling, are able to 
degrade basal lamina leading to BBB damage.145 Interestingly, Hz increases the 
transcription, translation, and activity of MMP9 in monocytes.146 Activation of MMP9 is 
also observed during P. falciparum infection120 and may contribute to the disruption of 
endothelial basement membranes and extravasation of blood cells.146  
The activity of MMP9 is controlled by its cognate inhibitor, TIMP1. HNE 
exposure initially repressed Mmp9 expression; however, by 24 h the level of mRNA was 
significantly increased. Notably, both 6 h and steady-state mRNA levels of HNE treated 
samples indicate severely impaired Timp1 expression (–2000-fold at 24 h by qRT-PCR).  
Taken together, Mmp9 induction coupled with Timp1 repression indicates a steady state 
MMP9/TIMP1 imbalance that may lead to increased proteolysis of the ECM (Table 3).146  
Mmp9 expression can be regulated through a variety of signaling cascades including NF-
κB, p38 MAPK, and ERK1/2 pathways.147-149 Given that HNE abrogates NF-κB 
mediated iNOS expression in both LPS stimulated- and serum deprived-RAW 264.7 
cells,68, 110 Mmp9 up-regulation in the present study is not a result of NF-κB activation.  
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Active MMP9 is capable of pro-TNF-α cleavage which releases the active 
cytokine and promotes Mmp9 expression.150 Thus, the increased expression of Tnf 
discussed previously may enhance a positive feedback cycle in this study. Importantly, 
analyses of postmortem brain tissue of CM patients identified elevated TNF mRNA and 
protein,151 and immunostaining studies identified significant cerebrum, brainstem, and 
cerebellar localization.152 These observations, along with the up-regulation of several 
collagen genes involved in ECM repair during malaria infection,122 are consistent with 
the occurrence of ECM damage. 
CM patients possess several traits including obstructed microvascular flow, 
attributable to the sequestration of blood cells including parasitized RBC and 
leukocytes.153 Intercellular adhesion molecule 1 (ICAM1), one of the most important 
receptors involved in cytoadherence,154 is upregulated in naturally-acquired malaria and 
may contribute to ECM degradation.154, 155 In the current study, HNE up-regulated Icam1 
expression at 6 and 24 h (Table 2). Through cell adhesion, ICAM1 aids ECM binding and 
may trigger macrophage accumulation and localized MMP9 activity. This hypothesis is 
supported by evidence that during septic shock, ICAM1 is involved in leukocyte influx 
and subsequent tissue damage.156 
 
Dyserythropoiesis 
The specific mechanism(s) leading to malarial anemia have not been clearly 
defined, but several factors including dyserythropoiesis are thought to play a role.157 
Casals-Pascual et al. provide evidence correlating dyserythropoiesis with Hz.158 Further, 
HNE and the supernatant of native Hz-fed monocytes have both been shown to dose-
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dependently inhibit erythroid-progenitor growth in culture.159 Repressed CCL5 has been 
correlated with dyserythropoiesis and may be a contributing factor.160 Interestingly, CM 
victims, which have been found with significant Hz accumulation in their brains,143 
exhibit decreased levels of CCL5.161 The significant repression of Ccl5 expression by 
HNE at 24 h supports a potential role for HNE in dyserythropoiesis. Moreover, impaired 
expression of two upstream regulators of Ccl5, namely Traf3 and Tsc22d3, may be 
directly involved in Ccl5 repression in the current study (Table 2).  
 
Part Two: Gene expression analysis of the response to 15-HETE 
 
Given the myriad of HNE-mediated gene expression changes presented in Part I 
of this chapter, it seems probable that other biologically active lipid oxidation products 
generated by Hz, including 15-HETE, may be also active in macrophage 
immunomodulation. Consequently, Part II focuses on steady-state gene expression 
changes induced by 15-HETE in activated RAW 264.7 cells in the context of a 
nonspecific malaria toxin that may be involved in disease pathophysiology.  
 
Functional analysis of gene expression changes induced by 15-S-HETE 
Cytotoxicity profiles of 15-HETE treated RAW 264.7 cells were determined by 
flow cytometry: LPS-stimulated cells were treated with increasing concentrations of 15-
HETE for 24 h, and changes in viable, apoptotic, and dead cell populations were 
measured. Figure 46 shows that concentrations up to 45 μM have no impact on cell 
viability. LPS stimulated macrophage-like RAW 264.7 cells were treated for 24 h with 40 
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μM 15-S-HETE, based on the estimate that trophozoites and Hz contained 33-39 μmol 
15-HETE/L RBC.32 Statistically significant (p ≤ 0.025) changes in gene expression (fold 
change ≥1.8 relative to stimulated cells) were identified by microarray analysis. 
Differentially expressed genes were sorted into lists based on the direction of regulation, 
and corresponding Gene Ontology (GO) categories were identified. Given that this study 
aims to explore potential alterations in gene expression that are incurred by 15-HETE 
during hemozoin phagocytosis, differentially expressed mRNAs were controlled by a 
particulate latex bead challenge under the same conditions (Figure 47). 15-HETE had a 
much greater effect on induction of gene expression than repression (293 transcripts 
versus 100 transcripts, respectively).  
 
 
Figure 46. Viability of 15-HETE-treated cells. LPS (0.1 μg/mL) stimulated RAW 264.7 
cells were untreated or treated with 15-HETE (0-45 μM) for 24 h and stained with 
apoptosis and necrosis-specific stains. Three populations were observed by flow 
cytometric analysis: viable cells, apoptotic cells, and necrotic cells. Viable cells are 
negative for both Alexa Fluor 488 conjugated annexin V and PI, apoptotic cells are 
positive for Alexa Fluor 488 conjugated annexin V, and necrotic cells are positive for PI. 
(C) The plot illustrates the % of viable cells within total cell populations treated with 
increasing concentrations of15-HETE.   
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Figure 47. Genes with significant differential expression mediated by 15-S-HETE. Venn 
diagrams show the intersection of genes that were transcriptionally altered by 40 μM 15-
HETE with those altered by latex bead treatment and serum-opsonized BH (0.1 mg/mL). 
Numbers represent statistically significant (p ≤ 0.025) transcripts up- or down-regulated 
≥1.8-fold  in 2 of 3 samples, relative to LPS stimulated, untreated cells at 24 h. (A) 
Decreased and (B) increased expression are shown separately.162 
 
 
Ingenuity Pathway Analysis (IPA) was used to identify biological interaction 
networks associated with 15-HETE mediated expression changes. Identifiers and relative 
levels of altered genes were imported and mapped by IPA for comparison to molecules 
within the Ingenuity knowledge base (IKB). Focus genes (i.e., imported genes that are 
eligible for generating interaction networks based on incorporation in IKB) were used to 
identify relationships based on known interactions in the literature. Each network is 
associated with a score indicating the likelihood that the focus genes occur in the network 
by random chance. Networks scoring 10 or higher (score is defined as –log (p-value)) are 
considered significant.  
 92
Among the transcripts modulated by 15-HETE exposure, 263 were eligible for 
analysis based on IPA criteria, mapping to 11 relevant interaction networks. The most 
significant network (Figure 48 A) has a score of 51 and associates 27 focus genes. 
Transcriptional regulators are among the products encoded by these genes (Bclaf1, Med1, 
Noc2l, Rnf4, and Zfp36l1). This network also contains Il1b, Cyp3a4, Gnas, and Adfp, all 
of which are involved in ‘lipid metabolism’ as well as ‘small molecule biochemistry’ (p = 
1.27 × 10-4).  
The second most significant interaction network (Figure 48 B) incorporates 18 
focus genes with a score of 29, and is indicative of ‘molecular transport’ (p = 9.42 × 10-7) 
and ‘cellular movement’ (p = 9.77 × 10-6). This network is enriched with focus genes 
encoding molecules associated with the plasma membrane such as Pkd2, Cd300a, 
Cldn11, Gypc,Klra4, peptidase Adam9 and transporters Atp1a2, Slc16a1,and Slc16a3. 
Consistent with these genes, the network predicted interactions with several other plasma 
membrane molecules (Tjp2, Bsg, Cdh1, Tspan3, Tspan4, Cd247, Itgb1, and Atp1b2) that 
were not present in the data file.  
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Figure 48. Ingenuity Pathway network analysis. Transcripts altered ≥1.8-fold (p ≤ 0.025) 
in 15-HETE treated RAW 264.7 cells (i.e., focus genes) were overlaid onto a global 
molecular network developed from information contained in the Ingenuity knowledge 
base (IKB).  Networks of these focus genes were then algorithmically generated based on 
their connectivity. Networks show direct interactions between focus genes altered by 15-
HETE treatment and associated molecules within IKB. Genes or gene products are 
represented as nodes, and the biological relationship between two nodes is represented as 
an edge (line).  White nodes represent IKB molecules that are associated with focus 
genes. All edges are supported by at least one reference from the literature, from a 
textbook, or from canonical information stored in the IKB. The intensity of node color 
indicates the degree of up- (red) or down- (green) regulation. Networks reflect (A) lipid 
metabolism and small molecule biochemistry and (B) molecular transport and cellular 
movement.162 
 
Molecular and cellular functions controlled by 15-S-HETE  
It is thought that Hz impairs cellular function through the generation and 
introduction of toxic species such as lipid peroxidation products into cells. Previously, the 
ability of BH and HNE to stimulate a transcriptional response was examined in 
macrophage-like cells.44 HNE significantly impacted a wide range of steady-state 
responses (e.g., macrophage activation, immune and inflammatory responses, NF-κB 
signal transduction, ECM degradation, and dyserythropoiesis) while BH, induced a 
modest, primarily phagocytic, response. Comparison of the number of gene expression 
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changes influenced by 15-HETE with HNE indicates that 15-HETE modulates a number 
of mRNA targets, but is a much less potent agent than HNE (Figure 49).  
 
 
Figure 49. Overlapping genes with significant differential expression. Datasets for each 
treatment (15-HETE, HNE, BH, and latex bead) group were generated from statistically 
significant (p ≤ 0.01) transcripts up- or down-regulated ≥1.8-fold in 2 of 3 samples 
relative to untreated LPS-stimulated cells. Venn diagrams show intersections of the 
resulting 15-HETE, HNE, and BH data subsets. (A) Increased and (B) decreased 
expression are shown separately.162 
 
Comparison of the biological functions modulated by 15-HETE (Table 5) with 
those affected by BH and HNE44 reveals that all three Hz constituents affected ‘Cell 
Cycle’, ‘Cell Morphology’, and ‘Cellular Assembly and Organization’ genes at 24 h. 
Although 15-HETE modulated a considerably smaller group of transcripts than HNE, a 
comparable response was observed for both the number of molecular and cellular 
functions and the specific categories affected. Both 15-HETE and HNE altered ‘Cell 
Death’, ‘Cellular Development’, ‘Cell Growth and Proliferation’, ‘Gene Expression’, and 
‘Small Molecule Biochemistry’. Additionally, 15-HETE affected several unique 
categories including ‘Carbohydrate Metabolism’, ‘Cellular Compromise’, ‘Drug 
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Metabolism’, ‘Lipid Metabolism’, ‘Molecular Transport’, ‘RNA Damage and Repair’, 
and ‘RNA Post-Translational Modification’. 
 
Table 5. Functional analysis of 15-S-HETE dataseta 
Biological Function p-value 
Carbohydrate Metabolism 6.42 ×10-6 
Cell Cycle 1.28 × 10-4 
Cell Death 1.93 × 10-5 
Cell Morphology 2.53 × 10-4 
Cellular Assembly and Organization 5.30 × 10-4 
Cellular Compromise 4.52 × 10-4 
Cellular Development 3.42 × 10-5 
Cellular Growth and Proliferation 3.81 × 10-4 
Drug Metabolism 3.81 × 10-4 
Gene Expression 2.22 × 10-4 
Lipid Metabolism 1.25 × 10-3 
Molecular Transport 3.81 × 10-4 
RNA Damage and Repair 3.79 × 10-4 
RNA Post-Transcriptional Modification 3.79 × 10-4 
Small Molecule Biochemistry 3.81 × 10-4 
a Ingenuity Pathway Analysis uses a right-tailed Fisher Exact Test to calculate p-values. 
Significance values for each dataset indicate the probability that the association between 
the genes and the given molecular and cellular functions are due to random chance. 
 
 
It was not surprising that IPA analysis identified a large group of lipid 
metabolism’ and ‘carbohydrate metabolism’ expression changes. Given that Il1b acts 
upstream of Cyp3a4, Ugdh, Gnas, Gm2a, Psen1, and Il15, stimulated expression of Il1b 
may be indirectly involved in the up-regulation of each of these genes in the current 
study. Additionally, expression of several ‘small molecule biochemistry’ transcriptional 
regulators including Bclaf1, Med1, Rnf4, Noc2l, and Zfp36l1 was identified.  
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Validation of microarray results 
qRT-PCR was used to confirm several genes susceptible to differential regulation 
by 15-HETE; analysis focused on selected genes implicated in the host response to 
malaria (Table 6). The results shown in Figure 50 are expressed as fold change relative to 
LPS-stimulated cells. In agreement with the microarray results in terms of magnitude and 
direction of change, 15-HETE stimulated the expression of Arf3 (ADP-ribosylation factor 
3), Cldn11 (claudin 11), Cxcl11 (chemokine (C-X-C motif) ligand 11), Mapk14 
(mitogen-activated protein kinase 14), Prdx1 (peroxiredoxin 1), and Sdc1 (syndecan 1), 
and repressed the expression of Egr1 (early growth response 1).  
 
Table 6. Taqman Gene Expression Assays Used for Quantitative Real-Time RT-PCRa 
Gene Assay ID Amplicon length 
Arf3 Mm00500194_m1 93 
Cldn11 Mm00500915_m1 86 
Cxcl11 Mm00444662_m1 82 
Mapk14 Mm00442497_m1 56 
Prdx1 Mm01621996_s1 70 
Sdc1 Mm00448918_m1 131 
Egr1 Mm00656724_m1 182 
a Each assay consists of two unlabeled PCR primers and a FAM dye-labeled TaqMan 
MGB (minor groove binder) probe. 
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Figure 50. Quantitative real-time RT-PCR validation of microarray results. RAW 264.7 
cells were stimulated with 0.1 μg/mL LPS and treated with 40 μM 15-HETE for 24 h 
prior to RNA extraction. Black bars represent fold-changes (treated, stimulated cells 
relative to stimulated cells) assessed by qRT-PCR ( X ± 99% confidence interval for 
quadruplicate measurements of n = 3 biological replicates). White bars represent values 
determined by microarray analysis for comparison. Abbreviations: Arf3 (ADP-
ribosylation factor 3), Cldn11 (claudin 11), Cxcl11 (chemokine (C-X-C motif) ligand 11), 
Egr1 (early growth response 1), Mapk14 (mitogen-activated protein kinase 14), Prdx1 
(peroxiredoxin 1), and Sdc1 (syndecan 1).162 
 
 
 
Differential gene expression in the context of malaria pathogenesis 
Gene expression alterations induced by 15-HETE in the current study were 
compared to two groups of transcripts. The first group consists of specific genes or gene 
products that are associated with human120 or murine122, 123 models of malarial infection, 
or Hz exposure136. The second group includes genes that are classified under specific GO 
processes that are over-expressed in the P. yoelii model124 and/or naturally-acquired P. 
falciparum infections119 (e.g., cell-cell signaling, defense response, immune response, 
inflammatory response, and signal transduction, among others). Differential expression 
mediated by 15-HETE treatment that correlates with either of the two groups described 
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above is listed in Table 7. Common transcripts were primarily associated with ‘cell-to-
cell signaling and interaction’ and ‘immune response’ (e.g., Fcgrt, Cd86, C5ar1, Ccr4, 
Mapk14, Pik3ap1, Tapbp, and Tnfaip6).  
 
Table 7. Selected genes affected by 40 μM 15-HETEa 
Symbol FC 
AB  
Probe ID 
Description 
Entrez 
ID 
Ref
Electron transport 119 
Ugdh 1.9 500013 UDP-glucose dehydrogenase 22235  
Cyp3a11 3.6 516253 
cytochrome P450, family 3, subfamily a, 
polypeptide 11 
13112 
 
Smox 5.1 560410 spermine oxidase 228608  
Regulation of transcription, DNA-dependent 119 
Rab11a 2.0 359489 RAB11a, member RAS oncogene family 53869  
Cdk9 2.1 392872 
cyclin-dependent kinase 9 (CDC2-related 
kinase) 
107951 
 
Fli1 2.3 407869 Friend leukemia integration 1 14247  
Zfp482 2.0 435236 Zinc finger protein 482 241322  
Fbxl11 -2.9 464056 F-box and leucine-rich repeat protein 11 225876  
Pspc1 2.0 474771 paraspeckle protein 1 66645  
Myst2 5.4 494053 MYST histone acetyltransferase 2 217127  
Mxd1 2.1 520449 MAX dimerization protein 1 17119  
Egr1 -4.7 524988 early growth response 1 13653  
Bclaf1 -1.9 549609 BCL2-associated transcription factor 1 72567  
Pparbp 1.9 553770 
peroxisome proliferator activated receptor 
binding protein 
19014 
 
Rnf4 2.5 567180 Ring finger protein 4 19822  
Tsc22d3 2.0 700170 TSC22 domain family 3 14605  
Fliih 4.6 706377 flightless I homolog (Drosophila) 14248  
Creg1 1.9 760346 cellular repressor of E1A-stimulated genes 1 433375  
Pou2f2 -4.4 911620 POU domain, class 2, transcription factor 2 18987  
Hlx1 2.1 915372 H2.0-like homeo box 1 (Drosophila) 15284  
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Table 7, continued. 
 
Protein biosynthesis 119, 124 
Eprs 4.9 455664 glutamyl-prolyl-tRNA synthetase 107508  
Protein folding 119 
Hspa4 3.5 578003 heat shock protein 4 15525  
Clpx 2.4 733670 caseinolytic peptidase X (E.coli) 270166  
Ubiquitin cycle 119 
Ube2l6 2.0 401185 ubiquitin-conjugating enzyme E2L 6 56791 120 
Cul7 0.4 742757 cullin 7 66515  
Fbxo3 1.9 832607 F-box only protein 3 57443  
Intracellular protein transport 119 
Sort1 2.4 339169 Sortilin 1 20661  
Ap1s2 2.0 605927 
adaptor-related protein complex 1, sigma 2 
subunit 
108012 
 
Arf3 4.4 652348 ADP-ribosylation factor 3 11842  
Response to stress 119 
Prdx1 2.1 530413 peroxiredoxin 1 18477 122 
Mapk14 2.2 755610 mitogen activated protein kinase 14 26416 120 
Prdx6 -2.0 825043 peroxiredoxin 6 11758  
Defense response 119, 124 
Klra18 2.5 806675 
killer cell lectin-like receptor, subfamily A, 
member 18 
93970 
 
Bst1 2.1 837914 bone marrow stromal cell antigen 1 12182  
Inflammatory response 119, 124 
Card12 2.2 336709 caspase recruitment domain family, member 12 268973  
Abcb1a 2.6 677412 
ding cassette, sub-family B (MDR/TAP), 
member 1A 
97570 
 
Ca2 4.0 574832 carbonic anhydrase 2 88269  
Cdkn1b 3.7 516253 
cytochrome P450, family 3, subfamily a, 
polypeptide 11 
104565 
 
Clu 4.0 379462 Clusterin 88423  
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Table 7, continued. 
 
Cr1l 1.9 538208 complement component (3b/4b) receptor 1-like 88513  
Cyp3a11 3.7 516253 
cytochrome P450, family 3, subfamily a, 
polypeptide 11 
88609 
 
Fyn 2.50 766362 Fyn proto-oncogene 95602  
H2-Q8 1.8 712519 histocompatibility 2, Q region locus 8 95937  
Hnrnpa3 4.8 903894 heterogeneous nuclear ribonucleoprotein A3 1917171  
Mrc1 2.9 331550 Mannose receptor, C type 1 97142  
Pole4 2.3 508321 
polymerase (DNA-directed), epsilon 4 (p12 
subunit) 
1914229 
 
Ppp3r1 2.7 716541 
protein phospatase 3, regulatory subunit B, 
alpha isoform (calcineurin B, type I) 
107172 
 
Procr 2.0 431405 protein C receptor, endothelial 104596  
Rrm1 5.6 865694 ribonucleotide reductase M1 98180  
Serpinb2 4.0 860577 
serine (or cysteine) proteinase inhibitor, clade B, 
member 2 
97609 
 
Leukocyte extravasation and signaling 
Arhgap1
2 
2.2 
465731 
Rho GTPase activating protein 12 
1922665  
Crkl 3.0 389169 
v-crk sarcoma virus CT10 oncogene homolog 
(avian)-like 
104686 
 
Ptk2b 2.6 867483 PTK2 protein tyrosine kinase 2 beta 104908  
Immune response 119, 124 
Gbp3 3.0 405120 guanylate nucleotide binding protein 4 55932 
122, 
124 
Ddx58 7.1 438990 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 230073  
Gbp1 2.9 586296 guanylate nucleotide binding protein 1 14468 
120, 
123, 
124 
Il1a 5.1 595893 interleukin 1 alpha 96542  
Il1b 2.4 734612 interleukin 1 beta 16176  
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Table 7, continued. 
 
Il15 1.9 876196 interleukin 15 16168  
Ifit3 3.2 888038 
interferon-induced protein with tetratricopeptide 
repeats 3 
15959 
 
Cxcl11 5.1 921243 chemokine (C-X-C motif) ligand 11 56066  
Cell cycle 124 
Pmp22 1.9 616997 peripheral myelin protein 18858  
Cdkn1b 3.7 704876 cyclin-dependent kinase inhibitor 1B (P27) 12576  
Ccnf 2.4 767163 cyclin F 12449  
Rhob -2.2 925472 ras homolog gene family, member B 11852  
Cell adhesion 119 
Cldn11 4.9 338333 claudin 11 18417  
Scarb2 2.5 561450 scavenger receptor class B, member 2 12492  
Signal transduction 124 
Rin1 -1.9 478326 Ras and Rab interactor 1 225870  
Ms4a4c 2.4 495283 
membrane-spanning 4-domains, subfamily A, 
member 4C 
64380 
 
Prkrir 3.4 561755 
protein-kinase, interferon-inducible double 
stranded RNA dependent inhibitor, repressor of 
(P58 repressor) 
72981 
 
Olfr472 -2.2 591718 olfactory receptor 472 258770  
Ywhag 4.1 606287 
3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, gamma polypeptide 
22628 
 
Gnas 1.8 646267 
GNAS (guanine nucleotide binding protein, 
alpha stimulating) complex locus 
14683 
 
Ms4a4c 3.2 791872 
membrane-spanning 4-domains, subfamily A, 
member 4C 
64380 
 
Ptger2 3.0 912597 prostaglandin E receptor 2 (subtype EP2) 19217  
G-protein coupled receptor protein signaling pathway 119 
Olfr1303 -2.0 366625 olfactory receptor 1303 258397  
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Table 7, continued. 
 
Slc19a2 1.9 763767 
solute carrier family 19 (thiamine transporter), 
member 2 
116914 
 
Olfr435 -3.2 810459 olfactory receptor 435 258647  
Olfr316 -1.9 903210 olfactory receptor 316 258064  
Cell-cell signaling 119 
Wnt6 2.0 590115 wingless-related MMTV integration site 6 22420  
Development 119 
Lrp6 -2.3 691244 
low density lipoprotein receptor-related protein 
6 
16974 
 
Egfl4 -2.2 914308 EGF-like-domain, multiple 4 269878  
Pgf 2.9 932795 placental growth factor 18654  
Metabolism 124 
Hsd17b4 2.2 303973 hydroxysteroid (17-beta) dehydrogenase 4 15488  
Echdc3 2.2 331450 
enoyl Coenzyme A hydratase domain containing 
3 
67856 
 
Atp2c1 2.0 388850 ATPase, Ca++-sequestering 235574  
Atp1a2 2.1 684165 
ATPase, Na+/K+ transporting, alpha 2 
polypeptide 
98660 
 
Oas3 -3.0 487213 2'-5' oligoadenylate synthetase 3 246727 120 
carbohydrate transport 119 
Slc35a4 2.5 318829 Solute carrier family 35, member A4 67843  
Protein transport 119 
Rab20 2.0 410549 RAB20, member RAS oncogene family 19332  
Rap2b 2.2 471908 RAP2B, member of RAS oncogene family 74012  
Exoc2 3.0 498825 exocyst complex component 2 66482  
Rheb 1.9 653270 RAS-homolog enriched in brain 19744  
Zfyve20 2.9 669220 zinc finger, FYVE domain containing 20 78287  
Nupl2 2.1 868036 Nucleoporin like 2 231042  
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Table 7, continued. 
 
Protein ubiquitination 119 
Trim12 2.7 454451 tripartite motif protein 12 76681  
Trim34 2.9 600486 tripartite motif protein 34 94094  
Cell differentiation 119 
Ndrg2 2.1 468211 N-myc downstream regulated gene 2 29811  
a Transcripts altered ≥1.8-fold (p ≤ 0.025) in 15-S-HETE-treated RAW 264.7 cells that 
are associated with (1) specific genes or gene products correlated to malarial or (2) genes 
that are classified with specific over-expressed GO biological processes in malaria 
models, are shown in the table. Fold changes (FC) represent the average of three 
independent biological experiments.  
 
Global responses to malaria infection have been examined at the molecular level 
in the blood of human victims,119, 120 malaria positive tissue,121 and murine122-124 and 
monkey125 malaria models using microarray technology. Perturbation of gene expression 
associated with erythropoiesis, glycolysis, metabolism, B-cell activation, and 
inflammation was frequently identified in these analyses; however, the specific agents 
responsible for mediating these expression changes remain unknown. Accumulating 
evidence led to the hypothesis that many of the adverse effects of malaria are not caused 
directly by the parasite, but by endogenous toxins generated during interactions with 
parasite-derived species such as Hz.58  
Unlike the mode of action behind the of HNE’s biological activity (forming 
adducts to cellular nucleophiles and subsequently modulating cell signaling) 15-HETE 
serves as a ligand for the nuclear PPARγ receptor,101 a ligand-activated transcription 
factor. In the current study, activated RAW 264.7 macrophage-like cells were treated 
with 15-HETE, and gene expression changes were identified. The number of expression 
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changes mediated by 15-HETE is modest relative to the global response to HNE (Figure 
49). mRNA levels were assessed at 24 h in the model to mimic a steady state response to 
15-HETE that would be relevant to malaria infection. Consequently, not only are 
downstream PPARγ signaling transcripts (e.g., Adfp, Ca2, Cyp3a4, M6pr, M6prbp1, 
Med1, Med7, and Sdc1) elevated in response to 15-HETE, but several secondary cascades 
are also stimulated (Table 7). 
 
Cytoadherence 
The balance between the removal of Plasmodia from circulation and their 
sequestration inside host cells is crucial for parasite survival during infection. 
Sequestration is mediated by cytoadherence, specifically the adherence of parasitized 
RBCs (PRBCs) and leukocytes to capillary and postcapillary venular endothelial cells 
(EC). This cytoadherance reduces blood flow and causes metabolic dysfunction163 and is 
thought to be a major factor associated with cerebral malaria (CM). Mechanism(s) used 
for adhesion and migration involve the expression of ligands and receptors on PRBCs or 
leukocytes and EC. In addition to constitutive adhesion molecules, cell-cell and cell-
matrix interactions are also mediated by cytokines or microbial products which enhance 
the expression of inducible adhesion molecules  
Investigation of potential arachidonic acid metabolite involvement in 
cytoadherence identified 15-HETE as an agent capable of stimulating basal adhesion of 
erythrocytes117 and monocytes to EC164, 165. In the current study, 15-HETE induced the 
expression of several integrin signaling transcripts (e.g., Crkl, Rap2b, Arf3). Furthermore, 
the expression of genes encoding Pkd2 and  Sdc1, which are involved in cell-cell and 
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cell-matrix interactions, and Ptpn14, which has alleged involvement in cell adhesion, was 
also induced by 15-HETE.  
 
Leukocyte extravasation and chemotaxis 
The inflammatory response to malaria, both acute and chronic, follows a 
predictable sequence of events. Following initial vascular changes, permeability increases 
resulting in edema. Enhanced cytoadherence results in the accumulation, adherence, and 
emigration of leukocytes through vascular endothelium, subsequently releasing molecular 
mediators which contribute to both the immune response and recruitment/activation of 
effector cells. Overwhelming evidence demonstrates that the pathophysiology of malaria 
involves both systemic and local cytokine release. The recruitment of phagocytes around 
cerebral capillaries has been observed in CM and likely explains increased chemotaxis 
and chemokinesis.166 CM is a severe complication of P. falciparum infection that is 
characterized by cytoadherence in cerebral microvasculature. Accumulation of Hz-loaded 
monocytes has been observed in brains of CM victims155 and may contribute to the 
disruption of endothelial basement membrane and subsequent extravasation of blood 
cells.146 Importantly, blood brain barrier (BBB) destruction and enhanced vascular 
permeability/edema are major factors associated with CM.144, 167  
 A potential contribution of 15-HETE toward increased vascular permeability has 
been examined in the lung. Administration of this hydroxylated fatty acid was shown to 
increase respiratory edema fluid production,168 suggesting a role as an inflammatory 
mediator. The current analysis identified the ‘Leukocyte Extravasation Signaling’ 
pathway as being significantly (p = 0.015) affected by 15-HETE. Specifically, the steady-
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state expression of Arhgap12, Cldn11, Crkl, Mapk14, and Ptk2b is up-regulated. 
Although 15-HETE is generally considered to have anti-inflammatory properties, 
activation of a large group of genes encoding inflammatory response molecules was 
observed (Table 7).  
 
15-HETE and MMP9 regulation 
15-HETE was recently shown to enhance IL1B expression and MMP9 activity in 
human monocytes.115 Comparison of these results with the current study identified a 
different response: While Il1b mRNA is elevated by 15-HETE, Mmp9 mRNA is down-
regulated (-4.8–fold by qRT-PCR). Mmp9 expression can be regulated through a variety 
of signaling cascades including NF-κB, p38 MAPK, and ERK1/2 pathways.149 It was 
proposed that the enhanced regulation of IL1B and MMP9 regulation in human 
monocytes may be associated with NF-κB signalling based on reports demonstrating NF-
κB-mediated MMP9 expression in LPS-stimulated RAW 264.7 cells.149 This hypothesis 
seems unlikely in LPS-stimulated RAW 264.7 cells as 15-HETE has been shown to 
impair NF-κB-mediated expression of  iNOS.68, 78 Furthermore, PPARγ ligands (other 
than 15-HETE) have been shown to inhibit MMP9 expression, secretion, and activity in 
macrophages and vascular smooth muscle cells169-171 and repress NF-κB signal 
transduction.172, 173 Consequently, NF-κB regulated transcription is not likely to be the 
basis of enhanced MMP9 expression in 15-HETE-treated human monocytes.115 
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Conclusions 
 
The host immune response to malarial infection is multifactorial, including 
complex innate and adaptive immune responses to the parasites, composite native Hz, 
Hz-derived lipid peroxidation products, and other cellular debris. Not unexpectedly, 
countless interactions between an array of malaria toxins and host cells result in adverse 
biological effects, prompting a reductionist examination of such complex systems. The 
survival strategy for parasites requires the detoxification of free heme released during 
RBC catabolism, and consequently the synthesis of Hz. The oxidation of fatty acids by 
Hz (or BH) is a rich chemistry which only now is being elucidated. Of these oxidation 
products (all R,S isomers of HETE’s, HODE’s, and HNE), HNE is unquestionably the 
most reactive. Additionally, concentrations of HNE found in Hz laden monocytes are the 
highest reported in any biological system.71 Consequently, HNE was chosen to begin 
exploration of the cellular response to the lipid component of Hz.  
A wide range of substantive modulations occurred in activated cells following 
HNE treatment at both 6 and 24 h. The early response predominantly involves an 
oxidative stress activity that involves induction of ARE and glutathione metabolism 
genes. Steady state gene expression changes are associated with a variety of documented 
malaria responses such as macrophage activation, immune and inflammatory responses, 
NF-κB signal transduction, ECM degradation, and dyserythropoiesis. The modest, 
primarily phagocytic, response to BH supports the hypothesis that Hz predominantly 
functions as a vehicle to generate and introduce toxic mediators (e.g., HNE, hydroxylated 
fatty acids) that are closely associated with the biomineral into phagocytic cells.69  
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In response to the large number of gene expression alterations mediated by HNE, 
the global response to 15-HETE was examined in macrophage-like cells. 15-HETE has 
previously been implicated as having a functional role in a variety of cellular processes 
such as inflammation, asthma, carcinogenesis, and atherosclerosis, however its precise 
role remains unknown. 15-HETE can be incorporated into membrane lipids, and alter 
vascular tone and EC permeability.116 Analyses demonstrated that the response to 15-
HETE was predominantly associated with altered expression of ‘lipid metabolism’ as 
well as ‘small molecule biochemistry’ genes. Notably, several genes related to 
cytoadherance, leukocyte extravasation, and inflammatory response were also 
differentially regulated by 15-HETE treatment. However, the small number of expression 
changes indicates that 15-HETE does not elicit a marked. Although these results add 
insight and detail to 15-HETE’s effect on gene expression in macrophage-like cells, it 
should be noted that there are limitations to any model system. 15-HETE represents but 
one structural HETE isomer that is associated with Hz; 5-, 8-, 9-, 11-, and 12-HETE have 
also been identified.78, 86 Although 5- and 15-HETE are reported to be the predominant 
isomers formed during iron catalyzed or Hz-mediated oxidation of AA,86, 92 12-HETE 
may exert greater biological activity.78 These findings suggest that upon hemozoin 
phagocytosis, the sum of individual HETE PPARγ ligands may mediate a synergistic 
immunomodulatory response.  
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CHAPTER IV 
 
HNE-MEDIATED DYSREGULATION OF SIGNAL TRANSDUCTION 
 
 
Introduction 
Hemozoin has long been suspected of contributing to immunomodulations that 
occur during Plasmodia infection. The Hz-associated lipid peroxidation product HNE 
exerts activity that parallels Hz. Specifically, several gene expression alterations 
associated with MMP9 and NF-κB regulation described in Chapter III suggest that HNE 
is a major contributor of the immunomodulation caused by native Hz.  
Sequestered Hz has been detected in brain tissue of cerebral malaria (CM) 
victims143 and has been suggested as a factor that contributes to inflammation, swelling, 
disruption of the blood brain barrier, and extravasation of blood cells.146 Notably, 
transcriptional activation of MMP9 was observed in human blood during P. falciparum 
infection,120 and Hz was shown to induce the expression, translation, and activity of 
MMP9 in human monocytes.146 In Chapter III it was shown that HNE up-regulated 
Mmp9 mRNA in macrophage-like cells.44 
MMP9 (gelatinase-B) is a member of the MMP family of zinc-dependent 
endoproteinases involved in ECM remodeling.144-146 The primary substrates of MMP9 are 
elastin and type IV collagen, major constituents of the basement membrane and ECM.174 
Canonical transcriptional regulation of MMP9 (Figure 51) is mediated by a variety of 
growth factors and cytokines (e.g., tumor necrosis factor (Tnf), interleukin 1 beta (Il-1b), 
epidermal growth factor (Egf), and transforming growth factor, beta 1 (Tgf-b1) that can 
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trigger a number of signaling cascades.147-149, 175 Post translation, several additional forms 
of MMP9 regulation are at play including spatial localization, extracellular zymogen 
activation, and binding with cognate tissue inhibitor of metallopeptidases (TIMP) protein.  
This tightly regulated system is essential to prevent tissue damage.  
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Figure 51. Canonical regulation of MMP9. MMP9 is expressed and processed as an 
inactive pro-enzyme. Upon proteolysis, MMP9 is activated. Although active, the 
proteolytic activity of MMP9 is maintained through the formation of a complex with 
MMP9’s cognate inhibitor, TIMP1. Active MMP9 can cleave both pro-TNF and pro-
IL1B from membrane bound forms to a soluble cytokines. Both of these cytokines have 
been shown to mediate signal transduction leading to expression of MMP9, thus 
completing a positive feedback loop. 
 
 
 
In addition to perturbed MMP9 regulation, the microarray results presented in 
Chapter III also highlighted alterations of NF-κB signal transduction. The LPS mediated 
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pathway to produce NO is well characterized and entails NF-κB signal transduction 
(Figure 52). In quiescent cells, NF-κB is sequestered by the inhibitor of κB (IκB)  
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Figure 52. Canonical NF-κB signal transduction. LPS binding to Toll-like receptor 4 
(TLR4) recruits adapter proteins (e.g., TRAF) which recruit the IKK complex. Active 
IKK phosphorylates IκB, triggering its polyubiquitination and subsequent degradation. 
NF-κB is then free to translocate to the nucleus and mediate the expression of iNOS, 
which ultimately generates NO. 
 
 
 
in the cytoplasm. Upon receiving an appropriate signal leading to its activation, IκB 
kinase (IKK) phosphorylates IκB leading to its degradation and subsequent release of the 
NF-κB complex. Once NF-κB is liberated from IκB, NF-κB translocates to the nucleus  
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and regulates gene expression including iNOS which is responsible for the production of 
NO. 
Given the suggestions of altered MMP9 regulation and NF-κB signal transduction 
in Chapter III, biochemical approaches were used to explore the mRNA and protein 
levels of members of these canonical pathways.  Chapter IV is divided into two parts: the 
effects of HNE and 15-HETE on MMP9 regulation are presented in Part I, and the effect 
of HNE on NF-κB is presented in Part II.   
 
Experimental 
 
Cell Culture 
Murine macrophage-like RAW 264.7 cells (ATCC, TIB-71) were maintained in 
RPMI 1640 medium (Cellgro) supplemented with 5% fetal bovine serum (Atlanta 
Biologicals) and 1 μg/mL penicillin-streptomycin (Cellgro) under standard incubation 
conditions (37 ºC, 5% CO2). Cells were plated 18-24 h prior to treatment at a density of 4 
× 106 cells/well in 6 well plates (qRT-PCR experiments) or 5 × 105 cells/well in 24 well 
plates (ELISA experiments).  
 
Cell Treatment 
Cells were washed once with Dulbecco’s PBS (DPBS) and treated with 10-35 μM 
HNE (Calbiochem) or 20-40 μM 15-S-HETE (Cayman Chemical) and LPS (1 μg/mL 
final concentration, Sigma) for 24 or 48 h. For inhibition studies, cells were pre-incubated 
for 1.5 h with 10 nM-30 μM of the appropriate inhibitor before HNE treatment and LPS 
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stimulation. U0126, SB203580, SP600125, and PDTC (Calbiochem) were added to cells 
to inhibit ERK1/2, p38, JNK, and NF-κB signaling cascades, respectively. Active MMP9 
was inhibited with 10 nM-30 μM of MMP9 inhibitor I (Calbiochem) at the time of 
HNE+LPS treatment. TNF signaling was blocked with a neutralizing TNFα antibody 
(Abcam) according to the manufacturer’s protocol at the time of treatment. 
 
RNA Isolation 
Cells were washed three times with DPBS and scraped from the wells. Three 
biological replicates (composed of 6 pooled wells each) per sample were prepared. Total 
RNA was isolated using the VersaGene cultured cell RNA purification and DNase 
treatment kits, following manufacturer’s recommendations and analyzed for quality 
(Agilent 2100 Bioanalyzer, Agilent Technologies, Palo Alto, CA).  
 
Real-Time Reverse Transcription Polymerase Chain Reaction 
Quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) 
was used to validate the expression levels of Mmp9 (Taqman assay Mm00442991_m1), 
Timp1 (Mm00441818_m1), Tnf (Mm00443258_m1), and Il1b (Mm00434228_m1) in 
HNE and 15-HETE treated cells. Triplicate measurements for n = 3 biological replicates 
per sample were performed. cDNA was reverse-transcribed from 0.5 μg of total RNA 
using random hexamer primers and Superscript II Reverse Transcriptase (Invitrogen). 
Reactions were purified using Qiagen’s PCR Purification Kit following the 
manufacturer’s protocol. Following RT, all assays were performed with Applied 
Biosystems TaqMan FAM labeled 20× probes (Table 1). Ywhaz was chosen as the 
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endogenous control based on results obtained from an Applied Biosystems mouse 
endogenous control array. cDNA amplification was performed using  TaqMan 2× 
Universal PCR Master Mix (Applied Biosystems) according to the manufacturer’s 
directions.  Standard Taqman cycling conditions were used as specified by the 
manufacturer.  Cycling and data collection were performed using the Applied Biosystems 
7900 HT instrument and analysis performed using the manufacturer’s SDS software 
package to calculate Ct values for each detector. Ct values were processed based on the 
comparative Ct method, where the relative transcript level of each target gene was 
calculated according to the equation 2–ΔCt, where ΔCt is defined as Cttarget gene – CtYwhaz. 
 
Enzyme-linked immunosorbant assays  
Enzyme-linked immunosorbant assays (ELISAs) were used to measure the levels 
of soluble proteins secreted into culture medium. Cell culture medium was collected and 
analyzed using commercial ELISA reagents (R&D Systems) according to protocol using 
96-well Immulon 2HB plates (Thermo Electron Corp.). Briefly, capture antibody was 
added to wells and incubated at 25 ºC overnight. Three washes (300 μL each) were 
performed after this and all subsequent steps using phosphate buffered saline (PBS) 
supplemented with 0.05% Tween-20. Wells were blocked with 300 μL of 5% Fraction V 
bovine serum albumin (Fisher Scientific) in PBS for 1 h at 37 ºC. Three-fold serial 
dilutions of collected culture medium (1:1–1:2187) in complete medium and two-fold 
dilutions of recombinant protein in complete medium were added to wells and incubated 
for 1 h at 37 ºC. Wells were incubated with the appropriate biotinylated detection 
antibody for 1 h at 37 ºC and subsequently incubated with streptavidin-HRP for 10 min at 
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37 ºC. After addition of 3,3',5,5',-tetramethylbenzidine liquid substrate (100 μL, Sigma 
Aldrich), the enzymatic reaction was quenched with 50 μL of 2M H2SO4. The absorbance 
of samples was then measured spectrophotometrically at 450 nm. Culture medium and 
recombinant protein were used as negative and positive controls, respectively. 
 
Zymography 
 LPS stimulated cells were treated 10 or 35 μM HNE and culture medium was 
collected at 48 h. Equal total protein was resolved on 10 % Novex-Zymogram gel 
containing gelatin (Invitrogen) under non-denaturing and non-reducing conditions. Post 
electrophoresis, gels were washed 2× with 2.5% Triton-X 100 for 30 min and then 
incubated with substrate buffer (50 mM Tris-HCl pH 7.5, 200 mM NaCl, 50 mM CaCl2, 
and 0.2% BRIJ-35) for 16 h at 37 ºC. Gels were stained with 10% acetic acid, 30% 
methanol, and 0.5% Coomassie Brilliant Blue (R-250) for 1 h, followed by destaining. 
Proteins with gelatinolytic activity were visualized as clear bands on a blue background. 
Apparent molecular weight was determined by comparison with Precision Plus Protein 
pre-stained Kaleidoscope standard (Bio-Rad). Zymograms were imaged (Bio-Rad 
Chemidoc XRS System) and the data analyzed using Quantity One software (Bio-Rad). 
The area and average intensity were measured for each band representing MMP9 activity.  
 
Determination of NO synthesis 
NO levels were estimated indirectly by the accumulation of the stable NO 
metabolite nitrite via the Griess assay. Twenty-four hours after treatment, supernatant 
(100 μL) was collected and combined with 100 μL Griess reagent (1:1, 1% sulfanilimide 
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in 5% phosphoric acid/0.1% N-(1-naphthyl)ethylenediamine). After five minutes, the 
absorbance of the azo-complex was measured at 540 nm using a Bio-Tek Synergy HT 
Multidetection Microplate Reader. Nitrite levels were determined by comparison with a 
standard curve. 
 
Immunoprecipitation 
 Cells (4 × 106/well) were incubated with 0 or 35 μM HNE for 1 h under standard 
incubation conditions, and subsequently lysed as described above. Anti-IKKα (3 μg) was 
incubated with 50 μL of MagnaBind amine-derivatized beads (Pierce) with 4 mM 
bis(sulfosuccinimidyl)suberate (BS3) in PBS for 1 h at RT mixing end-over-end. 
Reactions were quenched with 20 mM Tris (pH 8.5) for 15 min. Antibody cross-linked 
beads were separated using a magnet, and unbound antibody was removed by three 
washes with lysis buffer. Crude lysate (400 μg in 200 μL) was added to the beads and 
incubated with mixing overnight. Unbound lysate was removed and beads were washed 
3× with lysis buffer. IKKα was eluted with 4× LDS buffer (with 2% β-mercaptoethanol) 
at 70 ºC for 10 min.  
 
Immunoblotting 
 Cells were washed three times with ice-cold DPBS and lysed in 50 mM Tris-HCl 
(pH 7.4), 120 mM NaCl, 0.5% Nonidet P-40 (BioAffinity Systems Inc, Roscoe, IL), and 
1mM EDTA, supplemented with complete mini protease inhibitor tablet (Roche) and 
phosphatase inhibitor cocktails I and II (Sigma) on ice for 15 min, followed by sonication 
(30% amplitude, 8 sec). Cell lysates were cleared by centrifugation at 13,200 × g for 10 
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min. Protein concentration was determined with the BioRad DC protein assay. Protein 
(20-50 μg) was resolved on a 4-12% NuPAGE Bis-Tris gel (Invitrogen) and 
electrophoretically transferred to a polyvinylidene difluoride membrane (0.2 μM, 
Invitrogen). Membranes were blocked overnight at 4 ºC with 5% nonfat dry milk in Tris-
buffered saline (25 mM Tris-HCl (pH 7.4), 137 mM NaCl, 2.7 mM KCl)  containing 
0.1% Tween 20 (TBST). Blots were incubated with anti-phospho-IκB, anti-IκB, anti-
IKKα, anti-IKKβ, or anti-iNOS (Santacruz Biotechnology) in 5% nonfat milk in TBST 
for 2 h at RT. Membranes to be probed for HNE-protein adducts were treated with 265 
mM NaBH4 in MOPS buffer (100 mM, pH 8) for 10 minutes at room temperature with 
gentle shaking and subsequently washed 6 × 5 min with TBST. Blots were then blocked 
and incubated with anti-HNE-Michael Adduct (Reduced) Rabbit pAb antibody 
(Calbiochem) as described above. Primary antibody complexes were stained with goat 
anti-rabbit horseradish peroxidase secondary antibody (Santacruz Biotechnology) in 5% 
nonfat milk in TBST for 1 h at RT. Protein bands were visualized by enhanced 
chemiluminescence (Pierce ECL Western Blotting substrate). 
 
Peptide synthesis 
 The IKKα and IKKβ protein sequences were digested in silico with trypsin to 
determine the peptides containing the purportedly sensitive cysteine-178 and cysteine-
179, respectively: DVDQGSLCTSFVGTLQYLAPELFENK (IKKα) and 
ELDQGSLCTSFVGTLQYLAPELLEQQK (IKKβ).176-179 These model peptides were 
synthesized via a continuous flow fmoc solid phase peptide synthesis method on an 
Advanced Chemtech peptide synthesizer, purified by reverse phase HPLC, and 
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lyophilized as previously described.180 Identification of the peptides was confirmed by 
MALDI mass spectrometry. 
 
Peptide Adduction and analysis 
Peptides (90 μL, 1 mM) dissolved in 75:25 acetonitrile/50 mM phosphate buffer 
(pH 7.4) were incubated with 10 μL of 5 mM HNE (stock solution 64 mM in ethanol) for 
3 h at 37 ºC. Control reactions were prepared in parallel with an equivalent volume of 
ethanol as the experimental samples. Reaction mixtures were reduced with 10 μL of 1M 
NaBH4 for 10 min, neutralized with 10 μL of 1M HCl, and purified by reverse phase 
HPLC (Nova-Pak C18, 3.9×150 mm, Waters) monitoring an absorbance of 210 nM. 
Mobile phase A was 0.05% trifluoroacetic acid (TFA) in H2O, mobile phase B was 
0.05% TFA in acetonitrile. The gradient (500 μL/min) was as follows: 0–1 min, isocratic 
phase 5% B; 1–5 min, gradient to 15%B; 5–30 min, gradient to 35% B; 30–45 min, 
gradient to 90% B; 45–55 min, held at 90% B; 55–65 min, gradient to 5% B. Fractions 
were collected and analyzed by a Thermo Finnigan LCQ ion trap mass spectrometer 
(Thermo Fisher Scientific, Waltham, MA). MS/MS scans were acquired using an 
isolation width of 2 m/z and 30% normalized collision energy. The mass spectrometer 
was tuned prior to analysis using each synthetic peptide. Resulting MS/MS spectra were 
compared to simulated MS/MS fragmentation data using GPMAW 6.01.1 (Lighthouse 
Data). 
 
Nomenclature 
 Nomenclature for genes and proteins is as described by the Mouse Genome  
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Informatics (MGI) database guidelines: both murine and human protein names are 
capitalized (MMP9), murine genes are italicized with the first letter capitalized (e.g., 
Mmp9), and human genes are italicized and capitalized (e.g., MMP9). 
 
Results and Discussion 
 
Part I: Effects of Lipid Peroxidation Products on Matrix Metalloproteinase-9 
Regulation in LPS stimulated RAW 264.7 Cells 
 
 
It was recently reported that phagocytosis of Hz by human monocytes increased 
MMP9 mRNA, protein, and activity.146 The authors demonstrated that 10 μM 15-S-
HETE increased MMP9 activity and IL1B mRNA and secreted protein in monocytes. In 
contrast, 0.1 µM HNE had no effect on MMP9 activity, and an inhibitory effect at 1-10 
µM. Consequently, the source of Hz activity was attributed to the lipid peroxidation 
product 15-S-HETE.115 These observations are in opposition to the gene expression 
results presented in Chapter III that implicated HNE, not 15-HETE, in severe dysfunction 
of MMP9 regulation.44, 162 
 
Effects of HNE and 15-HETE on mRNA expression 
Since microarray results are semiquantitative by nature, quantitative real time RT-
PCR (qRT-PCR) analyses of stimulated cells treated with either HNE or 15-HETE were 
performed. Several genes encoding proteins associated with Mmp9 expression and 
activity were chosen for validation and fold changes were calculated relative to LPS-
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stimulated cells. As shown in Figure 53, HNE significantly up-regulated the levels of 
Mmp9 and Tnf mRNA, in direct contrast to decreased levels of Mmp9 and Tnf mediated 
by 15-HETE. Timp1 transcription was drastically reduced (-2000–fold) by HNE, yet 
unaltered by 15-HETE. Neither HNE nor 15-HETE treatment significantly altered Il1b 
levels. These expression results indicate that HNE stimulates canonical MMP9 pathways; 
however mRNA levels do not necessarily correlate with protein levels.  
 
 
Figure 53. Quantitative real-time RT-PCR validation. RAW 264.7 cells were stimulated 
with 0.1 μg/mL LPS and untreated (control) or treated with either 35 μM HNE (white 
bars) or 40 μM 15-HETE (black bars) for 24 h prior to RNA extraction. Fold-changes 
(treated, stimulated cells relative to untreated, stimulated cells) are shown ( X  ± 99% 
confidence interval for triplicate measurements of n = 3 biological replicates). 
Abbreviations: Mmp9, matrix metalloproteinase 9; Timp1, tissue inhibitor of 
metalloproteinase 1; Tnf, tumor necrosis factor; Il1b interleukin 1 beta. 
 
 
Effects of HNE and 15-HETE on Mmp9 and Timp1 secretion 
 Protein secretion of MMP9 induced by 10 or 35 µM HNE or 20 or 40 µM 15-
HETE was measured by ELISA in the culture medium at 24 or 48 h (Figure 54). In the 
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absence of LPS stimulation, MMP9 secretion was below detectable limits in untreated, 
HNE treated, or 15-HETE treated cells. LPS stimulation, however, resulted in a 
significant increase of Mmp9 in all samples. In agreement with the qRT-PCR data, HNE 
further enhanced the level of MMP9 as a function of time, indicating that HNE 
synergized with LPS signaling. 15-HETE did not alter MMP9 secretion in LPS 
stimulated cells.  
TIMP1 is a critical regulator of MMP9 activity in the extracellular space. 
Consequently, the level of TIMP1 secreted from cells was investigated (Figure 55). LPS 
stimulation resulted in a marked increase in TIMP1 protein. In accord with qRT-PCR 
data, HNE treatment severely impaired protein secretion, nearly to the level of 
unstimulated cells by HNE. 15-HETE, however, increased the level of TIMP1 measured. 
These results indicate that while 15-HETE seemingly imposes additional control of 
MMP9, HNE induces changes in favor of MMP9 activity, altering an otherwise 
exceptionally tightly regulated system. Similar to altered MMP regulation in these 
studies, HNE has been reported to induce the expression of MMP13 and repress the 
expression of TIMP1 in osteoarthritic tissues contributing to cartilage destruction.181   
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Figure 54. Determination of MMP9 levels by ELISA. RAW 264.7 cells were stimulated 
with 0.1 μg/mL LPS and treated with HNE or 15-HETE for 24 h (white bars) or 48 h 
(black bars). MMP9 secreted in the culture medium was assayed by ELISA, and levels 
were determined using a standard curve prepared with recombinant mouse MMP9 ( X  ± 
stdev, n≥3). Asterisks represent significant (p < 0.05) changes.  
 
 
 
Figure 55. Determination of TIMP1 levels by ELISA. RAW 264.7 cells were stimulated 
with 0.1 μg/mL LPS and treated with HNE or 15-HETE for 24 h (white bars) or 48 h 
(black bars). TIMP1 secreted in the culture medium was assayed by ELISA, and levels 
were determined using a standard curve prepared with recombinant mouse TIMP1 ( X  ± 
stdev, n≥3). Asterisks represent significant (p < 0.05) changes.  
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Measurement of MMP9 Activity by Zymography 
Given the shift in balance between elevated levels of MMP9 and decreased 
TIMP1, the activation state of MMP9 was examined. Since both pro- and active-forms of 
MMP9 are detected by ELISA, MMP9 protein levels do not necessarily correlate with 
activity. Thus, LPS stimulated cells were treated with 10 or 35 μM HNE for 48 h, and 
culture medium was tested by zymography using gelatin as a substrate (Figure 56). As 
shown by the clear bands against the dark background, MMP9s proteolytic activity 
increases with increasing HNE concentration. 
 
A B
LPS (1μg/mL)
HNE (μM)
+         +         +
0        10        35
active MMP9
 
 
Figure 56. HNE stimulates MMP9 secretion and activity. Cells were treated with HNE 
and immediately stimulated with LPS. (A) Culture medium was collected after 48 h and 
subjected to SDS-PAGE zymography. (B) The bands were quantified by scanning 
densitometry. Data shown are representative of three independent experiments. Asterisks 
represent significant (p < 0.05) changes.  
 
Role of active MMP9 in Mmp9 Regulation 
Active MMP9 has been shown to participate in a positive feedback loop 
mediating Mmp9 expression. Therefore, an MMP9 inhibitor was added during the 
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incubation of stimulated HNE treated cells to prevent proteolytic activity and determine 
whether active MMP9 activity contributes to MMP9 secretion. These experiments 
revealed that active MMP9 does in fact participate in downstream Mmp9 expression, 
translation, and secretion. As shown in Figure 57, MMP9 secretion mediated by HNE in 
LPS-stimulated cells was reduced by the inhibitor, whereas MMP9 secretion mediated by 
LPS stimulation was not. This is likely a consequence of the decreased level of TIMP1, 
and subsequent active state of MMP9, when cells are exposed to HNE, in contrast to the 
inactive MMP9 bound to TIMP1 in LPS-treated cells. 
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Figure 57. Active MMP9 mediates MMP9 Regulation. RAW 264.7 cells were stimulated 
with 0.1 μg/mL LPS and treated with an MMP9 inhibitor in the absence (black points) or 
presence (red points) of 35 μM HNE for 48. MMP9 secreted in the culture medium was 
assayed by ELISA, and levels were determined using a standard curve prepared with 
recombinant mouse MMP9 ( X  ± stdev, n≥3). 
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Effects on HNE and 15-HETE on Il1b and Tnf secretion 
There is considerable evidence that active MMP9 plays a role in the shedding of 
TNFα150 and IL-1β182 from membrane-anchored precursors. In turn, both of these 
cytokines can ultimately induce Mmp9 expression, initiating a positive feedback cycle.183 
Protein validation of secreted IL1B demonstrated that while HNE-treatment decreased 
the level of the cytokine, 15-HETE had no effect (Figure 58). The decrease of TNFα 
secretion influenced by 15-HETE was consistent with mRNA levels. However, while 
HNE increased Tnfa mRNA, secreted TNFα protein was decreased (Figure 59). This 
result may not necessarily be due to impaired translation, but to impaired cleavage of the 
membrane bound form. A second explanation may be that TNFα is bound to its cognate 
receptor and thus not in a soluble form for detection. Regardless, similar findings were 
observed in human monocytes where TNFα secretion was markedly increased by LPS, 
but inhibited by HNE in a dose-dependent manner.184  
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Figure 58. Determination of IL1B levels by ELISA. RAW 264.7 cells were stimulated 
with 0.1 μg/mL LPS and treated with HNE or 15-HETE for 24 h (white bars) or 48 h 
(black bars). IL1B secreted in the culture medium was assayed by ELISA, and levels 
were determined using a standard curve prepared with recombinant mouse IL1B ( X  ± 
stdev, n≥3). Asterisks represent significant (p < 0.05) changes.  
 
 
 
 127
 
Figure 59. Determination of TNF levels by ELISA. RAW 264.7 cells were stimulated 
with 0.1 μg/mL LPS and treated with HNE or 15-HETE for 24 h (white bars) or 48 h 
(black bars). TNF secreted in the culture medium was assayed by ELISA, and levels were 
determined using a standard curve prepared with recombinant mouse TNF ( X  ± stdev, 
n≥3). Asterisks represent significant (p < 0.05) changes.  
 
MMP9 feedback 
The mechanisms involved in TNF and IL1B secretion described above remain 
unknown. However, active MMP9 has previously been shown to cleave both TNF and 
IL1B from their membrane bound pro-form to their soluble active form.150, 182 Given that 
an ELISA will only detect soluble forms of these cytokines, LPS stimulated cells were 
treated with both HNE and the MMP9 inhibitor, and culture medium was assayed for 
secreted TNFα and IL1B. As shown in Figure 60, the presence of the MMP9 inhibitor 
reduced the levels of TNF, but not IL1B. These results suggest that active MMP9 cleaves 
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TNF, which subsequently binds its receptor leading to signal transduction and, ultimately, 
Mmp9 expression. 
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Figure 60. MMP9-mediated cytokine secretion. Stimulated cells were treated with HNE 
in the absence and presence of an MMP9 inhibitor. After 48 h (a) TNF and (b) IL1B 
secreted in the culture medium were assayed by ELISA ( X  ± stdev, n≥3). (black bars no 
MMP9 inhibitor, white bars MMP9 inhibitor). Asterisks represent significant (p < 0.05) 
changes.  
 
Tnf-mediated Mmp9 expression 
Although the level of TNF was lower then anticipated in HNE treated cells, there 
was still considerable amount of TNF secreted into culture medium. Given that TNFα 
signaling can contribute to Mmp9 expression, neutralizing Tnfα antibodies were used to 
block soluble Tnfα from mediating signal transduction (Figure 61). Without any lipid 
peroxidation product present, neutralization decreased LPS mediated Mmp9 secretion 
nearly to that of unstimulated cells. In the presence of HNE, MMP9 was reduced, but still 
present in a much greater quantity than the LPS control. This indicates that TNF 
synergizes with other mediators for MMP9 secretion in HNE treated cells. Blocking 
TNFα in 15-HETE treated LPS stimulated cells reduced MMP9 protein to that of the LPS 
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control, demonstrating that MMP9 secretion in 15-HETE treated stimulated cells is a 
consequence of LPS signal transduction. 
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Figure 61. Cytokine mediated Mmp9 expression. RAW 264.7 cells were stimulated with 
0.1 μg/mL LPS and treated with HNE or 15-HETE for 24 h (white bars) or 48 h (black 
bars) in the absence or presence of a neutralizing TNF antibody. MMP9 secreted in the 
culture medium was assayed by ELISA, and levels were determined using a standard 
curve prepared with recombinant mouse MMP9 ( X  ± stdev, n≥3). Asterisks represent 
significant (p < 0.05) changes.  
 
 
Role of NF-κB and MAP Kinases in Mmp9 regulation 
MMP9 is primarily regulated at the level of transcription by a number of 
pathways (i.e., NF-κB, p38, ERK1/2, and JNK), depending on cell type and source of 
stimulation; therefore, the specific signaling cascades leading to HNE-mediated MMP9 
expression in RAW 264.7 cells were investigated. Prior to HNE treatment and LPS 
stimulation, cells were incubated with chemical inhibitors, namely PDTC, SP600125, 
U0126, or SB203580, to prevent signaling through NF-κB, JNK, ERK1/2, or p38, 
respectively. Inhibitor concentrations were chosen according to literature values and the 
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range was extended in both directions to ensure pathway inhibition. After 48 h, culture 
medium was assayed for MMP9 secretion. While inhibition of NF-κB and JNK had no 
effect on the level of MMP9 (Figure 62, A and B), ERK1/2 inhibition decreased the level 
of MMP9 detected in both LPS and HNE+LPS treated cells (Figure 62, C). Importantly, 
p38 inhibition only attenuated MMP9 secretion in the presence of HNE (Figure 62, D). In 
agreement with previous studies, HNE promoted the activation of p38,110, 181 which 
synergized with ERK1/2 signaling mediated by LPS-stimulation. 
 
 
Figure 62. Effects of chemical inhibitors on MMP9 secretion. Cells were pre-treated with 
increasing concentrations of PDTC, SP600125, SB203580, and U0126 to inhibit NF-κB, 
JNK, p38, and ERK1/2, respectively. After 1.5 h, cells were treated with LPS in the 
absence or presence of 35 μM HNE for 48 h. Supernatant was assayed by ELISA to 
determine the level of secreted MMP9 ( X  ± stdev, n≥3). 
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Part 2: 4-Hydroxynonenal Impairs LPS-Mediated Expression of Inducible Nitric 
Oxide Synthase 
 
 Nitric oxide (NO) is a potent molecule that mediates several physiological 
responses including the degradation of foreign material within phagolysosomes via 
microbicidal burst. As demonstrated in Chapter II, however, RAW 264.7 cells incubated 
with HNE are unable to generate NO. Additionally, HNE was proven capable of altering 
the gene expression of several NF-kB pathway members, as was presented in Chapter III.  
Taken together, these results indicate that modulated NF-κB signaling impaired the 
generation of NO. Furthermore, these results suggest this NO deficiency as one possible 
explanation for the lack of Hz degradation within phagocytic cells.60 In order to 
investigate the regulation of NO, RAW 264.7 and J774 macrophage-like cells were 
treated with increasing concentrations of HNE in order to monitor the effects on NF-κB 
pathway. 
 
HNE impairs nitric oxide generation and inducible nitric oxide synthase expression in 
macrophage-like cells 
 
RAW 264.7 and J774 macrophage-like cells were treated with increasing 
concentrations of HNE (0-35 µM) and immediately stimulated with LPS to activate NF-
κB signal transduction. A time course of the effects of HNE on the generation of NO 
from macrophage-like cells is shown in Figure 63. While LPS stimulated NO in both 
model cell lines, incubation with HNE inhibited LPS-mediated NO production in a dose- 
and time-dependent manner. To determine whether inhibition of NO was a consequence 
of decreased iNOS expression, lysate was collected from LPS-stimulated cells cultured in 
the presence of HNE. In accord with the levels of NO detected at 24 h, Figure 64 shows 
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that iNOS expression is inhibited by HNE in a dose-dependent manner on both model 
cells lines. 
 
 
Figure 63. Time course of inhibition of NO production by HNE. (A) RAW 264.7 and (B) 
J774 macrophage-like cells were treated with HNE (0-35 μM) and immediately 
stimulated with LPS (1 μg/mL). Supernatants were collected every two hours and nitrite 
levels were determined via the Griess assay using a standard curve prepared with sodium 
nitrite ( X  ± stdev, n=3). 
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Figure 64. HNE impairs LPS-mediated iNOS expression. (A) RAW 264.7 and (B) J774 
macrophage cells were treated with increasing concentrations of HNE and immediately 
stimulated with LPS to initiate NF-κB signaling. After 24 h, cells were lysed and the 
expression of iNOS within cytosolic extracts was assessed by immunobloting. Data are 
representative of at least 3 independent experiments. 
 
 
HNE inhibits the phosphorylation and degradation of IκBα  
 LPS-mediated expression of iNOS signals through the NF-κB cascade. A critical 
step in this cascade is the tightly regulated degradation of IκB, a process that is initiated 
by phosphorylation of Ser-32 and -36 on IκBα and Ser-19 and -23 on IκBβ by the IκB 
Kinase (IKK) complex. In order to determine if iNOS expression is impaired as a result 
of impaired IκB degradation, the level of IκBα was assessed. Figure 65 (A and B) show 
that IκBα is degraded within 10 min of LPS stimulation in RAW 264.7 and J774 cells, 
respectively. In the presence of 35 μM HNE, however, degradation is inhibited. Since 
degradation is a direct consequence of IκB phosphorylation, levels of phosphorylated 
Ser-32 of IκB were determined using an antibody against phospho-Ser-32 of IκBα. As 
shown in Figure 65 (C and D), HNE treatment inhibits the phosphorylation of LPS-
stimulated RAW 264.7 and J774 IκB, respectively. Thus, HNE appears to prevent IκB 
degradation through impaired IκB phosphorylation, in accord with impaired IκB 
phosphorylation and abolished NO generation in serum-deprived RAW 264.7 cells 
treated with HNE.110 
 
 134
Time (min)
IkB
HNE (μM) 0 35  
0    5   10   15 0    5    10   15Time (min)
IkB
HNE (μM) 0 35  
0    5   10   15 0    5    10   15
Time (min)
pIkB
HNE (μM) 0 35  
0    5   10   15 0    5    10   15Time (min)
pIkB
HNE (μM) 0 35  
0    5   10   15 0    5    10   15
A B
C D
 
 
Figure 65. HNE inhibits LPS-mediated phosphorylation and degradation of IκBα. (A, C) 
RAW 264.7 and (B, D) J774 cells were untreated or treated with 35 μM HNE and 
stimulated with LPS for 0, 5, 10, or 15 min prior to lysing and the expression of total IκB 
and phosphorylated-IκB was determined by immunoblotting. Data are representative of at 
least 3 independent experiments. 
 
 
 
Phosphorylation of IκB is mediated by an active IκB kinase (IKK) complex. This 
complex is composed of three subunits, namely IKKα, IKKβ (which comprise the 
catalytic domain), and IKKγ (which serves a regulatory function). Because IKK appears 
inactive in HNE-treated cells, a trend that has also been reported for cells exposed to 
acrolein185 and 15-deoxyprostaglandin J2113, 186 which are structurally related to HNE, the 
levels of IKKα and IKKβ 2 h after HNE-treatment were assessed by immunoblotting. 
While IKKα and IKKβ levels appear stable, immunoblotting against reduced HNE-
Michael adducts demonstrates HNE-modified protein in the molecular weight range of 
IKKα and IKKβ (Figure 66 A). Figure 66 B shows that 12 h after HNE-treatment IKKα 
protein decreases with increasing concentration of HNE, yet IKKβ maintains a stable 
level. Given that HNE-modified protein can be cleared from cells through degradation,131 
it was proposed that IKKα may be modified by HNE.  The schematic shown in Figure 67 
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illustrates the workflow used to assess HNE-modified IKKα. Briefly, IKKα was purified 
from crude lysate by immunoprecipitation with an antibody against IKKα, and the IKKα 
eluent was examined for the presence of an HNE adduct by immunoblotting with an 
antibody against reduced HNE-Michael adducts. The results demonstrate that HNE does 
target IKKα in culture but provide no information regarding the site of HNE adduction.  
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Figure 66. HNE alters IKK protein levels. RAW 264.7 cells were stimulated with LPS 
and treated with increasing concentrations of HNE (0-35 μM) (A) Immunoblots against 
HNE-modified protein, IKKα, and IKKβ 2 h after HNE treatment (B) Immunoblots 
against IKKα and IKKβ 12 h after HNE treatment. 
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Figure 67. Scheme showing the identification of HNE-adducted IKKα. IKKα was 
purified from lysate using IKKα cross-linked magnetic beads. Bound IKKα was eluted, 
reduced to stabilize adducts, and immunoblotted using an antibody against reduced HNE 
Michael adducts.  
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HNE-IKK adduct mapping 
Structurally, IKKα and IKKβ are very similar (Figure 68): each subunit contains 
an N-terminal kinase domain, a leucine zipper region, and a C-terminal helix-loop-helix 
domain.187 Previous studies using RAW 264.7 demonstrated that the activity both IKKα 
and -β is abolished in the presence of auranofin, a thiol-reactive metal compound, 
suggesting that both IKK subunits contain a sensitive cysteine residue.179 The location of 
a sensitive cysteine within the activation loop of IKKβ was since demonstrated via site-
directed mutagenesis; substitution of Cys-179 with alanine (C179A) reversed the activity 
of auranofin and several other inhibitory compounds in independent studies.176, 177, 188 
Consequently, Cys178 and Cys179 within the activation loops of IKKα and IKKβ, 
respectively, are potential targets of HNE adduction.  
 
IKKα:          DLGYAK DV DQGSLCTSFVGTLQYLAPE
IKKβ:          DLGYAK EL  DQGSLCTSFVGTLQYLAPE
kinase domain LZ HLH
S176
S180
NBD
738-743
745
737-742
756
IKKα
IKKβ
S177
S181
165
166
191
192
 
Figure 68. Schematic representation of IKKα and IKKβ and alignment of the activation 
loops. Phosphorylation sites that are critical for kinase activation are indicated and 
underlined. Invariant residues are boxed and putative HNE binding sites are colored red. 
Adapted from references 177 and 189. 
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Synthetic peptides representing tryptic cleavages of both activation loops were 
individually incubated with HNE for 3 h at 37ºC, reduced with NaBH4, neutralized, and 
purified by reverse-phase HPLC. The ability of HNE to adduct the cysteine residues of 
both IKKα and IKK β peptides was investigated using mass spectrometry. Full scan MS 
analyses (Figure 69) demonstrated mass additions of 158 m/z for the molecular ions of 
both HNE-treated peptide samples, consistent with reduced HNE adduction via Michael 
addition (Table 8).   
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Figure 69. MS spectra of IKKα and IKKβ peptides. Full scan MS spectra were acquired 
for (A) IKKα peptide, (B) IKKβ peptide, (C) IKKα peptide incubated with HNE, and (D) 
IKKβ peptide incubated with HNE showing the doubly charged parent masses [M+2H]2+. 
The mass increases of both peptides incubated with HNE are consistent with the addition 
of a single reduced Michael adduct (158 Da) on each parent peptide [M+2H]2+. 
 
 
 
 
 139
Table 8. MS analysis of IKK activation loop peptides 
 
Sample Observed Molecular Ion (2+) Predicted Molecular Ion (2+)
IKKα 1437.6 1437.7 
IKKα + HNE 1516.2 1517.7 
IKKβ 1506.3 1505.8 
IKKβ + HNE 1584.2 1584.8 
 
 
The molecular ions were selected to undergo CID, the product ions were scanned, 
and the fragmentation patterns were analyzed. MS/MS spectra of the IKKα peptide 
DVDQGSLCTSFVGTLQYLAPELFENK and IKKβ peptide 
ELDQGSLCTSFVGTLQYLAPELLEQQK incubated with HNE are shown in Figures 70 
and 71, respectively. Given the high molecular weight of these tryptic peptides, low 
molecular weight species (<20% of the precursor m/z) were unable to be identified due to 
the low mass cutoff inherent to ion traps. However, inspection of the fragmentation 
patterns confirms an HNE adduct on the cysteine residue of both peptides: there is an 
addition of 158 Da on all b-ions C-terminal to the modified residue, and on all y-ions N-
terminal to the modified residue. Fragmentation patterns of control peptides were 
assessed for comparison and used to validate the formation of an HNE adduct at both 
cysteine residues. Based upon these results, it was determined that cysteine-178 and 
cysteine-179 was modified with a reduced HNE Michael adduct.  
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Figure 70. MS/MS spectrum of the synthetic peptide 
DVDQGSLCTSFVGTLQYLAPELFENK from IKKα incubated with HNE. The 
fragmentation pattern of the molecular ion [M+2H]+2 1516.2 is shown and is consistent 
with a reduced Michael adduct on the cysteine residue. Fragments containing an HNE-
modified residue are indicated with an asterisk. 
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Figure 71. MS/MS spectrum of the synthetic peptide 
ELDQGSLCTSFVGTLQYLAPELLEQQK from IKKβ incubated with HNE. The 
fragmentation pattern of the molecular ion [M+2H]+2 1584.2 is shown and is consistent 
with a reduced Michael adduct on the cysteine residue. Fragments containing an HNE-
modified residue are indicated with an asterisk. 
 
 
Conclusions 
 
It is generally accepted that lipid peroxidation products associated with native Hz 
are a major contributor of Hz activity. Consistent with these results, HNE has been 
reported to differentially influence signal transduction.71 The data presented within this 
chapter provide insight regarding the biological activity of HNE and its ability to 
stimulate (e.g., p38 MAPK) as well as inhibit (e.g., NF-κB) immune responses. The 
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ability of Hz to enhance MMP9 activity146 and the altered expression of several genes 
involved in Mmp9 regulation by HNE44 prompted exploration of the roles of lipid 
peroxidation products on MMP9 activity. The studies presented in Part I indicated that 
HNE, not 15-HETE, alters MMP9 regulation at multiple levels in activated immune cells 
(Figure 72). Stimulation of MMP9 by HNE occurs at the transcriptional level, primarily 
by the p38 MAPK cascade. Simultaneously, the expression of MMP9’s cognate inhibitor, 
TIMP1, is severely repressed by HNE, thus enhancing the activity of MMP9. Timp1 is 
regulated by STAT3 signaling,190, 191 and Stat3 (along with Stat1 and Stat5) is 
differentially expressed in response to HNE (Table 2). Therefore, altered expression of 
STAT3 may be responsible for repressed levels of TIMP1.  Altered Mmp9 and Timp1 
expression changes indicate an imbalance in favor of ECM destruction.146 Inhibition of 
active MMP9 decreased shedding of TNFα and repressed MMP9 secretion, indicating 
that active MMP9 participates in a positive feedback cycle. These results suggest possible 
mechanisms mediating ECM degradation in CM and other pathogeneses where lipid 
peroxidation is active.  
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Figure 72. Schematic depicting the proposed mechanism of MMP9 regulation by HNE in 
LPS-stimulated RAW 264.7 macrophage-like cells. p38 MAPK synergizes with LPS-
mediated ERK1/2 MAPK signaling initiating a positive feedback cycle: MMP9 secreted 
into the extracellular matrix (ECM) is in a pro-form. Upon cleavage of the cysteine-
switch motif, MMP9 becomes activated. Repressed expression of Timp1 results in basal 
levels of TIMP1 and, therefore, no inhibition of active MMP9. Active MMP9 cleaves 
TNF from its membrane-bound form to produce a soluble cytokine that enhances Mmp9 
expression.  
 
Studies described in Part II demonstrate that the production of NO, which is 
essential for robust microbicidal burst and innate immune activity, is inhibited by HNE. 
Data support that HNE inhibits murine macrophage NF-κB signaling at level of IKK 
activity (Figure 73). The lack of IκB degradation results in inhibition of NF-κB 
translocation, a trend observed in H1299 and Jurkat T cells,74 and impaired NF-κB-
mediated iNOS expression and NO production. The ability of HNE to modulate enzyme 
activity is well-established* and provides a rational explanation for the inactivation of 
IKK. The identification of sensitive cysteines within the activation loop of IKKα and 
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IKKβ suggest that HNE can impair IKK activity through the formation of adducts within 
the kinase domain. Furthermore, other cysteine residues (in addition to histidine and 
lysine) of IKK are also potential targets for modification that may result in IKK 
inactivation.  
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Figure 73. Schematic depicting the proposed mechanism of NF-κB inhibition 
in LPS-stimulated RAW 264.7 and J774 macrophage-like cells. LPS mediates the 
activation of IKK and subsequent phosphorylation of IκB. Release and degradation of 
IκB liberates NF-κB to mediate the expression of iNOS and, therefore, generation of NO. 
Treatment of cells with HNE, however, prevents the phosphorylation of IκB and all 
downstream signal transduction. Evidence indicates that HNE directly inhibits the 
activity of IKK through the formation of an adduct, likely in the activation loop of the 
IKK’s kinase domain. 
 
 
Synopsis and Future Directions 
 
In the preceding chapters, the biological activity of fatty acid oxidation products 
was explored in the context of macrophage immunomodulation. BH was shown to 
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mediate non-enzymatic lipid peroxidation resulting in the formation of HNE, HETEs, 
isoketals, and ghost membrane-derived oxidation products. The global responses to BH, 
HNE and 15-HETE were identified, and gene expression alterations suggested that HNE 
was likely a major source of Hz’s activity. Finally, the ability of HNE to simultaneously 
stimulate and inhibit signal transduction pathways was demonstrated. These results 
provide a wealth of knowledge about the heme moiety, HNE, and 15-HETE and their 
activity on macrophage-like cells, however, they also highlight several research 
challenges. While the effects of several constituent components of composite Hz on LPS-
stimulated cells are presented in this dissertation, the response to Hz during infection is 
exponentially more complicated with multiple stimuli activating innate immune cells and 
synergism occurring between biologically active species. Several studies are currently 
underway: the mechanisms leading to HNE-mediated repression of TIMP1 mRNA and 
protein (presented in Chapter IV Part I) are being examined, and IKK protein is being 
mapped for HNE adduction sites (suggested by the immunoprecipitation studies 
presented in Chapter IV Part II). A more complete understanding of the effects of 
individual Hz components should establish the molecular basis of native Hz mediated 
immunomodulation. Future research will likely be focused on integrating the complex, 
interacting pathways that govern immune responses by known, and as of yet unknown, 
components of Hz. Furthermore, this knowledge may provide the basis for new insights 
into approaches to treat malaria.  
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APPENDIX A 
 
MALARIA-RELEVANT GENE EXPRESSION CHANGES 
 
Selected genes that are associated with (A) specific genes or gene products 
correlated to malarial infection or (B) genes that are classified under specific 
overexpressed biological processes in malaria models that are modulated ≥1.8-fold by 35 
μM HNE or 0.1 mg/mL BH at 6 or 24 h are listed in Tables 1-9. Each table includes the 
gene symbol, gene description, fold-change relative to LPS-stimulated cells, Probset ID 
number, and literature reference, if applicable.  
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Table 9. Selected genes up-regulated by 35 μM HNE at 6 ha 
Gene 
Symbol Description 
Fold 
Change 
Affymetrix 
Probeset 
ID 
MGI 
Gene ID Ref 
Apoptosis123.124 
Dap death-associated protein 1.8 10423498 1918190  
Dnase2a deoxyribonuclease II alpha 1.8 10573461 1329019  
Sgpl1 sphingosine phosphate lyase 1 1.8 10369413 1261415  
Cell Cycle124 
Plk2 polo-like kinase 2 (Drosophila) 3.7 10407126 1099790  
Pdcd4 programmed cell death 4 3.6 10463997 107490  
Trp53inp1 transformation related protein 53 inducible nuclear pr 
3.4 10503259 1926609  
Plekho1 pleckstrin homology domain containing, family O member 1 
2.3 10500295 1914470  
Ccng1 cyclin G1 2.2 10385271 102890  
Riok3 RIO kinase 3 1.9 10453900 1914128  
Nek3 NIMA (never in mitosis gene a)-related expressed kinase 3 
1.8 10577492 1344371  
Cell-Cell Signaling123 
Trpv4 transient receptor potential cation channel, subfamily V, 
2.0 10532839 1926945  
Cldn11 claudin 11 1.8 10491313 106925  
Defense Response123.124 
Als2 amyotrophic lateral sclerosis 2 (juvenile) homologue (human) 
2.0 10354979 1921268  
Nlrp10 NLR family, pyrin domain containing 10 
1.9 10566709 2444084  
Immune Response123.124 
Procr protein C receptor, endothelial 4.3 10477717 104596  
Sqstm1 sequestosome 1 3.2 10385572 107931  
Il7r interleukin 7 receptor 3.1 10427628 96562  
Tnfrsf10b tumor necrosis factor receptor superfamily, member 10b 
2.4 10416230 1341090  
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Table 9, continued. 
 
Pglyrp3 peptidoglycan recognition protein 3 2.1 10493842 2685266  
Cd300lb CD300 antigen like family member 
B 
2.0 10392796 2685099  
Clec4d C-type lectin domain family 4, 
member d 
1.9 10541614 1298389  
Cd300a CD300A antigen 1.9 10382438 2443411  
Inppl1 inositol polyphosphate 
phosphatase-like 1 
1.9 10565996 1333787  
Icam1 intercellular adhesion molecule 1 1.8 10583519 96392  
Inflammatory Response123.124 
Pla2g7 phospholipase A2, group VII 
(platelet-activating factor a 
3.2 10445293 1351327  
Lipa lysosomal acid lipase A 2.9 10467139 96789  
Ly96 lymphocyte antigen 96 2.3 10344966 1341909 120 
Nlrc4 NLR family, CARD domain 
containing 4 
2.3 10452879 3036243  
Intracellular Protein Transport 
Zmat3 zinc finger matrin type 3 2.6 10497673 1195270  
Chml choroideremia-like 2.0 10360460 101913  
Napb N-ethylmaleimide sensitive fusion 
protein attachment protei 
1.9 10488387 104562  
Metabolic Process124 
Blvrb biliverdin reductase B (flavin 
reductase (NADPH)) 
3.6 10551347 2385271 121 
Htatip2 HIV-1 tat interactive protein 2, 
homologue (human) 
3.0 10553403 1859271  
Hbp1 high mobility group box 
transcription factor 1 
2.9 10399897 894659  
Camk1d Calcium 2.6 10479852 2442190  
Pgd phosphogluconate  dehydrogenase 2.4 10518570 97553 120 
Mocos molybdenum cofactor sulfurase 2.4 10454353 1915841  
Alox5ap arachidonate 5-lipoxygenase 
activating protein 
2.3 10527638 107505 120 
Crot carnitine O-octanoyltransferase 2.3 10528102 1921364  
Pik3cb phosphatidylinositol 3-kinase, 
catalytic, beta polypeptide 
2.3 10595924 1922019  
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Table 9, continued. 
Lpin1 lipin 1 2.2 10399478 1891340  
Gsr glutathione reductase 2.1 10571274 95804  
Mtmr10 myotubularin related protein 10 2.1 10553897 2142292  
Ulk1 Unc-51 like kinase 1 (C. elegans) 2.1 10532472 1270126  
Calr3 calreticulin 3 2.0 10579691 1920566  
Atp6v1a ATPase, H+ transporting, 
lysosomal V1 subunit A 
1.9 10439566 1201780  
Aldh6a1 aldehyde dehydrogenase family 6, 
subfamily A1 
1.9 10401473 1915077  
Ephx1 epoxide hydrolase 1, microsomal 1.9 10360684 95405  
Pgm2l1 phosphoglucomutase 2-like 1 1.9 10555303 1918224  
Adi1 Acireductone dioxygenase 1 1.9 10395058 2144929  
Pcyox1 prenylcysteine oxidase 1 1.9 10545910 1914131  
Hsd17b1
1 
hydroxysteroid (17-beta) 
dehydrogenase 11 
1.8 10531919 2149821  
Rpp38 Ribonuclease P 1.8 10479749 2443607  
Protein Folding123 
Dnajb4 DnaJ (Hsp40) homologue, 
subfamily B, member 4 
4.9 10502823 1914285  
Fkbpl FK506 binding protein-like 2.0 10444436 1932127  
Fkbp14 FK506 binding protein 14 1.8 10544885 2387639  
Regulation of Apoptosis123 
Serpinb9 serine (or cysteine) peptidase 
inhibitor, clade B, memb 
2.5 10404429 106603  
Bid BH3 interacting domain death 
agonist 
2.2 10547531 108093  
Bcl2l11 BCL2-like 11 (apoptosis facilitator) 2.0 10475866 1197519  
Regulation of Transcription, DNA-Dependent123 
Zbtb20 zinc finger and BTB domain 
containing 20 
3.6 10435789 
10435769 
1929213  
Creg1 cellular repressor of E1A-stimulated 
genes 1 
3.5 10351347 1344382 120 
Nr1d2 nuclear receptor subfamily 1, group 
D, member 2 
3.2 10417734 2449205  
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Table 9, continued. 
Bhlhb3 basic helix-loop-helix domain 
containing, class B3 
3.1 10549276 1930704  
Eid3 EP300 interacting inhibitor of 
differentiation 3 
2.8 10365286 1913591  
Phf21a PHD finger protein 21A 2.4 10474006 2384756  
Zscan29 zinc finger SCAN domains 29 2.4 10486712 2139317  
Myst1 MYST histone acetyltransferase 1 2.1 10557831 1915023  
Nfic nuclear factor I 1.9 10371176 109591  
Maf1 MAF1 homologue (S. cerevisiae) 1.9 10424833 1916127  
Mafg v-maf musculoaponeurotic 
fibrosarcoma oncogene family, prot 
1.9 10393881 96911  
Mapk14 mitogen-activated protein kinase 14 1.8 10443391 1346865 120 
Cep290 centrosomal protein 290 1.8 10366073 2384917  
Snapc5 small nuclear RNA activating 
complex, polypeptide 5 
1.8 10586176 1914282  
Rxra retinoid X receptor alpha 1.8 10470446 98214  
Bbx bobby sox homologue (Drosophila) 1.8 10439854 1917758  
Response to Stress123 
Srxn1 sulfiredoxin 1 homologue (S. 
cerevisiae) 
10.3 10477061 104971  
Gclm glutamate-cysteine ligase , modifier 
subunit 
7.4 10495763 104995  
Gsta1 glutathione S-transferase, alpha 1 
(Ya) 
6.8 10587323 
10587331 
1095417  
Hmox1 heme oxygenase (decycling) 1 6.0 10572897 96163 120 
121 
Dnajb4 DnaJ (Hsp40) homologue, 
subfamily B, member 4 
5.3 10502823 1914285  
Adrb2 adrenergic receptor, beta 2 3.9 10459288 87938  
Prdx1 peroxiredoxin 1 3.1 10507328 
10436048 
99523 122 
Idh1 isocitrate dehydrogenase 1 
(NADP+), soluble 
3.1 10355214 96413  
Hspa1b heat shock protein 1B 2.6 10450367 99517  
Hspa4l heat shock protein 4 like 2.1 10491780 107422  
Txnrd1 thioredoxin reductase 1 2.1 10365260 1354175  
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Hsph1 heat shock 105kDa/110kDa protein 
1 
2.1 10535904 1053590
4 
120 
G6pdx glucose-6-phosphate 
dehydrogenase X-linked 
2.0 10605338 105979  
Apex1 Apurinic 1.8 10414522 88042  
Ahsa2 AHA1, activator of heat shock 
protein ATPase homologue 2 (ye 
1.8 10384672 1916133  
Signal Transduction124 
Kitl kit ligand 3.9 10366052 96974  
Rasgrp3 RAS, guanyl releasing protein 3 3.7 10446965 3028579  
Cebpa CCAAT 3.4 10552140 99480  
Olfr26 olfactory receptor 26 3.4 10584470 109309  
Nrp1 neuropilin 1 3.0 10576639 106206  
Plekhm1 pleckstrin homology domain 
containing, family M (with RU 
3.0 10391918 2443207  
Cxcr4 chemokine (C-X-C motif) receptor 4 2.8 10357472 109563  
Ralgps1 Ral GEF with PH domain and SH3 
binding motif 1 
2.7 10481804 1922008  
Olfr933 olfactory receptor 933 2.5 10584479 3030767  
Rasgef1
b 
RasGEF domain family, member 
1B 
2.5 10531610 2443755  
Nkiras1 NFKB inhibitor interacting Ras-like 
protein 1 
2.5 10412900 1916971  
Arhgap2
2 
Rho GTPase activating protein 22 2.4 10413951 2443418  
Spa17 sperm autoantigenic protein 17 2.2 10592336 1333778  
Bcl6 B-cell leukemia 2.2 10438738 107187 120 
Raf1 v-raf-leukemia viral oncogene 1 2.2 10547034 97847  
Tgfbr1 transforming growth factor, beta 
receptor I 
2.1 10504817 98728 120 
Rit1 Ras-like without CAAX 1 2.1 10493309 108053  
Calcoco
1 
calcium binding and coiled coil 
domain 1 
2.1 10433057 1914738  
Arhgap2
7 
Rho GTPase activating protein 27 2.0 10391895 1916903  
Csf1r colony stimulating factor 1 receptor 2.0 10456071 1339758  
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Ick intestinal cell kinase 1.9 10587299 1934157  
Srpk2 Serine 1.9 10528484 1201408  
Pld2 phospholipase D2 1.9 10377859 892877  
Cd36 CD36 antigen 1.9 10528207 107899  
Ptpra protein tyrosine phosphatase, 
receptor type, A 
1.9 10476163 97808  
Gnat3 guanine nucleotide binding protein, 
alpha transducing 3 
1.9 10519905 3588268  
Mtss1 metastasis suppressor 1 1.8 10428857 2384818  
Lpar1 lysophosphatidic acid receptor 1 1.8 10513256 108429  
Tbc1d8b TBC1 domain family, member 8B 1.8 10602020 1918101  
Cacna1a calcium channel, voltage-
dependent, P 
1.8 10573348 109482  
Edg5 endothelial differentiation, 
sphingolipid G-protein-coupled 
1.8 10591412 99569  
Translation 
Impact imprinted and ancient 2.1 10454039 1098233  
Eif2c3 eukaryotic translation initiation 
factor 2C, 3 
1.8 10516348 2446634  
Ubiquitin-Dependent Protein Catabolic Process124 
Gclc glutamate-cysteine ligase, catalytic 
subunit 
8.2 10587266 104990 120 
 
Rnf128 ring finger protein 128 4.0 10602009 1914139  
Fbxl20 F-box and leucine-rich repeat 
protein 20 
2.2 10390574 1919444  
Herc3 hect domain and RLD 3 2.1 10538658 1921248  
Map1lc3
b 
microtubule-associated protein 1 
light chain 3 beta 
2.1 10576056 1914693  
Fbxo31 F-box protein 31 1.8 10582231 1354708  
Fbxo30 F-box protein 30 1.8 10361748 1919115  
Fbxl17 F-box and leucine-rich repeat 
protein 17 
1.8 10452430 1354704  
Rnf167 ring finger protein 167 1.8 10377927 1917760  
Ube4b ubiquitination factor E4B, UFD2 
homologue (S. cerevisiae) 
1.8 10518642 1927086  
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Other 
Arrdc3 arrestin domain containing 3 7.0 10406407 2145242  
Zdhhc18 zinc finger, DHHC domain 
containing 18 
2.9 10517070 3527792 120 
Gabarapl
1 
gamma-aminobutyric acid 
(GABA(A)) receptor-associated 
protein-like 1 
2.8 10542200 1914980 120 
Lrrfip2 leucine rich repeat (in FLII) 
interacting protein 2 
1.8 10589723 1918518  
a Genes up-regulated ≥1.8-fold (p ≤ 0.01) at 6 h in HNE-treated RAW 264.7 cells that 
are associated with (1) specific genes or gene products correlated to malarial infection or 
HNE exposure (references listed by gene in column 7), or (2) specific over-expressed 
biological processes in malaria models (references listed with ontology in column 1), are 
shown in the table. Fold changes (FC) represent the average of three independent 
biological experiments. Bold FC indicate that multiple probes gave analogous results 
(average FC is shown). 
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 Table 10. Selected genes down-regulated by 35 μM HNE at 6 ha 
Gene 
Symbol Description 
Fold 
Change 
Affymetrix 
Probeset 
ID 
MGI 
Gene ID Ref 
Apoptosis123.124 
Phlda1 pleckstrin homology-like domain, 
family A, member 1  -2.6 
10366346 1096880  
Bcl2a1c B-cell leukemia -2.5 10589884 1278327  
Ddit4 DNA-damage-inducible transcript 4  -2.5 10369290 1921997  
Stk17b Serine -2.4 10354588 2138162  
Bcl2a1b B-cell leukemia 
-2.3 
10587683 
10587690 
10595633 
1278326  
Tnfaip8 tumor necrosis factor, alpha-
induced protein 8  -2.2 
10455647 2147191  
Xaf1 XIAP associated factor 1  -2.1 10378068 3772572  
Cell Cycle124 
Lif leukemia inhibitory factor  -11.6 10373918 96787  
Plk1 polo-like kinase 1 (Drosophila) -8.6 10557156 97621  
Kif11 kinesin family member 11  -8.3 10462796 1098231  
Anln anillin, actin binding protein (scraps 
homologue, Drosophila) -7.3 
10591781 1920174  
Nuf2  NUF2, NDC80 kinetochore 
complex component, homologue 
(S. cerevisia) 
-6.8 
10359890 1914227  
Kif20b kinesin family member 20B  -5.8 10462632 2444576  
Ccnb1 cyclin B1 
-5.3 
10411739 
10562637 
10515836 
88302  
Ccna2 cyclin A2  -5.1 10497831 108069  
Sgol2 shugoshin-like 2 (S. pombe)  -4.8 10346365 1098767  
Cdca2 cell division cycle associated 2  -4.7 10421029 1919787  
Aspm asp (abnormal spindle)-like, 
microcephaly associated 
(Drosophilia) 
-4.5 
10350392 1334448  
Ccnf cyclin F  -4.1 10448506 102551  
Nek6 NIMA (never in mitosis gene a)-
related expressed kinase 6  -4.1 
10471844 1891638  
Fbxo5 F-box protein 5  -4.0 10361375 1914391  
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Mki67 antigen identified by monoclonal 
antibody Ki 67  -4.0 
10568714 106035  
Cdc25c cell division cycle 25 homologue C 
(S. pombe)  -3.9 
10458195 88350  
Sgol1 shugoshin-like 1 (S. pombe)  -3.3 10451805 1919665  
Nek2 NIMA (never in mitosis gene a)-
related expressed kinase 2  -3.2 
10352767 109359  
Ccng2 cyclin G2  -3.1 10523297 1095734  
Spag5 sperm associated antigen 5  -3.1 10379127 1927470  
Bub1b budding uninhibited by 
benzimidazoles 1 homologue, beta 
(S. cerevisia) 
-2.9 
10474769 1333889  
Smc4 structural maintenance of 
chromosomes 4  -2.7 
10492558 1917349  
Gsg2 germ cell-specific gene 2  -2.6 10388234 1194498  
Cks2 CDC28 protein kinase regulatory 
subunit 2  -2.5 
10353004 
10405185 
10424779 
1913447  
Espl1 extra spindle poles-like 1 (S. C)  -2.5 10427166 2146156  
Ndc80 NDC80 homologue, kinetochore 
complex component (S. cerevisia) -2.5 
10452709 1914302  
Birc5 baculoviral IAP repeat-containing 5 -2.4 10382998 1203517  
Ercc6l  excision repair cross-
complementing rodent repair 
deficient 
-2.4 
10606071 2654144  
Sass6 spindle assembly 6 homologue (C. 
elegans)  -2.4 
10495574 1920026  
Cdkn2d cyclin-dependent kinase inhibitor 
2D (p19, inhibits CDK4) -2.3 
10591517 105387  
Cenpa centromere protein A -2.3 10520521 88375  
E2f8 E2F transcription factor 8  -2.3 10563780 1922038  
Sesn2 sestrin 2  -2.3 10516932 2651874  
Cdc25a cell division cycle 25 homologue A 
(S. pombe)  -2.2 
10589420 103198  
Dbf4 DBF4 homologue (S. cerevisiae)  -2.2 10528077 1351328  
Fancd2 Fanconi anemia, complementation 
group D2  -2.2 
10540738 2448480  
Nusap1 nucleolar and spindle associated 
protein 1  -2.1 
10474984 2675669  
Cks1b CDC28 protein kinase 1b  -1.8 10499639 1889208  
Nsl1 NSL1, MIND kinetochore complex 
component, homologue S. cerev -1.8 
10352709 2685830  
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Cell-Cell Signaling123 
Pxk PX domain containing serine -3.3 10412624 1289230  
Agrn agrin  -2.0 10519270 87961  
Dlg7 discs, large homologue 7 
(Drosophila)  -1.9 
10419323 2183453  
Metabolic Process123 
Hdc Histidine decarboxylase  -8.8 10487238 96062  
Pbk PDZ binding kinase  -4.6 10416037 1289156  
Abca1 ATP-binding cassette, sub-family A 
(ABC1), member 1  -4.5 
10512949 99607  
Mmp9 matrix metalloproteinase 9  -4.1 10478633 97011  
Lipg lipase, endothelial  -3.1 10459772 1341803  
Fgr Gardner-Rasheed feline sarcoma 
viral (Fgr) oncogene homologue -3.0 
10508772 95527  
Dgkh diacylglycerol kinase, eta  -2.2 10421774 2444188  
Neil3 nei like 3 (E. coli)  -2.2 10578690 2384588  
Src Rous sarcoma oncogene  -2.2 10477970 98397  
Fbxo15 F-box protein 15  -2.0 10457077 1354755  
Fen1 flap structure specific 
endonuclease 1  -2.0 
10465912 102779  
Alpk1 alpha-kinase 1  
-1.9 
10502042 
10502050 
10502052 
1918731  
Cry2 cryptochrome 2 (photolyase-like)  -1.9 10485170 1270859  
Mthfs 5, 10-methenyltetrahydrofolate 
synthetase  -1.9 
10587695 
10595630 
1340032  
Rara retinoic acid receptor, alpha  -1.9 10381082 97856  
Anp32a acidic (leucine-rich) nuclear 
phosphoprotein 32 family, m -1.8 
10586064 108447  
Nab2 Ngfi-A binding protein 2  -1.8 10373313   
Pdss1 prenyl (solanesyl) diphosphate 
synthase, subunit 1  -1.8 
10469712 1889278  
Pgs1 phosphatidylglycerophosphate 
synthase 1  -1.8 
10383012 1921701  
Psmb10 proteasome (prosome, macropain) 
subunit, beta type 10  -1.8 
10581378 1096380  
Rad54l RAD54 like (S. cerevisiae)  -1.7 10515257 894697  
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Cytokine and Chemokine Mediated Signaling Pathway124 
Stat1 signal transducer and activator of 
transcription 1  -2.2 
10346191 103063  
Stat5a  signal transducer and activator of 
transcription 5A  -2.1 
10381172 103036  
Stat3 signal transducer and activator of 
transcription 3  -2.0 
10391301 103038  
Jak2 Janus kinase 2  -1.8 10462363 96629  
Defense Response123.124 
Mx2 myxovirus (influenza virus) 
resistance 2  -7.9 
10437224 97244  
Saa3 serum amyloid A 3  -7.3 10563597 98223  
Ccr1 chemokine (C-C motif) receptor 1  -3.2 10598004 104618  
Sp110 Sp110 nuclear body protein  
-2.6 
10347928 
10356278 
10582874 
1923364  
Hck Hemopoietic cell kinase  -2.3 10477250 96052  
Penk1 preproenkephalin 1  -2.0 10511363 104629  
Sbno2 strawberry notch homologue 2 
(Drosophila)  -2.0 
10370721 2448490  
Immune Response123.124 
Il1a interleukin 1 alpha  -67.1 10487588 96542  
Il6 interleukin 6  -46.9 10520452 96559  
Il1b interleukin 1 beta  -33.7 10487597 96543  
Il1f6 interleukin 1 family, member 6  -12.8 10469793 1859324  
Cfb Complement factor B  -7.4 10450325 105975  
H28 histocompatibility 28  -6.9 10502801 95975  
Il1rn interleukin 1 receptor antagonist  -6.9 10469816 96547  
Il27 interleukin 27  -6.5 10567987 2384409  
Gbp5 guanylate nucleotide binding 
protein 5  -6.3 
10496539 2429943  
Il10 interleukin 10  -5.4 10349603 96537  
Oasl2 2'-5' oligoadenylate synthetase-like 
2  -5.1 
10524621 1344390  
Clec2d C-type lectin domain family 2, 
member d  -4.7 
10542156 2135589  
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Rsad2 radical S-adenosyl methionine 
domain containing 2  -4.7 
10399710 1929628  
Cd40 CD40 antigen  -4.3 10478678 88336  
Il1rl1 interleukin 1 receptor-like 1  -4.0 10345791 98427  
Cd300lf CD300 antigen like family member 
F  -3.9 
10392845 2442359  
Gbp3 guanylate nucleotide binding 
protein 3  -3.8 
10496580 1926263  
Ccl6 chemokine (C-C motif) ligand 6  -3.4 10389222 98263  
Irf7 interferon regulatory factor 7  -3.4 10569102 1859212  
Gbp1 guanylate nucleotide binding 
protein 1  -3.1 
10496555 95666  
Il18rap interleukin 18 receptor accessory 
protein  -3.0 
10345824 1338888  
Il4ra interleukin 4 receptor, alpha  -2.9 10557326 105367  
Cxcl14 chemokine (C-X-C motif) ligand 14 -2.8 10409579 1888514  
Clec4n C-type lectin domain family 4, 
member n  -2.7 
10541605 1861231  
Irf8 interferon regulatory factor 8  -2.5 10576034 96395  
Il18 interleukin 18  -2.3 10585194 107936  
Pou2f2 POU domain, class 2, transcription 
factor 2  -2.1 
10560964 101897  
Clec12a C-type lectin domain family 12, 
member a  -2.0 
10542164 3040968  
Clec5a C-type lectin domain family 5, 
member a  -1.9 
10544273 1345151  
Ercc1 excision repair cross-
complementing rodent repair 
deficient 
-1.8 
10550650 95412  
Ltb Lymphotoxin B  -1.8 10444752 104796  
Traf3ip2 Traf3 interacting protein 2  -1.8 10362615 2143599  
Inflammatory Response123.124 
Ccl2 chemokine (C-C motif) ligand 2  -47.2 10379511 98259  
Ccl7 chemokine (C-C motif) ligand 7  -22.6 10379518 99512  
Ccl22 chemokine (C-C motif) ligand 22  -13.0 10574213 1306779  
Fcgr2b Fc receptor, IgG, low affinity IIb  -7.7 10360028 95499  
Fcgr1 Fc receptor, IgG, high affinity I  -4.4 10500335   
 
 159
 
Table 10, continued. 
 
Cd44 CD44 antigen  -2.7 10485405 88338  
Aoah acyloxyacyl hydrolase  -2.3 10403871 1350928  
Ccl4 chemokine (C-C motif) ligand 4  -2.2 10379721 98261  
Cd86 CD86 antigen -1.8 10439312 101773  
Jmjd3 jumonji domain containing 3  -1.8 10387372 2448492  
Intracellular Protein Transport 
Ap1s3 adaptor-related protein complex 
AP-1, sigma 3  -2.2 
10355967 1891304  
Tacc3 transforming, acidic coiled-coil 
containing protein 3  -2.1 
10521090 1341163  
Kpna2  karyopherin (importin) alpha 2  
-2.0 
10392284 
10453512 
10497503 
103561  
Rffl ring finger and FYVE like domain 
containing protein  -1.8 
10389087 1914588  
Regulation of Apoptosis123 
Csf2 colony stimulating factor 2 
(granulocyte-macrophage)  -14.0 
10385912 1339752  
Bcl2l1 Bcl2-like 1  -3.7 10488655 88139  
Notch1 Notch gene homologue 1 
(Drosophila)  -3.5 
10481056 97363  
Casp4 caspase 4, apoptosis-related 
cysteine peptidase  -2.2 
10582997 107700  
Casp7 caspase 7  -2.0 10464128 109383  
Hells helicase, lymphoid specific  -2.0 10462973 106209  
Ier3 immediate early response 3 -2.0 10444890 104814  
Regulation of Transcription, DNA-Dependent123 
Trim30 tripartite motif-containing 30  -7.2 10566358 98178  
Mxd1 MAX dimerization protein 1  -4.7 10545921 96908  
Jdp2 Jun dimerization protein 2  -4.3 10397351 1932093  
Top2a topoisomerase (DNA) II alpha  -3.7 10390707 98790  
Nfkbiz nuclear factor of kappa light 
polypeptide gene enhancer i -3.4 
10439936 1931595  
Nr1d1 nuclear receptor subfamily 1, 
group D, member 1  -3.4 
10390691 2444210  
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Axud1 AXIN1 up-regulated 1  -3.0 10597758 2387989  
Bhlhb2 basic helix-loop-helix domain 
containing, class B2  -3.0 
10540472 1097714  
Osm Oncostatin M  -3.0 10373912 104749  
Klf7 Kruppel-like factor 7 (ubiquitous)  -2.6 10355141 1935151  
Foxm1 forkhead box M1  -2.5 10542079 1347487  
Asf1b ASF1 anti-silencing function 1 
homologue B (S. cerevisiae)  -2.4 
10573261 1914179  
Foxp1 forkhead box P1  -2.4 10546661 1914004  
Nr4a1 nuclear receptor subfamily 4, 
group A, member 1  -2.3 
10427035 1352454  
Carhsp1 calcium regulated heat stable 
protein 1  -2.1 
10437590 
10497752 
1196368  
Hivep3 human immunodeficiency virus 
type I enhancer binding prot -2.0 
10507677 106589  
Id1 inhibitor of DNA binding 1  -2.0 10477169 96396  
Zfp367 zinc finger protein 367  -2.0 10410092 2442266  
Plagl2 pleiomorphic adenoma gene-like 2  -1.9 10488697 1933165  
Zfp36 zinc finger protein 36 -1.9 10561453 99180  
Akna AT-hook transcription factor  -1.8 10513666 2140340  
Arid5a AT rich interactive domain 5A 
(Mrf1 like)  -1.8 
10345445 2443039  
Batf2 basic leucine zipper transcription 
factor, ATF-like 2  -1.8 
10460767 1921731  
Hivep2 human immunodeficiency virus 
type I enhancer binding prot -1.8 
10361807 1338076  
Hlx H2.0-like homeobox  -1.8 10360834 96109  
Ikzf1 IKAROS family zinc finger 1  -1.8 10374333 1342540  
Nfkb1 nuclear factor of kappa light 
polypeptide gene enhancer in -1.8 
10502299 97312  
Nufip1 nuclear fragile X mental retardation 
protein interacting -1.8 
10416510 1351474  
Pcgf5 Polycomb group ring finger 5  -1.8 10462683 1923505  
Thra thyroid hormone receptor alpha  -1.8 10381006 98742  
Response to Stress123 
F3 coagulation factor III  -5.6 10495675 88381  
Gen1 Gen homologue 1, endonuclease 
(Drosophila)  -5.2 
10399391 2443149  
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Blm Bloom syndrome homologue 
(human)  -3.4 
10564978 1328362  
Ifi47 interferon gamma inducible protein 
47  -3.0 
10375515 99448  
Ddx58 DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 58  -2.5 
10512067 2442858  
Trip13 thyroid hormone receptor interactor 
13  -2.4 
10410560 1916966  
Dhx58 DEXH (Asp-Glu-X-His) box 
polypeptide 58  -2.2 
10391207 1931560  
Polq polymerase (DNA directed), theta  -2.2 10435581 2155399  
Ifih1 interferon induced with helicase C 
domain 1  -2.0 
10483110 1918836  
Eme1 essential meiotic endonuclease 1 
homologue 1 (S. pombe)  -1.9 
10390050 3576783  
Atad5 ATPase family, AAA domain 
containing 5  -1.8 
10379363 2442925  
Cry1 cryptochrome 1 (photolyase-like)  -1.8 10371400 1270841  
Rad51 RAD51 homologue (S. cerevisiae)  -1.8 10474902 97890  
Signal Transduction124 
Gpr109a G protein-coupled receptor 109A  -10 10533720 1933383  
Edn1 Endothelin 1  -9.2 10404783 95283  
Rnd1 Rho family GTPase 1  -6.7 10432236 2444878  
Adora2b adenosine A2b receptor  -5.5 10376832 99403  
Ms4a6c membrane-spanning 4-domains, 
subfamily A, member 6C  -3.6 
10461614 2385644  
Itgal integrin alpha L  -3.1 10557591 96606  
Arhgef3 Rho guanine nucleotide exchange 
factor (GEF) 3  -3.0 
10413419 1918954  
Bcar3 breast cancer anti-estrogen 
resistance 3  -3.0 
10495781 1352501  
Cish cytokine inducible SH2-containing 
protein  -3.0 
10588577 103159  
Rassf2 Ras association (RalGDS -2.9 10487894 2442060  
Arhgap1
1a 
Rho GTPase activating protein 
11A  -2.7 
10485963 2444300  
Cysltr1 cysteinyl leukotriene receptor 1  -2.7 10606355 1926218  
Pscd4 pleckstrin homology, Sec7 and 
coiled -2.6 
10425092 2441702  
Mt2 metallothionein 2  -2.5 10574023 97172  
Itgam integrin alpha M  -2.3 10557862 96607  
 162
Table 10, continued. 
 
Ms4a6d Membrane-spannin 
4-domains, subfamily A, member 
6D  
-2.3 
10466210 1916024  
Wdr67 WD repeat domain 67  -2.2 10424221 2684931  
P2ry2 purinergic receptor P2Y, G-protein 
coupled 2  -2.1 
10565962 105107  
Pik3cd phosphatidylinositol 3-kinase 
catalytic delta polypeptide -2.1 
10518686 1098211  
Bcl3 B-cell leukemia -2.0 10560685 88140  
Ccl17 chemokine (C-C motif) ligand 17  -2.0 10574226 1329039  
Fpr3  formyl peptide receptor 3  -2.0 10442098 1194495  
Irak3 interleukin-1 receptor-associated 
kinase 3  -2.0 
10372781 1921164  
Eif2ak2 eukaryotic translation initiation 
factor 2-alpha kinase -1.9 
10452980 1353449  
Lyn Yamaguchi sarcoma viral (v-yes-1) 
oncogene homologue  -1.9 
10503098 96892  
Hus1 Hus1 homologue (S. pombe)  -1.8 10384322 1277962  
Per1 period homologue 1 (Drosophila)  -1.8 10377439 1098283  
Ptger4 prostaglandin E receptor 4 
(subtype EP4)  -1.8 
10427461 104311  
Translation123.124 
Denr density-regulated protein  -2.3 10525657 1915434  
Ppp1r15
b 
protein phosphatase 1, regulatory 
(inhibitor) subunit 1 -1.8 
10349868 2444211  
Ubiquitin-Dependent Protein Catabolic Process124 
Socs3 suppressor of cytokine signaling 3  
-5.1 
10383010 
10393449 
1201791  
Usp18 Ubiquitin specific peptidase 18  -3.7 10541307 1344364  
Tnfaip3 tumor necrosis factor, alpha-
induced protein 3  -3.0 
10368144 1196377  
Herc5 hect domain and RLD 5  -2.5 10538590 1914388  
Cdc20 cell division cycle 20 homologue 
(S. cerevisiae)  -2.2 
10515744 1859866  
Isg15 ISG15 ubiquitin-like modifier  -2.2 10451287 1855694  
Ube2c Ubiquitin-conjugating enzyme E2C -2.0 10478572 1915862  
Uhrf1 ubiquitin-like, containing PHD and 
RING finger domains, 1 -1.9 
10446074 1338889  
Rabgef1 RAB guanine nucleotide exchange 
factor (GEF) 1  -1.8 
10526133 1929459  
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Table 10, continued. 
 
Ube2l6 ubiquitin-conjugating enzyme E2L 
6  -1.8 
10473356 1914500  
Usp37 Ubiquitin specific peptidase 37  -1.8 10355582 2442483  
Other 
Ifit2 interferon-induced protein with 
tetratricopeptide repeats 2 -6.5 
10462613 99449  
Ifi205 interferon activated gene 205  -4.3 10360406 101847  
Ifit1 interferon-induced protein with 
tetratricopeptide repeats 1 -4.0 
10462623 99450  
Ifi202b interferon activated gene 202B -3.9 10360398 1347083  
Ifi204 interferon activated gene 204 -3.9 10360382 96429  
Ifit3 interferon-induced protein with 
tetratricopeptide repeats 3 -3.8 
10462618 1101055  
Ifi203 interferon activated gene 203 -3.7 10360391 96428  
Samsn1 SAM domain, SH3 domain and 
nuclear localization signals, 1 -3.5 
10440393 1914992  
Ifitm2 interferon induced transmembrane 
protein 2 -1.9 
10553299 1933382  
a Genes down-regulated ≤1.8-fold (p ≤ 0.01) at 6 h in HNE-treated RAW 264.7 cells 
that are associated with specific over-expressed biological processes in malaria models 
(references listed with ontology in column 1) are shown in the table. Fold changes (FC) 
represent the average of three independent biological experiments. Bold FC indicate that 
multiple probes gave analogous results (average FC is shown). 
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Table 11. Selected genes down-regulated by 35 μM HNE at 24 ha 
Gene 
Symbol Description 
Fold 
Change 
ABI 
Probeset 
ID 
MGI 
Gene ID
Apoptosis123.124 
Sgk serum/glucocorticoid regulated 
kinase 
-6.6 929684 1340062 
Axud1 AXIN1 up-regulated 1 -1.8 907214 2387989 
Cell Cycle124 
Slfn1 schlafen 1 -15.0 371033 1313259 
Sass6 spindle assembly 6 homologue (C. 
elegans) 
-4.6 881483 1920026 
Nbn Nibrin -3.4 430613 1351625 
Plekho1 pleckstrin homology domain 
containing, family O member 1 
-2.4 624539 1914470 
Als2cr2 amyotrophic lateral sclerosis 2 
(juvenile) chromosome region, 
candidate 2 (human) 
-2.3 358886 2144047 
Pols polymerase (DNA directed) sigma -1.9 732359 2682295 
Cell-Cell Signaling123 
Kif1b kinesin family member 1B -5.8 744344 108426 
Tsc1 tuberous sclerosis 1 -3.1 550748 1929183 
Gata3 GATA binding protein 3 -2.3 580073 95663 
Ly6e lymphocyte antigen 6 complex, 
locus E 
-2.3 927958 106651 
Metabolic Process124 
Avil Advillin -8.1 530983 1333798 
Dio2 deiodinase, iodothyronine, type II -6.9 738397 1338833 
Cytokine and Chemokine Mediated Signaling Pathway124 
Stat1 signal transducer and activator of 
transcription 1 
-10.8 433757 103063 
Il6st interleukin 6 signal transducer -2.7 647028 96560 
Defense Response123.124 
1 myxovirus (influenza virus) 
resistance 2 
-43.4 837469 97244 
Irgm immunity-related GTPase family, 
M 
-15.0 804608 107567 
Dhx58 DEXH (Asp-Glu-X-His) box 
polypeptide 58 
-7.9 659648 1931560 
B2m beta-2 microglobulin -2.5 501966 88127 
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Table 11, continued. 
 
Immune Response123.124 
Irf7 interferon regulatory factor 7 -51.3 345690 1859212 
Ddx58 DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 58 
-17.4 439516 2442858 
Ibrdc3 IBR domain containing 3 -2.2 695308 1922484 
Inflammatory Response123.124 
Ccl5 chemokine (C-C motif) ligand 5 -22.7 516139 98262 
Fcgr1 Fc receptor, IgG, high affinity I -13.6 922856 95498 
Il6 interleukin 6 -11.2 924312 96559 
Fcgr2b Fc receptor, IgG, low affinity IIb -2.9 930585 95499 
Ccl7 chemokine (C-C motif) ligand 7 -2.3 562485 99512 
Regulation of Apoptosis123 
Ern1 endoplasmic reticulum (ER) to 
nucleus signalling 1 
-12.3 749047 1930134 
Tsc22d3 TSC22 domain family 3 -3.6 700170 1196284 
Traf3 Tnf receptor-associated factor 3 -2.3 613464 108041 
Casp1 Caspase 1 -2.0 924714 96544 
Regulation of Transcription, DNA-Dependent123 
Gatad2b GATA zinc finger domain 
containing 2B 
-3.9 332294 2443225 
Ssbp3 single-stranded DNA binding 
protein 3 
-2.7 602705 1919725 
Tspyl2 TSPY-like 2 -2.5 526767 106244 
Usf2 upstream transcription factor 2 -2.1 532994 99961 
Pcgf5 polycomb group ring finger 5 -2.1 315886 1923505 
Zfp30 zinc finger protein 30 -2.0 919271 99178 
Response to Stress123 
Gna13 Guanine nucleotide binding 
protein, alpha 13 
-2.5 576697 95768 
Insig2 insulin induced gene 2 -2.3 603014 1920249 
Signal Transduction124 
Rassf8 Ras association (RalGDS/AF-6) 
domain family 8 
-5.0 704046 1918573 
Rgs1 regulator of G-protein signaling 1 -3.9 923224 1354694 
Nr3c1 nuclear receptor subfamily 3, 
group C, member 1 
-3.0 477364 95824 
Tbc1d12 TBC1D12: TBC1 domain family, 
member 12 
-2.6 360619 2384803 
Spry1 Sprouty homologue 1 (Drosophila) -1.9 404045 1345139 
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Table 11, continued. 
 
Translation123.124 
Mknk1 MAP kinase-interacting 
serine/threonine kinase 1 
-5.5 679668 894316 
Eif2c2 eukaryotic translation initiation 
factor 2C, 2 
-5.2 526883 2446632 
Impact imprinted and ancient -4.4 627739 1098233 
Eif2c3 eukaryotic translation initiation 
factor 2C, 3 
-3.6 526537 2446634 
Ubiquitin-Dependent Protein Catabolic Process124 
Usp18 ubiquitin specific peptidase 18 -100.0 446807 1344364 
Fbxo39 F-box protein 39 -87.4 642750 3505735 
Fem1c Fem-1 homologue c (C.elegans) -4.1 762818 2444737 
Wsb2 WD repeat and SOCS box-
containing 2 
-2.6 740571 2144041 
Ube2l6 ubiquitin-conjugating enzyme E2L 
6 
-2.3 401185 1914500 
Sumo3 SMT3 suppressor of mif two 3 
homologue 3 (yeast) 
-2.0 463700 1336201 
Fbxl20 F-box and leucine-rich repeat 
protein 20 
-2.0 331560 1919444 
a Genes down-regulated ≤1.8-fold (p ≤ 0.01) at 24 h in HNE-treated RAW 264.7 
cells that are associated with specific over-expressed biological processes in 
malaria models (references listed with ontology in column 1) are shown in the 
table. Fold changes (FC) represent the average of three independent biological 
experiments.  
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 Table 12. Selected genes up-regulated by 35 μM HNE at 24 ha 
Gene 
Symbol Description 
Fold 
Change 
ABI 
Probeset 
ID 
MGI 
Gene ID Ref 
Apoptosis123.124 
Pdcd8 programmed cell death 8 2.1 26926 1349419  
Stk3 serine/threonine kinase 3 (Ste20, 
yeast homologue) 
1.9 56274 1928487  
Tnfaip8 tumor necrosis factor, alpha-
induced protein 8 
1.9 106869 2147191  
Cell Cycle124 
Nek2 NIMA (never in mitosis gene a)-
related expressed kinase 2 
17.0 18005 109359  
Psmc3ip proteasome (prosome, macropain) 
26S subunit, ATPase 3, interacting 
protein 
6.4 19183 1098610  
Zbtb36 zinc finger and BTB domain 
containing 36 
2.3 207259 2443302  
Atm ataxia telangiectasia mutated 
homologue (human) 
1.9 11920 107202 120 
 
Cell-Cell Signaling123 
Dlg7 discs, large homologue 7 
(Drosophila) 
12.1 218977 2183453  
Wnt6 wingless-related MMTV integration 
site 6 
4.4 22420 98960  
Cadps Ca<2+>dependent activator 
protein for secretion 
2.2 27062 1350922  
Hprt1 hypoxanthine guanine 
phosphoribosyl transferase 1 
1.9 15452 96217  
Metabolic Process124 
Asf1b ASF1 anti-silencing function 1 
homologue B (S. cerevisiae) 
9.7 66929 1914179  
Car12 carbonic anyhydrase 12 4.7 76459 1923709  
Defense Response123.124 
Cias1 cold autoinflammatory syndrome 1 
homologue (human) 
8.3 216799 2653833  
Ccl17 chemokine (C-C motif) ligand 17 3.1 20295 1329039  
Fgr Gardner-Rasheed feline sarcoma 
viral (Fgr) oncogene homologue 
2.8 14191 95527  
Immune Response123.124 
Csf3 colony stimulating factor 3 
(granulocyte) 
17.5 12985 1339751  
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Table 12, continued. 
 
Tnf tumor necrosis factor 8.7 21926 104798 129 
85 
124 
161 
Clec5a C-type lectin domain family 5, 
member a 
5.0 23845 1345151  
Raet1e retinoic acid early transcript 1E 3.8 379043 2675273  
Il10ra  Interleukin 10 receptor, alpha 3.7 340636 96538 120 
Cxcl1 chemokine (C-X-C motif) ligand 1 2.7 14825 108068  
Nfam1 Nfat activating molecule with ITAM 
motif 1 
2.7 623312 
489525 
1921289  
Tgfb1 transforming growth factor, beta 1 2.0 21803 98725  
Inflammatory Response123.124 
Pla2g7 phospholipase A2, group VII 
(platelet-activating factor 
acetylhydrolase, plasma) 
10.7 27226 1351327  
C5r1 Complement component 5, 
receptor 1 
3.4 338868 88232 120 
121 
Nlrc4 NLR family, CARD domain 
containing 4 
2.7 268973 3036243  
Cd14 CD14 antigen 2.2 12475 88318 120 
Intracellular Protein Transport123 
Nup85 Nucleoporin 85 3.3 445007 3046173  
Prdx1 peroxiredoxin 1 2.9 18477 
545161 
99523 122 
Pcna proliferating cell nuclear antigen 2.3 18538 97503  
Pex7 Peroxisome biogenesis factor 7 2.0 18634 1321392  
Nup210 Nucleoporin 210 1.9 54563 1859555  
Metabolic Process124 
Echdc3 enoyl Coenzyme A hydratase 
domain containing 3 
5.4 67856 1915106  
Gnaq guanine nucleotide binding protein, 
alpha q polypeptide 
3.0 14682 95776  
Suclg1 succinate-CoA ligase, GDP-
forming, alpha subunit 
1.8 56451 1927234  
Protein Folding123 
Ppid peptidylprolyl isomerase D 
(cyclophilin D) 
3.3 67738 1914988  
Ppil1 peptidylprolyl isomerase 
(cyclophilin)-like 1 
2.5 68816 1916066  
Regulation of Apoptosis123 
Birc5 baculoviral IAP repeat-containing 5 27.4 11799 1203517  
Mmp9 matrix metalloproteinase 9 5.2 17395 97011 120 
Igf1 insulin-like growth factor 1 2.1 16000 96432  
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Table 12, continued. 
 
Regulation of Transcription, DNA-Dependent123 
Top2a topoisomerase (DNA) II alpha 13.2 21973 98790  
Mcm6 minichromosome maintenance 
deficient 6 (MIS5 homologue, S. 
pombe) (S. cerevisiae) 
6.0 17219 1298227  
Tbl1xr1 transducin (beta)-like 1X-linked 
receptor 1 
3.5 81004 2441730  
Bzw1 basic leucine zipper and W2 
domains 1 
2.9 66882 1914132  
Hmga2 High mobility group AT-hook 2 2.1 15364 101761  
Response to Stress123 
Rad51 RAD51 homologue (S. cerevisiae) 16.4 19361 97890  
Pole polymerase (DNA directed), 
epsilon 
15.4 18973 1196391  
Sod2 superoxide dismutase 2, 
mitochondrial 
9.1 20656 98352 120 
121 
Tacc3 transforming, acidic coiled-coil 
containing protein 3 
7.3 21335 1341163  
Trip13 thyroid hormone receptor 
interactor 13 
7.1 69716 1916966  
Msh5 mutS homologue 5 (E. coli) 6.1 17687 1329021  
Signal Transduction124 
Pilra paired immunoglobin-like type 2 
receptor alpha 
13.5 640067 2450529  
Rasgrp3 RAS, guanyl releasing protein 3 4.4 240168 3028579  
Rab11a RAB11a, member RAS oncogene 
family 
4.3 53869 1858202  
Igbp1b immunoglobulin (CD79A) binding 
protein 1b 
2.8 50540 1354380  
Gpr183 G protein-coupled receptor 183 2.3 321019 2442034  
Translation123.124 
Eif4e eukaryotic translation initiation 
factor 4E 
4.2 13684 95305  
Eif4e2 eukaryotic translation initiation 
factor 4E member 2 
3.4 26987 1914440  
Pa2g4 proliferation-associated 2G4 2.3 18813 894684  
Eif5a eukaryotic translation initiation 
factor 5A 
1.9 549097 
925942 
106248  
Pet112l PET112-like (yeast) 1.8 229487 2442496  
Ubiquitin-Dependent Protein Catabolic Process124 
Ube2t ubiquitin-conjugating enzyme E2T 
(putative) 
7.1 67196 1914446  
Fbxo5 F-box only protein 5 4.4 67141 1914391  
Ggnbp1 gametogenetin binding protein 1 3.5 70772 3055306  
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Table 12, continued. 
 
Fbxo22 F-box only protein 22 3.0 71999 1926014  
Ube2i ubiquitin-conjugating enzyme E2I 3.0 22196 107365  
Ube2d3 ubiquitin-conjugating enzyme E2D 
3 (UBC4/5 homologue, yeast) 
2.4 66105 1913355  
Bre brain and reproductive organ-
expressed protein 
1.9 107976 1333875  
Other 
Gsn Gelsolin 2.5 437857 95851 120 
Rad23a RAD23a homologue  
(S. cerevisiae) 
2.2 330310 105126 120 
a Genes up-regulated ≥1.8-fold (p ≤ 0.01) at 24 h in HNE-treated RAW 264.7 cells that 
are associated with (1) specific genes or gene products correlated to malarial infection or 
HNE exposure (references listed by gene in column 7), or (2) specific over-expressed 
biological processes in malaria models (references listed with ontology in column 1) are 
shown in the table. Fold changes (FC) represent the average of three independent 
biological experiments. Bold FC indicate that multiple probes gave analogous results 
(average FC is shown). 
 
 
 171
Table 13. Selected genes up-regulated by 0.1 mg/mL BH at 6 ha 
Gene 
Symbol Description 
Fold 
Change 
Affymetrix 
Probeset 
ID 
MGI 
Gene ID Ref 
Cell Cycle124 
Rps6ka2  ribosomal protein S6 kinase, 
polypeptide 2  
2.6 10441565 1342290  
Plk2  polo-like kinase 2 (Drosophila)  2.2 10407126 1099790  
Plekho1  pleckstrin homology domain 
containing, family O member 1 
1.9 10500295 1914470  
Immune Response123.124 
Fabp3  fatty acid binding protein 3, 
muscle and heart  
4.2 10371502 
10508614 
95476  
F10  coagulation factor X  2.7 10570291 103107  
Il7r  interleukin 7 receptor  2.6 10427628 96562  
Hmox1  heme oxygenase (decycling) 1  2.5 10572897 96163 120 
121 
Aadacl1  arylacetamide deacetylase-like 1  1.9 10491083 2443191  
Eno2  enolase 2, gamma neuronal  1.8 10547807 95394  
Mtmr10  myotubularin related protein 10  1.8 10553897 2142292  
Signal Transduction124 
Gprc5a  G protein-coupled receptor, family 
C, group 5, member A  
2.3 10542335 1891250  
Bcar3  breast cancer anti-estrogen 
resistance 3  
1.9 10495781 1352501  
Plxna2  plexin A2  1.9 10352867 107684  
Adra1a  adrenergic receptor, alpha 1a  1.8 10416099 104773  
Plekhm1  pleckstrin homology domain 
containing, family M (with RU 
1.8 10391918 2443207  
Gpr176  G protein-coupled receptor 176  1.7 10486102 2685858  
Other 
Slamf7 SLAM family member 7  3.4 10360173 1922595 121 
Hk3 hexokinase 3  1.8 10409376 2670962 120 
a Genes up-regulated ≥1.8-fold (p ≤ 0.01) at 6 h in BH-treated RAW 264.7 cells that are 
associated with (1) specific genes or gene products correlated to malarial infection or 
HNE exposure (references listed by gene in column 7), or (2) specific over-expressed 
biological processes in malaria models (references listed with ontology in column 1) are 
shown in the table. Fold changes (FC) represent the average of three independent 
biological experiments. Bold FC indicate that multiple probes gave analogous results 
(average FC is shown). 
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Table 14. Selected genes down-regulated by 0.1 mg/mL BH at 6 ha 
Gene 
Symbol Description 
Fold 
Change 
ABI 
Probeset 
ID 
MGI 
Gene ID
Immune Response123.124 
Csf2  colony stimulating factor 2 
(granulocyte-macrophage)  
-3.0 10385912 1339752 
Il1rl1  Interleukin 1 receptor-like 1  -2.0 10345791 98427 
Metabolic Process124 
Dusp2  dual specificity phosphatase 2  -1.8 10475782 101911 
Gfod1  glucose-fructose oxidoreductase 
domain containing 1  
-1.8 10408879 2145304 
Phlda1  pleckstrin homology-like domain, 
family A, member 1  
-1.8 10366346 1096880 
a Genes down-regulated more than 1.8-fold (p ≤ 0.01) at 6 h in BH-treated RAW 
264.7 cells that are associated with specific over-expressed biological processes in 
malaria models (references listed with ontology in column 1) are shown in the 
table. Fold changes (FC) represent the average of three independent biological 
experiments.  
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Table 15. Selected genes down-regulated by 0.1 mg/mL BH at 24 ha 
Gene 
Symbol Description 
Fold 
Change 
ABI 
Probeset 
ID 
MGI 
Gene ID
Cell Cycle124 
Hectd3 HECT domain containing 3 -70.8 567598 1923858 
Smarcb1 SWI/SNF related, matrix 
associated, actin dependent 
regulator of chromatin, subfamily 
b, member 1 
-3.0 889629 1328366 
Mre11a meiotic recombination 11 
homologue A (S. cerevisiae) 
-2.6 553944 1100512 
Smc4l1 SMC4 structural maintenance of 
chromosomes 4-like 1 (yeast) 
-2.1 789567 1917349 
Camk2g calcium/calmodulin-dependent 
protein kinase II gamma 
-2.0 390021 88259 
Camk2b calcium/calmodulin-dependent 
protein kinase II, beta 
-1.9 868597 88257 
Cell-Cell Signaling123 
Rab3a RAB3A, member RAS oncogene 
family 
-2.1 914789 97843 
Metabolic Process124 
Alas2 aminolevulinic acid synthase 2, 
erythroid 
-9.3 880116 87990 
Rpap1 RNA polymerase II associated 
protein 1 
-7.8 587339 1916175 
Pdgfb platelet derived growth factor, B 
polypeptide 
-6.0 788848 97528 
Pomt1 protein-O-mannosyltransferase 1 -3.4 914042 2138994 
Regulation of Apoptosis123 
Tnfsf13b Tumor necrosis factor (ligand) 
superfamily, member 13b 
-4.7 386868 1344376 
Bok Bcl-2-related ovarian killer protein -4.3 364104 1858494 
Regulation of Transcription, DNA-Dependent123 
Setdb1 SET domain, bifurcated 1 -47.8 751594 1934229 
Fos FBJ osteosarcoma oncogene -3.6 463565 95574 
Esrra estrogen related receptor, alpha -2.6 923547 1346831 
Yeats2 YEATS domain containing 2 -2.0 654721 2447762 
Asxl2 additional sex combs like 2 
(Drosophila) 
-1.9 540321 1922552 
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Table 15, continued. 
 
Signal Transduction123 
Wfikkn2 WAP, follistatin/kazal, 
immunoglobulin, kunitz and netrin 
domain containing 2 
-24.5 419373 2669209 
Olfr112 olfactory receptor 112 -6.1 690941 2177495 
Cdgap Cdc42 GTPase-activating protein -4.7 827470 1333857 
Ms4a6b membrane-spanning 4-domains, 
subfamily A, member 6B 
-3.5 920843 1917024 
Dner delta/notch-like EGF-related 
receptor 
-2.9 618695 2152889 
Frag1 FGF receptor activating protein 1 -1.9 431551 2385286 
Irf3 interferon regulatory factor 3 -1.8 925384 1859179 
Translation123.124 
Eif2s3x eukaryotic translation initiation 
factor 2, subunit 3, structural gene 
X-linked 
-4.1 772876 1349431 
Pars2 prolyl-tRNA synthetase 
(mitochondrial)(putative) 
-1.9 606179 2386296 
Ubiquitin-Dependent Protein Catabolic Process124 
Pja2 praja 2, RING-H2 motif containing -50.5 656636 2159342 
Ube2r2 ubiquitin-conjugating enzyme E2R 
2 
-2.6 546015 1914865 
a Genes down-regulated more than 1.8-fold (p ≤ 0.01) at 6 h in HNE-treated 
RAW 264.7 cells that are associated with specific over-expressed biological 
processes in malaria models (references listed with ontology in column 1) are 
shown in the table. Fold changes (FC) represent the average of three independent 
biological experiments.  
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Table 16. Selected genes up-regulated by 0.1 mg/mL BH at 24 ha 
Gene 
Symbol Description 
Fold 
Change 
ABI 
Probeset 
ID 
MGI 
Gene ID Ref 
Cell Cycle124 
Ereg Epiregulin 12.8 593765 107508  
Cops5 COP9 (constitutive 
photomorphogenic) homologue, 
subunit 5 (Arabidopsis thaliana) 
1.9 330594 1349415  
Metabolic Process124 
Pcsk2 proprotein convertase 
subtilisin/kexin type 2 
7.4 732125 97512  
Ppie peptidylprolyl isomerase E 
(cyclophilin E) 
3.6 530121 1917118  
Stard4 StAR-related lipid transfer 
(START) domain containing 4 
3.1 551930 2156764  
Blvra biliverdin reductase A 2.2 664457 88170  
Dusp14 dual specificity phosphatase 14 2.1 928759 1927168  
Immune Response123.124 
Il1a interleukin 1 alpha 6.0 595893 96542  
Ccl6 chemokine (C-C motif) ligand 6 5.3 928327 98263  
Tollip toll interacting protein 2.5 858428 1891808  
Il20 interleukin 20 2.4 879278 1890473  
H2-T23 histocompatibility 2, T region locus 
23 
2.2 558496 95957  
Intracellular Protein Transport123 
Srp9 signal recognition particle 9 2.1 927925 1350930  
Metabolic Process 
Gpt1 glutamic pyruvic transaminase 1, 
soluble 
2.6 556768 95802  
Regulation of Transcription, DNA-Dependent123 
Irf4 Interferon regulatory factor 4 4.6 386166 1096873  
Taf7 TAF7 RNA polymerase II, TATA 
box binding protein (TBP)-
associated factor 
3.4 535868 1346348  
Rnpc2 RNA-binding region (RNP1, RRM) 
containing 2 
3.0 528719 2157953  
Rqcd1 rcd1 (required for cell 
differentiation) homologue 1 (S. 
pombe) 
1.8 686770 1928902  
Signal Transduction124 
Rab33a RAB33A, member of RAS 
oncogene family 
2.8 732409 109493  
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Table 16, continued. 
 
Olfr313 olfactory receptor 313 2.2 721885 3030147  
Gipc1 GIPC PDZ domain containing 
family, member 1 
2.1 794773 1926252  
Rhebl1 Ras homolog enriched in brain like 
1 
1.9 456283 1916409  
Ubiquitin-Dependent Protein Catabolic Process124 
Rbx1 ring-box 1 3.2 494826 1891829  
Asb1 ankyrin repeat and SOCS box-
containing protein 1 
2.1 569408 1929735  
Ube2l3 ubiquitin-conjugating enzyme E2L 
3 
2.0 336987 109240  
Other 
Cd2 CD2 antigen 95.7 919536 88320 121 
124 
Pstpip2 proline-serine-threonine 
phosphatase-interacting protein 2 
6.1 725778 1335088 120 
a Genes up-regulated more than 1.8-fold (p ≤ 0.01) at 6 h in HNE-treated RAW 264.7 
cells that are associated with (1) specific genes or gene products correlated to malarial 
infection or HNE exposure (references listed by gene in column 7), or (2) specific over-
expressed biological processes in malaria models (references listed with ontology in 
column 1) are shown in the table. Fold changes (FC) represent the average of three 
independent biological experiments. 
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 Table 17. Common genes differentially regulated by 0.1 mg/mL BH and 35 μM HNEa 
Fold 
Change Gene 
Symbol Description Probe ID 
Time 
(h) 
BH HNE 
MGI 
Gene ID
Il1rl1 interleukin 1 receptor-like 1 10345791 6 -2.0 -4.0 98427 
Phlda1 pleckstrin homology-like 
domain, family A, member 1 
10366346 6 -1.8 -2.6 1096880 
Csf2 colony stimulating factor 2 
(granulocyte-macrophage) 
10385912 6 -3.0 -14.0 1339752 
Cd80 CD80 antigen 10435712 6 -1.8 -2.5 101775 
Trem1 triggering receptor expressed 
on myeloid cells 1 
10445746 6 -2.4 4.5 1930005 
Dusp2 dual specificity phosphatase 2 10475782 6 -1.8 -2.0 101911 
Plekhm1 pleckstrin homology domain 
containing, family M (with RU 
10391918 6 1.8 3.0 2443207 
Serpinb9
b 
serine (or cysteine) peptidase 
inhibitor, clade B, mem 
10404439 6 2.2 2.8 894668 
Plk2 polo-like kinase 2 (Drosophila) 10407126 6 2.2 3.7 1099790 
Il7r interleukin 7 receptor 10427628 6 2.6 3.1 96562 
Abcc5 ATP-binding cassette, sub-
family C (CFTR 
10438478 6 2.3 3.0 1351644 
Plekho1 pleckstrin homology domain 
containing, family O member 1 
10500295 6 1.9 2.3 1914470 
BC00404
4 
cDNA sequence BC004044 10526853 6 1.9 3.6 2136853 
Plxna1 plexin A1 10546184 6 1.9 2.4 107685 
Mtmr10 myotubularin related protein 10 10553897 6 1.8 2.1 2142292 
Hmox1 heme oxygenase (decycling) 1 10572897 6 2.5 6.3 96163 
Slc6a8 solute carrier family 6 
(neurotransmitter transporter, cr 
10600210 6 2.0 2.6 2147834 
Centa2 centaurin, alpha 2 638602 24 -2.6 -3.9 2663075 
Ms4a6b membrane-spanning 4-
domains, subfamily A, member 
6B 
920843 24 -3.5 -4.0 1917024 
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Table 17, continued. 
 
Olfr112 olfactory receptor 112 690941 24 -6.1 -2.4 2177495 
Pdxk pyridoxal (pyridoxine, vitamin 
B6) kinase 
480631 24 -2.7 -2.7 1351869 
Tmem26 transmembrane protein 26 604942 24 -12.3 -2.6 2143537 
8030453
O 22Rik 
RIKEN cDNA 8030453O22 
gene 
769847 24 2.0 2.0 1924459 
Blvra biliverdin reductase A 664457 24 2.2 1.8 88170 
Ephx1 epoxide hydrolase 1, 
microsomal 
907012 24 3.6 3.2 95405 
Hmgb1 high mobility group box 1 900889 24 2.1 2.7 96113 
Metapl1 methionine aminopeptidase-like 
1 
536468 24 2.8 1.9 1913809 
Phb Prohibitin 392862 24 2.2 2.5 97572 
Tuba4 tubulin, alpha 4 509694 24 1.9 2.5 1095410 
a Genes consistently regulated 1.8-fold up or down (p ≤ 0.01) at 6 or 24 h in BH- and 
HNE-treated RAW 264.7 cells. Fold changes (FC) represent the average of three 
independent biological experiments.  
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